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ABSTRACT 
Pancreatic cancer is one of the most lethal malignancies worldwide; the early diagnosis 
of this disease remains challenging and there are few effective therapies, with palliative 
chemotherapy being the main treatment option for patients with locally advanced or 
metastatic disease. Alteration of cellular energy metabolism is one of the hallmarks of 
tumours. Therefore, I proposed that the study of metabolic enzymes such as pyruvate 
kinase M2 (PKM2) and lactate dehydrogenase A (LDHA), which serve as key regulators 
of cellular energy metabolism in proliferating cells and mediators of aerobic glycolysis, 
could play an important role in the diagnosis and therapy of pancreatic cancer. 
Expression of PKM2 and LDHA was evaluated by immunohistochemistry in pancreatic 
cancer specimens. I found that the majority of PDAC strongly expressed PKM2 and 
LDHA at significantly higher levels compared with normal pancreatic tissues and benign 
pancreatic disease. PKM2 and LDHA expression directly correlated with tumour size 
and were expressed at higher levels in poorly differentiated tumours compared to well 
differentiated ones. Tumour cell proliferation, as detected by Ki67 staining, was 
significantly higher in tumours with strong PKM2 and LDHA expression compared to 
those with weak PKM2 and LDHA expression. Conversely, the number of CD8+ tumour 
infiltrating lymphocytes (TILs) was significantly higher in tumours with weak PKM2 
and LDHA expression than in those with strong PKM2 and LDHA expression. Patients 
with tumours that had strong PKM2 and LDHA expression had a significantly worse 
overall survival compared with those that had weak PKM2 and/or LDHA expression (7.0 
months vs. 27.9 months, respectively, p = 0.003, log rank test). Plasma PK and LDH 
concentrations were also significantly higher in pancreatic cancer patients compared to 
healthy controls (45.5 vs 21.6 U/L and 685 vs 194 U/L respectively, P < 0.0001). 
Shikonin (a Chinese herbal medicine) inhibited PKM2 activity and had a strong 
cytotoxic effect on pancreatic cancer cell proliferation with an IC50 of 2-3µM and 1-2 
µM for 24 and 72 hours interaction time, respectively. Treatment of pancreatic cancer 
cell lines with combination of PKM2 activator IV (TEPP-46) and LDHA inhibitor 
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(FX11) was synergistically inhibited pancreatic cancer cell proliferation, with 
combination indices (CI) of 0.48 and 0.45 for Miapaca-2 and BxPc-3 cell lines, 
respectively. Additionally, in the pancreatic cancer xenograft model, TEPP-46 and FX11 
in combination significantly delayed both subcutaneous and orthotopic tumour growth 
compared to the control group (P ˂ 0.0001). The combination treatment also reduced 
expression of PKM2 and LDHA, and significantly decreased Ki-67 expression compared 
with controls (P ˂ 0.0001). Orthotopic xenografts treated with the combination therapy 
had a high number of CD8+TIL cells around the tumours.  
In conclusion, PKM2 and LDHA overexpression in pancreatic cancer is associated with 
poor outcome. As such, high expression of these two enzyme may contribute to the 
aggressiveness of pancreatic cancer and confer anergy against the host anti-tumour 
immune response. Tetramerisation of PKM2 in combination with inhibition of LDHA 
synergistically inhibited pancreatic cancer cell proliferation and growth both in vitro and 
in vivo and may represent a novel strategy for pancreatic cancer therapy.  
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CHAPTER 1: PANCREATIC CANCER 
1.1: Background: 
Cancer is a leading cause of morbidity and mortality in the world. The World Health 
Organization (WHO) estimated that about 14 million people are diagnosed with cancer 
every year and 8.2 million died of cancer in 2012. According to WHO, new cancer cases 
are expected to rise by 70% over the next two decades (1). In the UK, more than 331,000 
new cancer cases were diagnosed in 2011 and around 162,000 people died from cancer 
in 2012 (2). Pancreatic cancer is the 10th most prevalent cancer worldwide and the 4th 
most common cause of cancer death (1). According to Cancer Research UK statistics, 
8,773 patients were diagnosed with pancreatic cancer in the UK in 2011 and 8,662 
people died with pancreatic cancer during 2012, so approximately 24 people are 
diagnosed with and die of pancreatic cancer every day (3). The risk of pancreatic cancer 
increases with age; three-quarters of patients diagnosed with this disease are over the age 
65 and the disease rarely occurs before the age of 40 (4). 
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of pancreatic 
cancer cases. Prognosis of pancreatic cancer is very poor; five-year survival is less than 
4% and this has not changed over the last 40 years. Moreover, pancreatic cancer has the 
worst survival rate among the 21 most common cancers in the UK (3). The poor 
prognosis of patients with pancreatic cancer is attributed to late diagnosis when surgical 
resection is often not possible. However, if patients are diagnosed earlier and are able to 
undergo surgical resection, the 5 year survival improves dramatically to 25% (5). 
Surgical resection remains the only curative treatment for pancreatic cancer; however, 
this is feasible in less than 20% of patients. The management of locally advanced or 
metastatic disease is challenging with most patients just receiving palliative single-agent 
or combination chemotherapy (6-8).  
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1.2: Pancreatic cancer symptoms: 
Symptoms of pancreatic cancer do not usually present until an advanced stage and 
generally depend on the location of the tumour. More than 50% of pancreatic tumours 
develop in the head of pancreas. The most important symptom that appears in patients 
with tumour of the head of the pancreas is painless jaundice, which occurs as a result of 
obstruction of the bile duct. Another symptom that presents in most patients in this group 
is upper abdominal and back pain (7). On the other hand, symptoms associated with 
tumours in the body and tail of pancreas are upper abdominal and back pain without 
jaundice. Rapid weight loss and new onset diabetes are two other symptoms that may 
occur, and may be associated with short survival of patients. 
1.3: Development of pancreatic cancer: 
PDAC develops in a similar manner to the common adenocarcinoma sequence in 
different solid organ tumours, such as the breast, cervix and colon (8,9). Invasive PDAC 
develops through a series of premalignant lesions, which are characterized by gradually 
increasing dysplasia (10). Precursor lesions include pancreatic intraepithelial neoplasia 
(PanIN), intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic 
neoplasms (MCN). Within the pancreatic ducts, PanIN progresses from flat form 
(PanIN-1A) to papillary lesion without dysplasia (PanIN-1B), then to papillary lesion 
with dysplasia and finally to carcinoma in situ (PanIN-3) (4,10) (see Figure 1.1). 
 
Figure 1.1: Development of pancreatic cancer. Adapted from Herreros-Villanueva et al. 2013 (10).  
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The PanIN lesion model is the best understood mechanism for the development of 
PDAC in humans. Recent research has also indicated that pancreatic tumorigenesis could 
be generated through progression of tubular complexes, which develop from flat 
metaplastic lesions within the acinae (acinar ductal metaplasia, ADM). The development 
and progression of PanIN and ADM lesions into pancreatic adenocarcinoma is triggered 
by a series of genetic alterations. Mutations in the K-ras gene are the most common and 
tend to occur at an early stage, followed by mutations in the tumour suppressor gene p16 
and mutations in p53, SMAD4 and BRCA2 in the later stages of the process (4,10–12). 
1.4: Risk factors:  
A number of risk factors have been identified for the development of pancreatic cancer. 
Similar to other cancers, age is one of the main risk factors for pancreatic cancer, with 
over 80% of pancreatic cancer cases developing between the ages of 60 and 80 (4,13). 
Family history of pancreatic cancer is also an important risk factor. The chance of 
developing pancreatic cancer is increased 2.3 fold in an individual with a first degree 
relative with pancreatic cancer and 16-64 fold if they have two or more first degree 
relatives with pancreatic cancer (4,13–15). Some other familial cancers such as 
melanoma and certain hereditary forms of breast, ovarian and colon cancer, as well as 
some rare familial cancer syndromes such as Lynch Syndrome (microsatellite 
instability), Li-Fraumeni Syndrome (P53 mutation), and Familial Adenomatous 
Polyposis (APC mutation), are associated with an increased risk of developing pancreatic 
cancer (4,13). These individuals are at increased risk of developing pancreatic cancer 
when compared to the general population and recent international guidelines recommend 
regular surveillance once patients are over the 40 years. In the UK, high risk patients are 
eligible to be screened as part of the pan-European EUROPAC registry (The European 
Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer- http://www.europac-
org.eu) which is evaluating the utility of surveillance in this group of patients (16). An 
estimated 4 out of 10 patients with hereditary pancreatitis will develop pancreatic cancer, 
while individuals with chronic pancreatitis have a nearly 15 fold increased risk. Obesity 
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and diabetes mellitus are also associated with a 2-fold risk of developing this disease 
(3,4,13). Smoking is another strong risk factor for the development of PDAC, with one 
out of four patients having a smoking history. Finally, high dietary meat and fat intake 
may contribute to the development of pancreatic cancer, while diets rich in vegetables 
and fruits may reduce that risk (17). 
1.5: The stages of pancreatic cancer:   
Staging of cancer is an important way to describe the extent of tumour growth, predict 
prognosis and plan treatment strategies. Cancer stages are classified in several ways. The 
American Joint Committee on Cancer (AJCC) stage pancreatic cancer by the TNM 
system, which gives information about the cancer through three key letters T (primary 
tumour), N (regional lymph nodes) and M (distant metastasis) (see Appendix 1 table 1).  
After the T, N and M categories are determined, the stage of pancreatic cancer is 
assigned by combining the TNM information. The stage grouping is expressed by 
combination of stage letter with Roman number from 0 to IV (see Appendix 1 table 2). 
Additional factors that are not formally part of TNM or stage system, such as the extent 
of resection (R), grades and or tumour proliferation are also useful in determining 
patient’s prognosis.  
 
  
18 
 
1.6: Diagnosis of pancreatic cancer: 
1.6.1: Biomarkers: 
Due to the asymptomatic development of pancreatic cancer and lack of accurate 
biomarkers, the early diagnosis of pancreatic cancer remain extremely challenging. 
Therefore, the discovery of novel biomarkers, which can diagnose pancreatic cancer at 
an early stage when patients can undergo curative surgical resection, is of the upmost 
importance.    
Blood is simple to obtain from the patient and can be easily analysed in clinical 
laboratories. However, the wide range of proteins in the blood complicated the protocol 
for discovery of new biomarker. 
In theory, the discovery of biomarkers for detection of early stage pancreatic cancer 
could improve survival rates. In the last forty years many sensitive and selective 
biomarkers have been discovered for some cancers, which significantly improved 
survival rates, however, the early diagnosis of pancreatic cancer remain difficult and 
pancreatic cancer has the worst survival rate among most common cancer worldwide (3).   
Carbohydrate antigen 19-9 (CA19-9) is the only standard serum biomarker that is in 
current use for diagnosis of pancreatic cancer and the only serum marker that has been 
approved by US Food and Drug Administration (FDA) for monitoring patients with 
pancreatic cancer (10).  
CA19-9 has a sensitivity of 79–81% and specificity of 82-90% for the diagnosis of 
pancreatic cancer in symptomatic patients, however, CA19-9 can be elevated in chronic 
and acute pancreatitis, cholangitis, obstructive jaundice and liver cirrhosis (10,18). 
CA19-9 is a sialylated lewis antigen of the MUC1 protein. Approximately 7-10% of the 
population do not secrete the Lewis antigen, which is another limitation of CA19-9 in the 
diagnosis of pancreatic cancer (19). 
Carcinoembryonic antigen (CEA) is another serum biomarker that has been used for 
more than a decade as a biomarker for the diagnosis of pancreatic cancer, with a 
sensitivity of 25-54% and specificity of 75-91%. Due to its low sensitivity and because it 
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is elevated in colorectal, stomach and breast cancer as well as pancreatic cancer, CEA is 
not currently used for the diagnosis of pancreatic cancer (10,20).    
Many serum biomarkers have been studied so far, but none of them have shown better 
selectivity and sensitivity than CA19-9 for early diagnosis of pancreatic cancer. 
Recently, serum PKM2 has been identified as a diagnostic and prognostic marker with 
comparable sensitivity and selectivity to serum CA19-9 in pancreatic cancer (5,20,21). 
Serum PKM2 has some advantages over C19-9 for the diagnosis of pancreatic cancer. 
Blood PKM2 level is not affected by cholestasis and correlates with the presence of 
pancreatic cancer metastasis, the previous research studies have also shown a direct 
correlation between plasma PKM2 and stage of pancreatic cancer (5,20,22). PKM2 can 
also easily be quantified in blood by immune-enzymatic assay.     
Recently, the combination of two or more tumour markers has been utilised for the early 
diagnosis of pancreatic cancer. Schulze et al (2000) found that the combination of PKM2 
and CA19-9 significantly increased the sensitivity up to 96% without reducing 
specificity for the diagnosis of pancreatic cancer (23).   
More recently, O'Brien et al (2015) studied the combination of multiple serum 
biomarkers and found that the combination of CA19-9 and CA125 elevated and was able 
to detect pancreatic cancer up to two years prior to clinical diagnosis in some patients 
(24). 
To summarise, the identification of highly sensitive and selective blood biomarkers is 
likely to lead to early detection of pancreatic cancer, resulting in curative surgical 
resection and improves patient’s survival rate. 
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1.6.2: Imaging and tissue acquisition: 
1.6.2.1:  Transabdominal ultrasound (TAUS): 
Transabdominal ultrasonography (TAUS) is the most commonly used technique for 
initial evaluation of abdominal pain and jaundice, the two most common symptoms of 
pancreatic cancer. The accuracy of TAUS for the diagnosis of pancreatic cancer is 
approximately 50 to 70% (25,26). The role of transabdominal ultrasonography is also 
limited to confirming the presence of a mass lesion, diagnosing a dilated biliary tree, 
excluding cholelithiasis and detecting ascites and hepatic metastases (27). Contrast-
enhanced Doppler ultrasonography can improve the accuracy of pancreatic tumour 
diagnosis, with a reported sensitivity and specificity of 90% and 95%, respectively 
(25,28). On the other hand, intervening bowel gas and differential skill of the operator 
may decrease the sensitivity of ultrasonography for detection and staging of pancreatic 
tumours (25,27).  
1.6.2.2:  Computerised tomography (CT): 
Computerised tomography (CT) is the most commonly used imaging technology for 
diagnosis and staging of pancreatic cancer. Typically a multidetector row computerised 
tomography (MDCT) with intravenous contrast is used, which takes just a few minutes. 
It has an accuracy for detection of pancreatic carcinoma of 85-100% and accurately 
predicts resectability in 80-90% of patients (25,27,29).          
1.6.2.3:  Magnetic resonance imaging (MRI): 
Magnetic resonance imaging is another useful imaging technique for diagnosing 
pancreatic tumours. MRI images are formed from the radiofrequency signal obtained 
from the relaxation of hydrogen nuclei, which are present throughout the body, are 
exposed to strong magnetic field. Recently, contrast enhanced MRI has been confirmed 
as a useful imaging technique for identification of tumours. Pancreatic MRI can be 
combined with magnetic resonance cholangiopancreatography (MRCP) to evaluate 
biliary pathology including other causes of biliary obstruction (27). There are no 
significant differences between MRI and CT in pancreatic tumour detection and in 
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predicting resectability. However, MRI often less commonly available, is more 
expensive and takes longer than CT; as well, it is less effective at looking for the 
presence of lung metastases (30,31). MRI is a useful imaging technique for staging of 
pancreatic tumours, differentiation of an inflammatory pancreatic mass from PDAC and 
detection of liver metastasis. The sensitivity of MRI for detection of pancreatic tumour 
ranges from 88-96% (32).   
1.6.2.4:  Endoscopic ultrasonography (EUS):  
Endoscopic ultrasonography was initially developed in the 1980s with mechanical radial 
scanning transducers. EUS is highly sensitive for pancreatic cancer lesions and is more 
accurate than MDCT and MRI for detection of tumours, especially for tumours less than 
2cm (25,27). Furthermore, it is highly sensitive for detecting vascular infiltration by the 
tumour and lymph node metastasis (25,33). The main disadvantage of EUS is that it is an 
invasive technique and has limited visualization for detecting metastatic spread to the 
peritoneum and liver (25). On the other hand, EUS when combined with fine needle 
aspiration or biopsy can enable cytological diagnosis at the same time, with a sensitivity 
and specificity of 91% and 95%, respectively (34). EUS-FNA is now the main mode of 
obtaining a cytological diagnosis of pancreatic carcinoma (35).     
1.6.2.5:  Endoscopic retrograde cholangiopancreatography (ERCP): 
Endoscopic retrograde cholangiopancreatography is a common procedure for acquisition 
of diagnostic material in pancreatic carcinoma, which is typically obtained via biliary 
brush cytology (25,27). At the time of the ERCP the ampulla, duodenum and stomach 
are also visualized, so any signs of tumour invasion or gastric outlet obstruction can be 
diagnosed. In patients with obstructive jaundice a biliary stent can also be placed at the 
same time. The main disadvantages of these invasive methods are the potential 
complications of acute pancreatitis, infection, bleeding and visceral perforation (<3%). 
The sensitivity of biliary brush cytology for the diagnosis of pancreaticobiliary 
malignancy is low. Recently, some cytological techniques have improved sensitivity of 
pancreaticobiliary malignancy diagnosis to approximately 43 to 60% (36,37). Pancreatic 
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duct brushing has also been reported, with one study showing a sensitivity and 
specificity of 66% and 100%, respectively (38).        
1.6.2.6:  Positron emission tomography (PET): 
Positron emission tomography is a non-invasive imaging technique, which uses different 
radiolabeled compounds such as the radiolabeled glucose analogue 18F-
fluorodeoxyglucose, which can detect metabolic active tissues. A malignant tumour is 
characterized by an increased concentration of intracellular glucose due to upregulation 
of glucose transporters, hexokinase and phosphofructokinase activity. The sensitivity and 
specificity of FDG-PET for detection of pancreatic tumours is 71-100% and 64-90%, 
respectively (25,39). FDG-PET may also be useful for detecting distant metastasis in 
pancreatic cancer (25). PET can be superimposed with computed tomography (PET-CT) 
to further improve diagnosis of pancreatic tumour lesions, with a sensitivity of 87% and 
specificity of 83%. Furthermore, contrast-enhanced PET-CT has shown better 
performance with a sensitivity and specificity of 91% and 88%, respectively (40). 
1.7: Treatment of pancreatic cancer: 
1.7.1: Surgery: 
Complete removal of the tumour by surgery is the most effective treatment for pancreatic 
cancer. However, only 10-20% of patients are eligible to undergo radical surgery 
because pancreatic cancer is usually diagnosed at an advanced stage (5,41). The survival 
rate after resection is still very low with a median survival of only 10 to 20 months and a 
five year survival of around 25% (5,42). For tumours in the head of the pancreas, a 
Whipple's operation (Pancreatoduodenectomy) is the most common type of surgery 
performed (43). For tumours in the tail of the pancreas a distal pancreatectomy is 
undertaken. However, at the time of surgery if patients are found to have locally 
advanced disease involving the arteries or metastatic disease, curative surgical resection 
is usually not possible and a palliative gastric and biliary bypass may be performed. An 
alternative is subsequent endoscopically placed duodenal and biliary stents.  
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1.7.2: Chemotherapy: 
Chemotherapy is used for the palliative treatment of pancreatic cancer, as well as in the 
neoadjuvant and adjuvant setting (44,45). Chemotherapy may improve the quality of life 
and survival length. Gemcitabine is the most commonly used chemotherapy in the USA 
and Europe and generally shows better efficacy over 5-fluorouracil (46). GemCap 
(Gemcitabine given with Capecitabine) combination chemotherapy is also used (47). 
Recently, the combination chemotherapy FOLFIRINOX (5-fluorouracil, leucovorin, 
irinotecan, oxaliplatin) has shown significant improvement in survival length in patients 
with metastatic disease when compared to Gemcitabine alone, albeit with considerable 
toxicity (6).  
1.7.3: Radiotherapy: 
Radiotherapy is a type of cancer therapy that uses high energy radiation to kill cancer 
cells. Radiotherapy is used less frequently when compared with chemotherapy and 
surgery. In some cases radiotherapy is offered to patients with metastatic pancreatic 
cancer to relieve symptoms. Combination chemotherapy with radiotherapy 
(chemoradiation) has been shown to have better results than chemotherapy alone for the 
treatment of locally advanced disease.  
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Figure 1.2: Algorithm for management of pancreatic cancer. (A) Clinical assessment and diagnosis of pancreatic cancer. (B) Treatment algorithm for patients 
with pancreatic cancer.
 1.8: Glycolysis and aerobic glycolysis: 
Glucose plays an essential role as an energy source for cell survival and as a carbon 
source for anabolic pathways. Catabolism of glucose, called glycolysis, is a central 
pathway in metabolism. In the presence of ample amounts of oxygen, most normal cells 
rely on the energy (ATP) that is generated from oxidative phosphorylation in 
mitochondria. During this process, pyruvate generated from the degradation of glucose is 
transported to the mitochondria and used as a substrate in the TCA cycle to generate 
ATP for biological activity of the cell. In contrast to normal cells, cancer cells have 
adapted to generate significant amounts of their ATP in the conversion of glucose to 
lactate, even in the existence of adequate amount of oxygen, a process known as the 
Warburg effect or aerobic glycolysis (48–50). In 1920, Otto Heinrich Warburg explained 
metabolism in tumour cells and discovered that the cancer cells utilize high quantities of 
glucose and produce lactate even in the presence of sufficient amounts of oxygen 
(51,52). Warburg considered the impairment of cellular respiration to be caused by 
defects in mitochondria and enhanced utilization of the high amounts of glucose to cope 
with the high energy demand by cancer cells (53). Later, the observation of high glucose 
uptake by malignant cells was emphasized by the use of 18F-fluorodeoxyglucose as a 
tracer for positron emission tomography to detect occult tumour masses (48,53,54). 
Warburg also proposed that the defect of mitochondrial respiration was a primary cause 
of malignancy. However, modern research findings showed that mitochondrial 
dysfunction is not common in most types of cancer. Accumulating evidence supports the 
hypothesis that mutations in oncogenes and tumour suppressor genes (which activate 
oncogenes or inactivate tumour suppressors) lead to altered metabolism and cause the 
development of a tumour (50,55–57).  
Mutations have a significant effect on metabolic enzymes activities and have a crucial 
role in aerobic glycolysis of cancer. Mutations of oncogenes and tumour suppresser 
genes such as Myc, phosphatidylinositol 3-kinase (PI3K), phosphatase and tensin 
homolog (PTEN), and p53 are commonly shown to be altered and have a great impact on 
reprogramming cell metabolism and tumorigenesis (Figure 1.2) (49,56,58,59). Alteration 
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of the PI3K/Akt pathway has been frequently found in cancer and has a key role in 
various tumours (56). Activated PI3K phosphorylates (activates) AKT and stabilizes 
hypoxia inducible factor-1 (HIF-1). PTEN tumour suppresser gene is inactivated by the 
PI3K enzyme antagonise and stimulate glycolysis through AKT and HIF-1 activation 
(60). The activated Akt directly controls glycolytic enzymes and enhances glucose 
uptake through activation of glycolysis enzymes, for instance phosphofructokinase 
(PFK) and hexokinase (HK) (56,61). Mammalian target of rapamycin (mTOR) is also 
activated by AKT, which indirectly affects other metabolic pathways by activating HIF-
1, even under normal concentrations of oxygen (61). Pyruvate dehydrogenase kinases 
(PDKs) is then activated by HIF-1 and inhibit the access of pyruvate into the TCA cycle 
(56). Transcription of most glycolytic enzymes, including LDHA and glucose 
transporter-1 (GLUT-1), are activated by the oncogenic transcription factor (myc), which 
consequently increase both glucose uptake and production of lactate, it can also regulate 
genes associated with glutamine metabolism. Taken together, alteration of myc oncogene 
enhances both glycolysis and glutaminolysis, which are associated with tumour 
aggressiveness (49,50,56).  
The tumour suppressor protein p53 is also one of the most crucial mutated proteins 
involved in the alteration of glycolysis in various types of cancer. Besides its role in 
controlling cell cycle and death, p53 also has an inhibitory effect on the glycolytic 
pathway (56,62). p53 upregulates TIGAR (TP53-induced glycolysis and apoptosis 
regulator) expression, causes reduction of the level of fructose-2,6- bisphosphatase and 
decreases the rate of glycolysis (63). Additionally, p53, in normal cells, directly induces 
oxidative phosphorylation by up-regulation of cytochrome c oxidase 2 (SCO2), which is 
necessary for the appropriate assembly of the SCO complex of the electron transport 
chain. Accordingly, the loss of p53 function, as shown in cancer cells, directs 
metabolism from mitochondrial respiration towards glycolysis (Figure 1.2) (56,64). 
Another factor that further promotes alteration of metabolism in cancer cells is the 
expression of the spliced variant form of PKM2, which is characterized by the low 
activity toward its substrate leading to the reduction of oxygen consumption and 
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increased lactate production (53,57,59). The expression of spliced form of PKM2 also 
enhances glucose uptake, increases the rate of glycolysis and directs glycolysis toward 
production of glycolytic intermediates, such as amino acids, lipid and nucleotides, which 
are required for biosynthesis of new cells (51,52,55).   
  
 
 
Figure 1.3: Illustration of cancer cell metabolism. Oncogenes and tumour suppressor genes signalling 
pathways regulate cancer cell metabolism. Adapted from Jang et al. 2013 (56). 
 
1.9: Inhibition of glycolytic enzymes as a target for cancer therapy: 
Alteration of glucose metabolism is one of the features of cancer cells. In contrast to 
normal cells, tumours rely on glycolysis for energy (ATP) generation rather than 
mitochondrial oxidative phosphorylation (48–50). There is increasing evidence that 
glycolysis is required for proliferation, invasion and metastasis of tumour cells. Thereby, 
the inhibition or attenuation of glycolysis may restrict the capacity of tumour to 
proliferate, invade adjacent tissues and migrate to distant organs (56,65). 
The inhibition of hexokinase (HK), phosphofructokinase (PFK) and pyruvate kinase 
(PK) enzymes, which are regulated irreversible and rate limiting steps of glycolysis, can 
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attenuate the increased rate of glycolysis in the cancer cells. Similarly, pyruvate 
dehydrogenase kinase (PDK), pyruvate dehydrogenase (PDH) and lactate dehydrogenase 
(LDH) enzymes also play a crucial role in glycolysis and mitochondrial oxidation 
phosphorylation. Inhibition of these enzymes is another strategy for attenuating the 
increased rate of glycolysis in tumour cells (65,66).  
Hexokinase is the first rate limiting step of glycolysis that catalyses the conversion of 
glucose to glucose-6-phosphate. Lonidamine is an indazole-3-carboxylic acid derivate 
that can inhibit phosphorylation of glucose through inhibition of hexokinase II (HK-II). 
Lonidamine has been evaluated in phase III trials but widespread clinical application has 
been limited by significant hepatic and pancreatic toxicities (56,65,66). 3-bromopyruvate 
(3-BrPA) is another anticancer and strong alkylation agent, which has recently been 
shown to have a potent glycolysis and mitochondrial oxidative phosphorylation 
inhibitory effect through targeting HK-II and LDH enzymes. Moreover, 3-BrPA is a 
pyruvate and lactate analogue that has shown potent anticancer activity in preclinical 
studies (67–69). Similar to Lonidamine and 3-BrPA, 2-deoxyglucose (2-DG) is another 
glycolysis inhibitor; it is a glucose analogue and acts as a competitive inhibitor of 
glucose metabolism. Hexokinase II phosphorylates 2-DG to 2-DG-phosphate, but unlike 
glucose-6-phosphate, cannot be further metabolized and is not converted to fructose-6-
phosphate by the action of phosphohexokinase isomerase enzyme. As a result, 
significantly reduced ATP generation leads to inhibition of cell cycle progression and 
finally cell death. 2-DG also showed promising anticancer activity effects in pre-clinical 
and early clinical phase trials (66,68–70).  
Several other glycolysis inhibitor drugs have been developed and shown to have anti-
cancer activity both in cell culture and in xenograft models, and some drugs have entered 
clinical trials (56,65,66,69,70) (Figure 1.3).  
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Figure 1.4: Summary of inhibition of glycolytic enzymes. These drugs have been shown to inhibit 
glycolysis and produce anticancer effects. (WZB117: 3-Fluoro-1,2-phenylene bis(3-hydroxybenzoate), 3-
BrPA: 3-bromopyruvate, 2-DG: 2-deoxyglucose, LON: lonidamine, DMA: 5,5-dimethylamiloride,  
FX11: 2,3-Dihydroxy-6-methyl-7-(phenylmethyl)-4-propyl-1-naphthalenecarboxylic Acid, DCA: 
dichloroacetate , BX-320: N1-[3-[[5-Bromo-2-[[3-[(1-pyrrolidinylcarbonyl)amino]phenyl]amino]-4-
pyrimidinyl]amino]propyl]-2,2-dimethylpropanediamide , BPTES: Bis-2-(5-phenylacetamido-1,3,4-
thiadiazol-2-yl)ethyl sulphide). 
 
There are several potential obstacles to the use of glycolysis enzyme inhibitors as an 
anticancer therapy. Indeed, glycolysis enzymes are required for glucose metabolism in 
normal cells, so that inhibition of glycolysis severely depletes ATP generation and can 
cause serious disorders through the impairment of glucose consumption. Some normal 
tissues such as brain, testis and retina use glucose as the main source of energy. In this 
case, the inhibition of glycolysis may have a toxic effect for these particular tissues (50).  
In line with this observation, I focused on the study of PKM2 and LDHA enzymes in 
PDAC. Activation of PKM2 and inhibition of LDHA can inhibit cancer cell proliferation 
and might not be harmful for normal cells (50,52,54). Interest in PKM2 and LDH-A as a 
target for pancreatic cancer treatment comes from the observation that these enzymes are 
frequently upregulated during tumorigenesis and offer the possibility of a therapeutic 
intervention aimed at correcting these altered activities (52,59,71–74).  
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1.10: Pyruvate kinase:     
Pyruvate kinase (PK, EC: 2.7.1.40) is a highly regulated glycolytic enzyme found in all 
living organisms. This enzyme catalyses the last step of glycolysis and mediates the 
transferring of a phosphate group from phosphoenolpyruvate (PEP) to adenosine 
diphosphate (ADP) to produce pyruvic acid and adenosine triphosphate (ATP) (21,75–
78). 
PK has four different isoenzymes, which mainly depends upon the metabolic response of 
various cells and tissues. Both L and M genes encode PK isoenzymes (75,76,78,79). The 
L gene encodes both L- and R-PK isoenzymes. Tissues with high gluconeogenesis, for 
instance liver and kidney, are characterized by the expression of L-PK isoenzyme; 
however, erythrocytes express R-isoenzyme. The M gene encodes both M1 and M2 
isoenzymes. Those tissues that require a high amount of energy, for instance brain and 
muscle, express M1-PK. However, M2-PK is found in lung tissues and all cells with 
high proliferation, such as tumour cells, embryonic cells and adult stem cells (21,75,78–
81).  
The PKM gene consists of 12 exons and 11 introns and encodes both M1 and M2 
pyruvate kinase isoenzymes. M1- and M2- PK isoenzymes are different splicing 
products (exon 10 for PKM2 and exon 9 for M1PK)(57,71,77). The amino acid 
composition of human M1- and M2-PK is very similar and the homology between these 
two isoenzymes is about 96%. The differences are only in 23 amino acids within 56 
amino acids stretch (aa 378-434) at the carboxy terminus of the M2-PK protein. Notably, 
44 amino acids of the 56 amino acids belong to the C-domain of the M2-PK protein and 
is involved in the formation of a tetrameric isoform of PKM2 from two dimers 
(77,82,83). Furthermore, this difference in C-domain amino acids is responsible for the 
different regulation mechanism and kinetic characteristics between M1- and M2-PK 
(Figure 1.4A).  
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Figure 1.5: Illustration of pyruvate kinase gene transcription and alterative splicing of PKM1 and PKM2 
mRNA. A) The PKM-gene consists of 12 exons and 11 introns and encodes both of M1 and M2-PK 
isoenzymes, these two isoenzymes are different splicing products, exon 10 for PKM2 and exon 9 for 
M1PK. B) The structure and differences between PKM1 and PKM2 proteins, both proteins consist of 531 
amino acids and the compositions are very similar and have about 96% homology. (ACS: PKM2 active 
site, AS: allosteric activator FBP, and, NLS: nuclear localisation signal sequence.)    
 
The PKM2 monomer is composed of 531 amino acids and divided into four domains 
which are the N (aa 1-43), A (aa 44-116 and 219-389), B (aa 117-218) and C (aa 390-
531) domains (Figure 1.4B). In contrast to the other PK isoenzymes which are 
characterized by tetrameric structures, PKM2 occurs either in dimeric or tetrameric 
isoform. The dimeric structure of PKM2 is formed by the intracellular interaction of two 
monomers in the A-domain region, while the tetrameric structure occurs as a result of the 
association of the interface of the C-domain of two dimers. Moreover, the tetrameric 
isoform of PKM2 is characterised by high affinity to its substrate PEP (Km, 0.03mM); 
however, the dimeric isoform has a low affinity for PEP (Km, 0.46mM) (57,71,77,83–
85). PKM2 is mainly in the tetrameric isoform in normal cells, whereas the dimeric 
  
32 
 
isoform of PKM2 is usually found in cancer cells and has therefore been known as 
tumour PKM2.  
Tumour cell metabolism differs substantially from normal cell metabolism. As well as 
other characteristic differences of cancer, tumours show increases in glycolysis and 
glutaminolysis rates, whereas gluconeogenesis is decreased. The most important 
advantages for an increasing rate of glycolysis in tumour cells are production of energy 
without oxygen consumption and glycolytic intermediates, such as amino acids, 
nucleotides, phospholipids and triglycerides, which are used as precursors of new cells 
(see Figure 1.6) (51–53,86). 
During tumorigenesis, the specific PK isoenzymes, for instance PKM1 in the brain and 
L-PK in the liver, disappear and the expression of PKM2 predominates (87). PKM2 
plays a key role in the regulation of cellular metabolism and the balance between energy 
generation and production of glycolytic intermediates. In the presence of ample amounts 
of oxygen, tumour cells obtain energy from the degradation of glutamine by 
glutaminolysis but when oxygen is absent, glutaminolysis is inhibited and 
tetramerisation of PKM2 occurs by increasing the level of fructose 1,6 biphosphate, and 
glycolysis shift toward energy production (21).    
Egenbrodt et al. first described the inactive dimeric form of PKM2 as a characteristic 
metabolic marker of tumour. He studied the level of PKM2 in patients with pancreas, 
lung, kidney, liver and breast cancer and found high level of the inactive dimeric form of 
PKM2 in the blood and tissues, and termed it tumour PKM2 (21). 
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1.10.1: Structure of pyruvate kinase: 
The structure of pyruvate kinase (PK) structure has been studied in both eukaryotic and 
prokaryotic cells and in most cases has been observed to exist primarily as a hetero-
tetramer of four identical subunits (50-60 kDa). Each subunit consists of an 
approximately 531 amino acid residues and is assembled to form a tetrameric structure 
with 2-2-2 symmetry. Each PK subunit is also composed of four different domains, 
which are A, B and C and the N- terminal domains (75,88,89). The active site pocket is 
located between the A and B domains and based about 39 Å from the effector site, which 
is positioned in the C-domain. In the tetrameric structure, neighbouring C-domains build 
the C–C or ‘small’ interface, and adjacent A-domains build the A–A or ‘large’ interface. 
The B-domain contributes a mobile lid at one end of the (α/β)8-barrelled A-domain and 
modulates access to the active site (89) (Figure 1.5).  
PK is a highly conserved homo-tetrameric enzyme across distant phylogenetic groups, 
whereas, the mechanism of PK activity regulation differs between various species 
(77,90,91). In the tetrameric structure of PK, three different binding pockets with 
affinities for a variety of molecules have been identified and are well defined in 
mammals, bacteria, yeast and trypanosomatids. The binding site pockets are composed 
of the active site pocket, the effector site pocket and the amino acid binding site pocket 
(89). Most PK isoenzymes show binding of the PEP substrate at the active site pocket 
and fructose 1, 6 biphosphates (FBP) binds at the effector site pocket. FPB is an 
allosteric activator of PK and can modulate the activity of PK through binding 
(activation) or release (inhibition) of the effector binding site pocket. FBP can regulate 
the activity of three out of four mammalian PK isoenzymes, including R-PK, L-PK and 
PKM2, while the M1PK isoenzyme is constitutively in an active form. The activity of 
M1-PK can be inhibited by binding of phenylalanine or proline amino acid at the amino 
acid binding site pocket (92,93). 
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Figure 1.6: Illustration of pyruvate kinase structure and binding sites. A) X-ray crystallographic structure 
of pyruvate kinase monomer complex (PK-FBP-OX-Mg complex). PK monomer consists of N domain 
(blue colour), A domain (yellow colour), B domain (red colour) and C domain (pink colour). B) 
Tetrameric structure of PK and the binding sites. (i) Represents the active site which has bound with 
oxalate, ATP, K and Mg. (ii) Represents the effector sit that hosts FBP, and (iii) represents the amino acid 
binding site which has bound proline. The dashed lines represent the interaction sites between monomers 
(A-A and C-C domains interaction), Morgan HP et al. 2014  (89). 
 
1.10.2:   Regulation of pyruvate kinase M2: 
PKM2 occurs either in a highly active tetrameric or nearly inactive dimeric isoform. 
PKM2 is mainly in the tetrameric form in normal cells, whereas the dimeric form is 
usually found in tumour cells (81). The ratio of tetrameric to dimeric isoform of PKM2 is 
not a fixed value and depends greatly upon the level of metabolic intermediates, 
especially the intracellular concentration of FBP. FBP is an allosteric activator of PKM2 
and upon elevation induces re-association of the highly active tetrameric form from the 
combination of two molecules of an inactive dimeric form of PKM2 (21,81). As a result 
of tetramerisation of PKM2, energy is produced by the conversion of glucose to lactate, 
until the level of FBP decreases to a minimal level. The dimeric form of PKM2 is then 
re-produced from the dissociation of the tetrameric form, and the levels of metabolic 
intermediates increase and become available for synthesis of macromolecules for new 
cells. These processes continue until the level of FBP increases to a sufficient point to 
begin another cycle of tetramerisation (Figure 1.6) (21,81).  
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Similar to FBP, the amino acid serine has been also identified as an allosteric activator of 
PKM2. Serine can activate PKM2 in a similar manner to PFB but the interaction occurs 
independently and in a different location of the FPB active pocket. Serine biosynthesis is 
an anabolic pathway required for cell proliferation and growth (93). In the presence of 
sufficient amounts of serine, PKM2 is completely active and facilitates the utilization of 
maximum amount of glucose through glycolysis, whereas, when the intracellular 
Figure 1.7: Regulation of pyruvate kinase type M2 in glycolysis pathway by fructose 1.6- biphosphates 
(77). (HK: hexokinase, PFK: 6-phosphofructo 1-kinase, GAPDH: glyceraldehyde 3-dehydrogenase, LDH: 
lactate dehydrogenase, PPP: pentose-P-pathway). Adapted from Mazurek S et al. 2011 (77). 
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concentration of serine decreases, the activity of PKM2 is rapidly decreased and directs 
glycolysis toward the anabolic pathway for biosynthesis of serine to compensate the low 
concentration of serine (57). Additionally, decreasing PKM2 activity alters the glycolytic 
pathway from the production of lactate in the cytosol to the production of citrate in the 
mitochondria and this switch provides a sufficient amount of energy required for rapid 
cell proliferation. Interestingly, succinyl-amino-imidazole-carboxamide-ribose-5-
phosphate (SAICAR), an intermediate of the de-novo purine nucleotide synthesis 
pathway, has also emerged to regulate PKM2 activity. The binding pocket of SAICAR is 
close to the binding site of FBP on PKM2 (94). Upon starvation of glucose, cellular 
concentration of SAICAR has been observed to elevate in an oscillatory manner. 
Increased concentration of SAICAR induces PKM2 activity, elevates rate of glucose and 
glutamine utilization and also promotes cancer cell proliferation and survival.      
The tetrameric to dimeric ratio of PKM2 is also regulated by post translational 
modifications (PTM) as well as interaction with oncoproteins which facilitates 
dissociation of the tetrameric to dimeric form of PKM2. PTM in the A-domain of PKM2 
plays a crucial role in dissociation of subunits and reduction of PKM2 activity. 
Fibroblast growth factor receptor 1 (FGFR1) directly phosphorylates PKM2 at tyrosine 
105 (Y 105) and inhibits the formation of tetrameric form of PKM2 by disruption of the 
allosteric activator and FBP binding (Figure 1.7). Animal studies have shown that the 
phosphorylated tyrosine 105 suppress PKM2 activity and promotes tumorigenesis 
(53,57,95). Acetylation is another common modification used in the regulation of various 
cellular processes, including metabolic enzymes. Acetylation of PKM2 at lysine 305 
occurs under high concentrations of glucose and suppresses PKM2 activity to direct 
glycolysis toward the anabolic pathway and tumorigenicity. PKM2 also contributes to 
the elimination of excess amounts of intracellular reactive oxygen species (ROS) (96). 
An elevation of intracellular concentration of ROS can damage cell components and 
compromise viability of the cell. Therefore, control of ROS level is very important for 
proliferation and survival of the cells. Research findings have shown that the sharp 
elevation in cellular ROS, suppresses PKM2 activity through oxidation of PKM2 at 
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cysteine 358, which then drives glucose flux toward the pentose phosphate pathway and 
induce tumorigenesis (96) (Figure 1.7).    
 
Figure 1.8: Illustration of glycolytic regulation of pyruvate kinase M2 activity. PKM2 activity is not only 
regulated by glycolytic intermediates, but also various factors stimulate different post translational 
modifications of PKM2. Adapted from Iqbal et al. 2014 (53). 
 
 
In addition to the PTM, numerous viral oncoproteins can control oscillation between 
dimeric to tetrameric PKM2 in tumour cells. Direct interaction of PKM2 with different 
oncoproteins, such as human papilloma virus type 16 (HPV-16 E7) and tyrosine kinase 
pp60v-src, induces dimerization of PKM2 by different mechanisms. The human 
papilloma virus type 16 produces the E7 oncoprotein that binds directly to PKM2 and the 
tyrosine kinase pp60v-src phosphorylates PKM2, as a result, the tetrameric form of 
PKM2 dissociates to the dimer and promotes tumorigenesis (21,81,84). 
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1.10.3: Non-metabolic function of PKM2 (or nuclear function of PKM2): 
In addition to its role in cancer metabolism, PKM2 has been shown to have a nuclear 
function that further contributes to tumorigenesis. PKM2 is translocated into the nucleus 
as a response to apoptotic and interleukin-3 signals (51,97,98). Nuclear PKM2 interacts 
with Oct-4 through the C-terminal residues (residues 307-531) and enhancing Oct-4 
mediated transactivation (99). Oct-4 is a crucial protein for the maintenance of 
pluripotent embryonic stem cells. Nuclear PKM2 has also been shown to act as an HIF-1 
co-activator. Luo et al. observed that nuclear PKM2 interacts with HIF-1α in a 
prolylhydroxylase-3 (PHD-3) dependent manner and increases transcription activity of 
HIF-1α, resulting in an increase in expression of its target genes such as GLUT-1, LDH 
and PKM2 (53,100).  Recently, Jumonji C domain-containing dioxygenase (JMJD5) has 
been identified to bind directly to PKM2, causing disruption of PKM2 tetramerisation 
and promoting translocation into the nucleus. Moreover, nuclear JMJD5-PKM2 is a 
heterodimeric protein and promotes HIF-1α mediated transactivation activity for 
metabolic reprogramming (101).        
Yang et al. demonstrated that PKM2 (not M1-PK) can translocate into the nucleus under 
the activation of epidermal growth factor receptor (EGFR) in human cancer cells. The 
EGFR signaling induces activation of Src tyrosine kinase and phosphorylates β-catenin 
at Y333. PKM2 then binds to phosphorylated tyrosine peptides of β-catenin via K433, 
leading to the recruitment of both proteins to the cyclin D1 (CCND1) and MYC 
promoters and transactivation of both genes (102). PKM2- β-catenin complex enhances 
expression of c-MYC and cyclin D1 through dissociation of histone deacetylase 3 
(HDAC3) from cyclin D1 promoter. PKM2 dependent β-catenin transactivation is 
involved in EGFR and promotes tumorigenesis. PKM2 also up-regulates expression of c-
MYC, which in turn up-regulates the transcription of hnRNPs (heterogeneous nuclear 
ribonucleoproteins) that promotes the alternative splicing of PKM2 over M1-PK 
(53,103). Moreover, in response to EGFR signaling, PKM2 phosphorylates histone H3 at 
threonine 11 position, resulting in dissociation of HDAC3 from CCND1 and c-MYC 
promoter and acetylation of histone H3 at K9. Upon EGF stimulation, PKM2, as a 
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protein kinase, also involves in histone modification to control CCND1 and c-Myc 
expression in tumour cells (104) (Figure 1.8). Furthermore, the levels of nuclear PKM2 
were found to be correlated with histone H3 phosphorylated threonine 11 status in brain 
tumour and reduced patient survival.   
However, the mechanism of switching PKM2 function between protein kinase and 
pyruvate kinase remained controversial. A recent study found that the dimeric form of 
PKM2 is a protein kinase and regulates gene transcription. Gao et al. also demonstrated 
that the dimeric from of PKM2 is an active protein kinase, while the tetrameric form is 
an active pyruvate kinase. They also showed that nuclear PKM2 is in a dimeric form and 
the expression of mutant PKM2 promotes cell proliferation, indicating that protein 
kinase activity is essential for cell proliferation (86). This study found a crucial link 
between metabolic transformation and gene expression.     
Another study reported that the acetylation at K433 promotes PKM2 to act as a protein 
kinase rather than pyruvate kinase and induces accumulation of PKM2 in the nucleus. Lv 
et al. observed that PKM2 is acetylated at K433, under mitogenic or oncogenic 
stimulation, by p300 acetyltransferase. Consequently, acetylated PKM2 interferes with 
FBP binding, prevents PKM2 activation, promotes protein kinase activity and 
accumulation of PKM2 in nuclear. Moreover, acetylated PKM2 promotes tumour cell 
proliferation and progression through phosphorylation of STAT-3 at Y705 and histone-3 
(57,105) (Figure 1.8). 
In summary, PKM2 translocates into the nucleus under certain circumstance, 
accumulating in the dimeric form and functioning as a protein kinase to promote tumour 
cell proliferation and progression.  
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Figure 1.9: Illustration of non-metabolic function of PKM2. The scheme shows the mechanism of nuclear 
translocation and functions of PKM2. Nuclear PKM2 acts as a protein kinase or transcriptional coactivator 
to promote tumour cell proliferation and growth. Adapted from Iqbal et al. 2014 (53). 
 
1.10.4:  PKM2 as a target therapy:  
Cell division and proliferation require high amounts of glycolytic intermediates, such as 
nucleotides, lipids and amino acids, on one side, and generation of energy on the other. 
Therefore, blocking of either energy production or production of glycolytic intermediates 
may lead to inhibition of cell proliferation (83,106). PKM2 plays an important role in 
tumour progression and could be a potential therapeutic target for inhibition of tumour 
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cell proliferation and growth. Fixation of PKM2 in either form may lead to inhibition of 
tumour progression (77,83,106). In the presence of high amount of glucose, fixation of 
PKM2 in dimeric form leads to inhibition of energy production and tumour progression. 
However, in the presence of glutamine, accumulation glycolytic intermediates induce 
cell proliferation, therefore, fixation of PKM2 in tetrameric form can lead to inhibition of 
cell proliferation due to the block of production of glycolytic intermediates which 
required for cell division (77,83,106). Various studies have demonstrated that interfering 
PKM2 expression by short hairpin RNA (shRNA) and microRNA (miRNA) can induce 
apoptosis, reduce glycolysis  activity and tumorigenicity (83,107,108), and also enhance 
the sensitivity of tumour toward the treatment (83,109,110).    
In the past several years much work has been done to identify PKM2 inhibitors. The 
active derivate of leflunomide (ARAVA), also known as A77 1726, was a first 
compound identified as a PKM2 inhibitor. ARAVA is well known in rheumatology as a 
pyrimidine synthesis inhibitor. ARAVA was firstly described as a dihydroorotate 
dehydrogenase inhibitor which is a key enzyme in pyrimidine denovo synthesis. 
However, ARAVA can also inhibit PKM2, resulting in inhibition of glycolytic flux rate 
and cell proliferation (111).   
Recently, Vander Heiden et al. (2010) screened more than 100,000 small organic 
molecules to identify a suitable inhibitor for PKM2. In the presence of 125 µM fructose 
1, 6 biphosphate, approximately 5,500 compounds inhibited 50% of PKM2 activity and 
the lowest IC50 compound called compound 3 was used in cell culture. After 36 hours of 
interaction between compound 3 (250µM) and the H1299 cell line, cell death was 
increased, at least a part of cytotoxicity was due to the PKM2 inhibition by compound 3 
(78). Shikonin and its analogues are another class of PKM2 inhibitor. Shikonin is a 
Chinese herbal medicine and has well-known anti-inflammatory, anti-bacterial and anti-
tumour effects (Figure 1.9). Shikonin inhibited tumour cell glycolysis with an 
approximately 100 times lower IC50 than compound 3, and had selectivity toward PKM2 
over the other PK isoenzymes (106,112).  
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In contrast to the inhibitors, PKM2 activators induce intense glycolysis in tumour by 
tetramerisation of PKM2 and reduction of glycolytic intermediates. Several studies have 
shown that restoring PKM2 activity may revert the metabolic state of tumours towards 
that in normal cells. PKM2 activator can reduce production of glycolytic intermediates 
and inhibit translocation of the dimeric form into the nucleus, causing inhibition of 
cancer cell proliferation and progression (52,113). Therefore, discovery and development 
of small molecule activator could be important for cancer treatment (Figure 1.9).  
The first class of small molecule activators were identified by high throughput screening 
(HTS) of 300,000 compounds of the NIH molecular library. Two main classes of 
chemical compounds were identified. The two chemical compounds were substituted 
thieno [3, 2-b] pyrrolo [3, 2-d] pyridazinone and substituted N.N’-diarylsulfonamide with 
an AC50 of 63nM and the maximum PKM2 activation of 122%. The pyridazinone 
molecule initially did not require significant optimization as a small molecule activator 
of PKM2, but solubility was low (< 0.2 µg/ml). After several substitutions and 
optimization of the molecular probe, the solubility was significantly increased (29.6 
µg/ml), but the activity slightly decreased (AC50 =92nM). The PKM2 activator identified 
from this effort known as TEPP-46. On the other hand, the substituted N.N’-
diarylsulfonamide compound developed and optimized to the several molecular 
activators, however, the only molecular activator with an identity of DASA-58 was 
shown the high selectivity and potency toward activation of PKM2. DASA-58 has not 
only improved potency (38 nM) but also significantly increased its aqueous solubility 
(51.2 µg/ml). The two small molecular activators were tested against all PK isoenzymes 
and found to have a specific activity toward PKM2 over the other isoenzymes (113–
115).   
Following the identification of TEPP-46 and DASA-58, further studies of the 
characteristics of these two molecules as PKM2 activator were done. Interestingly, the 
activators efficiently induced tetramerisation of PKM2 in cell culture. Initially, it was 
suggested that the activators would interact with the allosteric activator binding site, but 
structure analysis showed the PKM2 tetramer in a complex with two molecular 
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activators and four FBP molecules. Interestingly, the molecular activators bind to the 
pocket on the PKM2 subunit interface (binding on the C-C` interface of two opposing 
dimers) away from the FBP binding site, so that the interaction enhanced association of 
PKM2 subunits and stabilized tetrameric structure. Furthermore, TEPP-46 was showed 
to impair tumour growth in xenograft model in a dose of 50 mg/kg twice a day. (113). 
The same research group has developed a third class of PKM2 activator from 2-oxo-N-
aryl-tertrahydroquinoline-6-sulfonanide. The activator was identified from the previous 
HTS and initially had an AC50 of 790nM. Several derivatives were developed but only 
one of them showed to have a low nanomolar potency (AC50 = 90 nM), selective over the 
other PK isoforms and good cellular permeability (116). 
Another research group identified nine small PKM2 activators by screening 13,000,000 
small molecules in silico against the PKM2 structure. After several modification a more 
promising PKM2 activator has developed. The PKM2 activator is derived from 5-((2,3-
dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)-2-methyl-1-(methylsulfonyl) indoline 
scaffold, with low nanomolar potency (AC50 =17 nM), selectivity over the other PKM2 
isoenzymes, good cellular permeability and liver microsome stability (117). 
In addition, two further PKM2 activators were identified from two HTS of small 
molecules. The first PKM2 activator was based on the sulphonamide scaffold and the 
lead compound was modified and synthesised several derivatives, the AC50 of most 
promising one was lower than 14 nM (118). The other HTS has identified 
benzodiazolopyrimidinone as a lead compound with AC50 of 3.5 µM and the maximum 
activity of 148%. The lead compound was modified by using structure based approach, 
as a result PKM2 activator was synthesised with an AC50 of 86 nM (119). Moreover, the 
x-ray crystallography study showed that the binding site location of these two molecular 
activators were similar binding site location of DASA-58 on PKM2 enzyme (118,119). 
Finally, another PKM2 activator was recently identified by using fragment based 
screening. The lead compound was pyrrolo-carboxy amide fragment with AC50 of 36 
µM. The initial compound was modified and synthesised a series of compounds with an 
AC50 of lower than 11 nM. The molecular activators identified from this effort were 
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examined both in vitor and in vivo. In the absence of serine, the molecular activators 
inhibited cell proliferation in a lung cancer cell line and impeded tumour growth in an 
A549 xenograft tumour model (120).  
 
 
 
Figure 1.10: Structures of the most popular PKM2 inhibitors and activators. A) Chemical structure of the 
most common PKM2 inhibitors. B) Chemical structures, half-maximum activating concentrations and 
maximum activation vales of most common PKM2 activators. 
 
 
1.11:   Lactate dehydrogenase (LDH): 
Lactate dehydrogenase (LDH, EC 1.1.1.27) mediates inter-conversion of pyruvate and 
lactate using nicotinamide adenine dinucleotide (NAD+) as a cofactor (Figure 1.10A). 
Lactate dehydrogenases (LDHs) are a family of 2-hydroxyacid oxidoreductases that are 
found in almost all animal tissues, as well as in microorganisms, bacteria and plants 
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(121). Lactate dehydrogenase is a homo- and hetero- tetrameric (144 kDa) enzyme 
comprised of two major subunits A and B (36 kDa), resulting in five isoenzymes that 
catalyse the reversible conversion of pyruvate and lactate (Figure 1.10). LDHA (also 
known as LDH-5, LDH-M or A4) is encoded by the ldh-a gene and predominates in 
skeletal muscle and liver, while, LDHB (also known as LDH-1, LDH-H or B4) is 
encoded by the ldh-b gene and is mainly found in heart and brain (Figure 1.10) 
(49,121,122). LDH-C is another type of lactate dehydrogenase, which is mainly 
composed of X-subunits. LDH-C is a less common type of lactate dehydrogenase, which 
is encoded by the ldh-c gene. LDH-C is found in human spermatozoa and has been 
proposed to play a role in male fertility (121,123). The genetic loci of the three LDH 
isoforms show about 75% sequence identity, indicating extensive conservation in amino 
acid composition of the LDH subunits (121).  
LDH isoenzymes have different electrophoretic mobility depending on the availability of 
the B subunit. Therefore, LDHB is the faster and LDHA the slowest moving LDH 
isoenzyme. LDHA and LDHB show different kinetic properties, of which LDHA needs a 
higher concentration of pyruvate substrate to reach maximum activity. The Km value for 
pyruvate is about 158 and 58 µM for both LDHA and LDHB, respectively. Additionally, 
at a concentration of pyruvate substrate required for optimum activity of LDHA, the 
LDHB isoenzyme is inhibited with Ki for pyruvate substrate of 3900 and 770 µM for 
LDHA and LDHB, respectively (50,121,124). Accordingly, a high Km value for LDHA 
indicates a low affinity for pyruvate substrate and is suited to the tissues frequently 
exposed to oxygen limitation; however, a low Km value of LDHB indicates a high 
affinity for pyruvate and is more suited to the aerobic metabolism. This so called 
“aerobic anaerobic theory” was hypothesized in 1975 by Kaplan. However, later 
research showed that human erythrocytes, which lack mitochondria, primarily express 
LDHB. LDH isoenzymes also have a different distribution pattern between individual 
organs of the same type in different animal species, which was not clearly explained by 
the Kaplan theory (50,121).  
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Figure 1.11: Illustration of lactate dehydrogenase functions and gene expression. (A) LDH catalyses inter-
conversion of pyruvate and lactate with regeneration of NAD+. (B) LDH is a homo- and hetero-tetrameric 
enzyme consisting of A and/or B subunits, resulting in five different isoenzymes. Adapted from Doherty 
JR et al. 2013 (49).    
 
Figure 1.12: Human Lactate dehydrogenase A, LDHA isoform found in skeletal muscle. 
 
Despite the different kinetic properties of LDHA and LDHB in cytosol, both catalyse the 
inter-conversion of pyruvate to lactate. In most tissues, LDH isoenzyme activity depends 
on the glycolytic flux and is always close to equilibrium. The LDH equilibrium reaction 
may significantly deviate when extensive change occurs in cell glycolytic flux and 
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energy metabolism. This is the only situation where the different physiological roles of 
LDH isoenzymes have been observed. For instance, during exercise or overworking of 
muscle, glucose uptake and glycolytic flux significantly increase. In this situation LDHA 
isoenzyme is highly activated to overcome the high glycolytic flux and energy demand 
by conversion of pyruvate to lactate with regeneration of NAD+ to sustain glycolysis 
(50). A similar situation has been detected in tumour, overexpression of LDHA in cancer 
is required for progression and growth of tumour (54). In contrast to muscle and cancer 
cells, LDHB is predominately expressed in brain cells (50).   
LDH is mainly detected in cytosol and involved in cytosolic glycolysis. LDH is also 
detected in peroxisomes, mitochondria and nuclei with performing different biological 
functions.  
LDHA predominates in peroxisomes and is mainly found in the matrix (125,126). The 
main function of peroxisomes is shortening of long chain fatty acids that cannot be 
handled by mitochondria. The long chain fatty acid is degraded to butyryl-CoA by β-
oxidation, then transfer from peroxisomes into mitochondria. Research findings showed 
that mitochondrial respiratory chain cannot re-oxidize NADH which is generated from 
peroxisomes β-oxidation, however, in the presence of pyruvate, LDHA can reconvert 
NADH to NAD+. Lactate and pyruvate exchange is possibly done through 
monocarboxylate transporter (MCT) complex display on the peroxisome membrane 
(125,126).       
In mitochondria, lactate derived from glycolysis can be reused as fuel or as a precursor 
of gluconeogenesis (50,127,128). The re-oxidation of lactate occurs in mitochondria of 
the original cells, in adjacent cells or in distant cells, after release of lactate into the 
extracellular medium. For instance, the heart takes up and re-oxidates lactate produced 
during muscle overworking, whilst, that originating in astrocytes is an important energy 
substrate for adjacent neurons (50). MCT proteins facilitate the transfer of released 
lactate across the cell membranes. Moreover, mitochondria can take up lactate through 
MCT proteins and oxidized to pyruvate by mitochondrial LDH (127,128). In 
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mitochondria, PDH quickly metabolizes and decreases pyruvate concentration, favoring 
the oxidation of lactate by LDH (50).     
LDH isoenzyme activity varies with tissue types. LDHA is predominantly expressed in 
the liver mitochondria; however, myocardium mitochondria was characterized by 
expression of LDHB (129). This difference in LDH isoenzymes was due to the 
predominant pathway in different organs, for instance, lactate is taken by liver more 
likely to undergo gluconeogenesis, whereas in the myocardium is more likely to undergo 
oxidation. Despite these differences, it is thought that the redox state of the mitochondria 
dictates the ability of the tissues to oxidize lactate, not the particular LDH isoform (129). 
Mitochondrial LDH is based in the intermembrane space, matrix fraction and inserted 
also into the inner membrane (Figure 1.12) (129). The mitochondrial and cytosolic LDH 
has different kinetic properties.  
Besides the crucial role in cellular energy metabolism, LDHA shows additional functions 
in nucleus. The subunit of LDH-A binds to single stranded DNA (ssDNA) and functions 
similarly to the other ssDNA-binding proteins, which are involved in nuclear enzymatic 
activities for DNA transcription and/ or replication (130). This observation was 
confirmed by recent research that identified the location of nuclear LDH in a 
transcriptional active region of chromosomes. RNA in polytenic chromosomes was also 
stimulated when LDHA enzyme was injected into the Chironomus Salivary gland cells 
(50). Recently, Zhang and co-work explained the role of nuclear LDH in DNA 
transcription and showed that nuclear LDH is one of the main components of the 
transcriptional complex of histone 2B gene (H2B) (131). LDHA subunit, in this 
transcriptional complex, is in association with GAPDH and through the coordination of 
the activity of these two enzymes, maintain the ratio of NAD/NADH, which is required 
for optimum expression of H2B. 
In contrast to cytoplasmic LDH, in which the minimum functional unit was shown to be 
a dimer, the nuclear LDH is mainly a monomer. The supramolecular structure formed 
with GAPDH or with other components of the transcriptional complex presumably 
maintains catalytic activity of nuclear LDH. In vitro studies have shown that the 
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monomers of LDH and GAPDH can form catalytically active complexes in the nucleus 
(50). Due to being widely distributed in cell nuclei, the LDHA subunit could be involved 
in regulation of gene transcription and participates in cell survival pathways. 
 
Figure 1.13: Illustration of mitochondrial lactate dehydrogenase functions and localization. Adapted from 
Brooks G et al. 1999 (129). 
 
 
1.11.1:   Lactate dehydrogenase A structure: 
Crystallography of LDHA shows that this enzyme is usually in a tetrameric form with an 
arrangement of 2-2-2 symmetric structure. Each subunit of LDHA consists of 
approximately 330 amino acids with bilobal structure, and also each monomer of LDHA 
independently has full biological functions (124,132). The study of crystal structure of 
LDHA have identified two domains, the larger domain adopts Ross-mann fold and is 
located in 20-162 and 248-266 residues regions, which provides a binding site for 
NADH cofactor. The smaller domain is a substrate binding pocket, which is located at 
the interface with the adjoining mixed α/β domain (50,121). The mechanism of enzyme 
substrate reaction is started by interaction of NADH cofactor with LDHA in a His195, 
which prepares the binding site for pyruvate binding. Subsequently, substrate gains 
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access to the binding site cavity through the interaction with Arg109 and His195. The 
main functions of His195 are proton exchanger and to facilitate the orientation of 
pyruvate for its interaction with NADH. Arg109 is a polarized carbonyl group of 
pyruvate substrate by forming H-bond, followed by closure of the active site loop 
(restudies 99-110). As a consequence, the active site loop facilitates transformation of 
hydride and prevent the access of solvent (50,121,124,132). 
The crystallography study also shows that the active site of human LDHA is located in a 
deep position within the enzyme and accessibility to this cavity is very narrow. In normal 
condition, both pyruvate substrate and NADH cofactor are hosted by active site cavity. 
Furthermore, the LDHA active site loop is very polar and rich in cation residue 
particularly arginine and this characteristic explained why the inhibitors discovered so 
far contains carboxylate groups (50,122) (figure 1.13).  
 
 
 
 
 
 
Figure 1.14: The LDHA active site structure and catalytic reaction. The LDH-A active side loop 
naturally hosts both pyruvate and NADH. The picture illustrates the catalytic reaction and hydrogen bond 
between pyruvate substrate, NADH cofactor with active site loop and the most important amino acids in 
the active site cavity. 
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1.11.2:   Metabolic symbiosis and lactate acidosis: 
The first step in glucose metabolism is the generation of two molecules of pyruvate with 
reduction of NAD+ from one molecule of glucose, a similar process in both normal and 
cancer cells. In the normal cell, pyruvate enters into the mitochondria and TCA cycle 
after decarboxylation to acetyl-CoA and NADH is re-oxidized by highly active 
mitochondrial respiratory chain. However, in the cancer cell, LDHA converts pyruvate to 
lactate with regeneration of NAD+ to sustain energy production by glycolysis (51,52). 
Oxidation of one mole of glucose through aerobic glycolysis generates two moles of 
lactate and two of ATP. In contrast to the normal cell, which relies on the catabolic 
pathway to generate maximum energy through full oxidation of glucose to CO2 and H2O. 
The tumour cell is characterized by anabolic pathway aiming at obtaining 
macromolecules for building new cells. PKM2 plays a crucial role in the regulation of 
glucose metabolism and the balance between energy generation and the production 
glycolytic intermediates (51,53,57,59). 
Catabolic metabolism pathway is not only specific to the tumour cells, but also observed 
in some circumstance of normal cells especially during requirement of rapid cell 
division, for instance, during development of embryonic cells, wound healing or during 
immune response activation (50). In contrast to the past thought, normal proliferating 
cells and a large fraction of cancer cells depend mainly on glycolysis for production of 
new macromolecules, and gain a significant fraction of their energy (ATP) from 
mitochondrial oxidative phosphorylation. Moreover, glycolytic energy becomes one of 
the major energy source when the hypoxic microenvironment prevent mitochondria 
functions, such as in hypo-vascularized tumour region or in the healing wound bed (50). 
The increased rate of lactate production is regulated by the activity of LDHA. High 
levels of lactate production contribute to the development of extracellular acidosis, 
which strongly participates in tumour invasion, migration, angiogenesis, metastasis and 
resistance to the chemotherapy (50,133). Lactate is not only the end product of aerobic 
glycolysis, but can also be used as a metabolic fuel by oxidative cancer cells. This 
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phenomenon resembles a process that have been described for brain and skeletal muscle 
that involve what are known as cell-cell and intracellular lactate shuttles (50,134).  
Cancer cells can be categorized into two types: aerobic tumour cells, which are located 
near to the blood vessels and hypoxic tumour cells, which are further away from vascular 
network (Figure 14). The symbiosis between hypoxic tumour cells, which produce 
lactate, and aerobic tumour cells, which consume lactate, was observed. Generally, 
hypoxic tumour cells actively uptake glucose through GLUT1 and glucose then converts 
to pyruvate through series glycolytic enzymes activity. Finally, pyruvate is converted to 
lactate by the action of LDHA activity (135,136). Hypoxic tumour cells generate two 
moles of lactate and two ATP from glycolysis of one mole of glucose. Lactate is then 
extruded from the hypoxic tumour cell into the extracellular milieu by MCT4. Lactate 
derived from hypoxic tumour cells can be used as a major source of metabolic fuel in 
well oxygenated tumour cells. Aerobic tumour cells then take up lactate through MCT1 
and use as a main source of energy generation. Aerobic tumour cells convert lactate to 
pyruvate through the action of LDHB activity and pyruvate then enter into the TCA 
cycle in mitochondria and generate energy through mitochondrial oxidation 
phosphorylation. As a result, aerobic tumour cells generate 18 mole ATP from the re-use 
of one mole of lactate and spare glucose, which can then diffuse longer distance into the 
tumour to feed glycolytic cells (50,134–136). MCT1 and MCT4 play a key role in this 
process. The details of metabolic symbiosis between hypoxic and aerobic tumour cells 
are described in Figure 1.14.   
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Figure 1.15: Illustration of metabolic symbiosis between aerobic and hypoxic tumour regions. Hypoxic 
tumour cells utilize high amount of glucose and produce lactate, however, aerobic tumour cells can use 
lactate as an energy source for bioactivity and spares the glucose for hypoxic tumour cells. Adapted from 
Semenza GL et al. 2008 (136).   
 
 
1.11.3:   Inhibition of Lactate dehydrogenase A as a target therapy: 
Up-regulation of LDHA has been observed in many types of cancer and has a crucial 
role in tumour progression (49,54,133). Targeting LDHA is commonly considered as a 
potential therapeutic target for cancer treatment. Previous research findings have proven 
that the inhibition of LDHA by using siRNA or small molecule inhibitors, increase the 
rate of oxygen consumption, reduce glucose uptake and lactate production and also 
attenuate tumour growth and progression (49,54,72,137). However, the most currently 
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available LDHA inhibitors have low potency with high doses are required and 
potentially have high level of systemic toxicity (Figure 1.15). 
Oxamate and gossypol are two chemical compounds that have long been known as 
LDHA inhibitors. Oxamate is an analogue of pyruvate substrate and a competitive 
inhibitor of LDHA. Oxamate is not toxic in healthy animals up to 3 g/kg, but has poor 
selectivity and potency toward LDHA (50,122,138). Oxamate also shows very low cell 
membrane permeability, therefore, the inhibition of cancer cell glycolysis requires high 
concentrations of oxamate in vitro and has little effect in vivo. Interestingly, oxamate is 
still considered to be one of the most important LDHA reference inhibitors. Several 
oxamate derivatives later have been synthesised aiming to improve selectivity and 
potency of LDHA inhibition, but none of them shows anticancer activity effect (50).    
Gossypol is a natural poly-phenol di-aldehyde derivative found in cotton seeds and can 
inhibit LDHA through competition with NADH cofactor. Gossypol is not specific to 
LDHA but can interact with other cell components, interrupting some biological activity 
and causing nonspecific toxicity (50). In contrast to oxamate, gossypol shows an 
inhibitory effect at low concentrations (micro-molar) in vitro. Several analogues of 
gossypol have been synthesised. The 8-deoxyhemigossylic acid derivatives, which were 
originally synthesised as anti-malarial agents, have been found to be the most selective 
LDHA inhibitors. Among these compounds, 2,3-dihydroxynaphtalen-1-carboxylic acid 
(which is known as FX11) has a high selectivity and potency toward LDHA inhibition 
(49,50,122). Previous research findings showed that the FX11 can inhibit cancer cell 
proliferation in vitro and impede tumour growth in xenografts model (54,72,122). Ann 
Le et al. (2010) found that the FX11 can enhance oxygen consumption, reduce ATP 
generation and lactate production, induce oxidation stress and finally cancer cell death 
(72). On the basis of in vitro and in vivo inhibitory effect and availability in market, I 
chose FX11 in combination with PKM2 activator as a potential therapeutic approach in 
pancreatic cancer.  
Galloflavin, another LDH inhibitor was found by a structure-based virtual screening 
strategy. Galloflavin is a derivate of garlic acid that can inhibit both LDHA and LHDB 
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(139). The inhibitory effect of Galloflavin was tested in several cancer cell lines and the 
results showed that Galloflavin inhibit LDH with an IC50 of 90-150µM and also reduce 
lactate production. Moreover, Galloflavin has good cellular permeability with little 
toxicity to mitochondrial respiration or the normal cell metabolism. Apoptosis is the 
main reason for cell death in most cancer cell lines treated with Galloflavin; however, in 
some other cell lines, Galloflavin induces oxidative stress due to an increase of ROS 
production and finally cell death (50,139,140).   
Another chemical compound that shows moderate potency toward LDHA inhibition is 2-
thio-6-oxo-1,6-dihydropyrimidine, which was identified by HTS of library small 
molecules (141). Later, several modifications were made to the molecular structure of 
this compound to improve its selectivity and potency toward LDHA inhibition; however, 
none of the modified compounds were shown to decrease lactate production in cell 
culture. Recently, the discovery of quinolone 3-sulfonamides as a potent LDHA inhibitor 
has been announced. Despite its high potency (nano-molar) and 10-80 fold selectivity 
over the LDHB, these chemical compounds are not acceptable for in vivo use because of 
their low clearance. One of the other limitations of these chemical compounds is a direct 
effect of mitochondrial function rather than inhibition of LDHA at doses of 10µM and 
above (48). 
Ex-novo design is another strategy that has been used to design a potent LDHA 
inhibitors. A new LDHA inhibitor was synthesised by adding hydroxyl (-OH) and 
carboxyl (COOH) into an N-hydroxyindole (NHI) scaffold (122). A number of 
derivatives were synthesised and tested in vitro. NHI-1 derivative was found to have the 
most promising anticancer activity effect. Later, a methyl ester of NHI-1 was designed, 
which showed a better cellular permeability and inhibited 80% of lactate production in a 
concentration of 200µM (142). Subsequently there were no further experiments done on 
these compounds. 
Fragment based lead generation (FBLG) is another strategy that has been used to design 
potent LDHA inhibitors. This method is based on screening of chemical compounds to 
identify small chemical fragments, which may bind weakly to the biological target. This 
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preliminary test was done with the aid of NMR spectroscopy and/or surface Plasmon 
resonance. The identified chemical fragments were then grown or combined to generate 
compounds with high selectivity and potency. Moorhouse et al. (2011) was the first to 
use this strategy for finding an LDHA inhibitor (143). More recently, a research team at 
AstraZeneca has found some high potent LDHA inhibitors by using this strategy. The 
most potent compound was shown to have an IC50 of lower than 0.27µM in an enzymatic 
activity assay but there was no any inhibitory effect in cell culture assay. This inactivity 
in cell culture probably related to the low cellular permeability. Moreover, the dimethyl 
ester derivate showed less potency toward LDHA inhibition compared to the original 
molecule, but it could inhibit production of lactate in cell culture with an IC50 of 4.8µM 
(144). Similarly, a research team at ARIAD Pharmaceuticals used this approach to 
identify LDHA inhibitors. One of the most promising compounds they reported had an 
IC50 of 13µM of enzymatic activity assay, and was able to decrease lactate production in 
cell culture at a concentration of 200µM (132). 
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Figure 1.16: Chemical structure of the most popular lactate dehydrogenase A inhibitors. (A) Oxamate.   
(B) FX-11, 2, 3-dihydroxynaphtalen-1-carboxylic acid. (C) Galloflavin, (D) 2-thio-6-oxo- 1, 6-
dihydropyrimidine derivative, (E) NHI-1, obtained from N-hydroxyindole. Inhibitors obtained through the 
fragment-based approach at (F) AstraZeneca and (G) ARIAD Laboratories. 
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1.12: Combination therapy:  
Although pancreatic cancer is very aggressive and is often resistant to chemotherapy, 
ongoing studies have aimed to develop better adjuvant, neoadjuvant and combination 
(two or more chemotherapy drugs) agents to improve outcomes. The combination of 
chemotherapy with glycolytic enzyme inhibitors or inhibition of two glycolytic enzymes 
together have recently been tried in experimental studies. Aberrant glucose metabolism 
is one of the main differences between cancer and normal cells; therefore, targeting 
glycolytic enzymes is considered a feasible strategy for inhibition of cancer cell 
proliferation and growth. Zhou et al. (2010) observed that combination of Taxol and 
Oxamate (LDHA inhibitor) overcame the resistance of therapy, increased the inhibitory 
effect and promoted cell apoptosis in breast cancer (145). Similarly, Zhao et al. (2011) 
found that combination of Trastuzumab with a glycolytic inhibitor, such as 2-deoxy 
glucose or oxamate, synergistically inhibits breast cancer cell proliferation and growth 
both in vitro and in vivo (146). In addition, Ann Le et al. (2010) found that the 
combination of FX11 (LDHA inhibitor) and FK866 (NAD+ synthesis inhibitor) blocks 
pancreatic cancer cell progression in cell culture and a xenograft model (72). 
Furthermore, Maftouh et al. (2014) reported that combination of Gemcitabine with 
LDHA inhibitor (N-hydroxyindole derivative, NHI) synergistically inhibit cell 
proliferation, growth and induce apoptosis in pancreatic cancer. Combination of 
Gemcitabine with LDHA inhibitor also inhibits pancreatic cancer cell invasion and 
migration (74). However, studies evaluating the use of both PKM2 and LDHA together 
have not been undertaken and is the focus of this study.  
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1.13: The cell cycle: 
The cell cycle involves the duplication of the cell contents and division of cells through a 
tightly controlled sequence of events that takes place inside the cell. The cell cycle is an 
essential mechanism for reproduction in all living organisms from unicellular to 
multicellular species. In the adult body cell division occurs and is necessary for replacing 
dead cells. The mechanism of cell cycle differs from one organism to another and it 
occurs at various times of the organism’s lifespan. However, certain characteristics of the 
cell cycle is common between all organisms (147). The most crucial and common feature 
of cell division between all organisms is the transfer of genetic information from the 
original cell to the next generation of cells. For production of two genetically equivalent 
daughter cells, first of all, chromosomal DNA must be faithfully duplicated into two 
identical and complete copies, and then the duplicated chromosomes should be precisely 
divided into two daughter cells (147,148).  
The cell cycle in eukaryotic cell is more complex and very tightly controlled. The cell 
cycle has four major phases, which are gap 1 phase (G1), S-phase, gap 2 phase (G2) and 
M phase. The first three phases (G1, S, and G2) together are known as interphase. The S 
and M phases are the most important phase of cell division. During the S phase 
duplication of DNA occurs and requires approximately 12 hours (147). However, the M 
phase takes much less time in the mammalian cell cycle and usually lasts about one hour. 
In this phase all the energy of the cell focuses on division into two identical daughter 
cells. In M phase both nucleus and cytoplasmic divisions occur. Distribution of 
duplicated chromosomes between two daughter nuclei occur during division of the 
nucleus (or mitosis), followed by division of the cytoplasm (or cytokinesis) and finally 
two identical daughter cells are produced (Figure 16), (147–149).   
Between the S and M phases, the cell cycle has two extra gap phases. These two phases 
provide extra time for the cell to grow, duplicate its proteins and organelles that are 
necessary for chromosome duplication and prepare the cell for division (Figure 1.16). G1 
phase is the first phase of interphase, in which the cell grows and biosynthesis of proteins 
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activated. Restriction point is the last step of G1 phase that controls the cell cycle 
mechanism. However, if the extracellular conditions are unfavourable the cell cycle is 
delayed and may enter into the resting state called G0. On the other hand, G2 is a second 
gap phase after S phase, in which cell growth continues and provides time to prepare 
suitable conditions to enter M phase (147,148). Any deregulation of the cell cycle or 
defect in G1 and G2 gap checkpoints lead to uncontrolled cell proliferation and this 
phenomenon is a characteristic feature of tumour development (150,151). 
 
Figure 1.17: The cell cycle mechanism. Adopted from Alberts B et al. 2008 (147). 
 
1.13.1:  Proliferation marker Ki67: 
Ki67 is a nonhistone nuclear protein that is strongly associated with cell proliferation and 
known as a cell proliferation marker. It was first identified by Gerdes in Kiel, Germany 
(after which was named “Ki”); after immunisation of mice with the Hodgkin’s 
lymphoma cell line L428 (67 comes from the clone number in the 96-well plate in which 
it was found). In human the Ki67 gene is detected on the long arm of chromosome 10 
(10q25) and consists of 15 exons and 14 introns (152,153). The expression of Ki67 
antigen varies during the different phases of cell cycle. The location of Ki67 in a cell 
depends on the cell cycle, during interphase Ki67 antigen is essentially found in the 
nucleolar cortex and in the dense fibrillar components of the nucleolus. However, during 
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mitosis Ki67 is located in the periphery of the condensed chromosomes (152). Overall 
research evidence demonstrated that the expression of Ki67 is low during G1 and early S 
phases, but reaches a maximum during mitosis. On the other hand, a sharp decrease in 
Ki67 expression is seen during anaphase and telophase, while Ki67 does not express in 
resting G0 phase (152–155). 
In spite of the information about location, sequence and nature of the Ki67 protein, little 
is known about its function. Ki67 protein is phosphorylated via serine and threonine and 
it plays a crucial role in cell proliferation. The inhibition of Ki67 leads to arrest of cell 
proliferation as shown either by microinjection of blocking antibodies or by inhibition of 
dephosphorylation (152,153).  
1.14:  CD8 tumour infiltrating lymphocytes (Cytotoxic T-lymphocytes): 
The host immune response is one of the most crucial weapons against tumour cells; 
however, the failure of this system to find and eliminate cancer cells may lead to tumour 
development (156,157). CD8-T cells (Cytotoxic T lymphocytes) are important 
components of tumour infiltrating lymphocytes that play a crucial role in the anti-tumour 
immune response. Immunohistochemistry studies have shown anti-tumour activity and 
favourable effects of tumour infiltrating CD8- lymphocytes on survival of patients with 
pancreatic, lung, ovarian, colorectal, renal and esophageal tumours (158). Furthermore, 
several studies have shown a direct correlation between increasing number of CD8+TIL 
and tumour cell apoptosis (158,159). These results clearly indicate that the tumour 
infiltrating CD8 lymphocytes inhibit tumour growth and induce apoptosis in cancer cells. 
The CD8 molecule is a heterodimer transmembrane glycoprotein with alpha and beta 
chains that covalently bonded together by disulfide linkage. Every chain has a single 
immunoglobulin like domain which is bound by a polypeptide segment to the cell 
membrane (160). CD8 cells work as a co-receptor for T-cell receptor and have a specific 
affinity for the major histocompatibility class I complex (MHC I) (160). CD8 stabilises 
the interaction between T-cell and cell presenting antigen through the MHC I. When 
CD8 cell and T-cell receptor attach to the MHC I molecule, the T-cell receptor becomes 
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more sensitive to antigen and approximately increase its sensitivity by 100-fold more 
than in the absence of CD8 (160). 
CD8+TILs can eliminate infected and tumour cells (target cells) through the 
perforin/granzyme and FasL/Fas pathways (161). In the former pathway, when a 
cytotoxic CD8-T cell attaches to the target cell, CD8 cells secrete a cytoplasmic granule 
that contains perforin and granzyme proteins. The perforin protein plays an important 
role in their cytotoxic activity by forming pores on the plasma membrane of the target 
cell to facilitate the delivery of granzyme which induces apoptosis (Figure 1.17), 
(161,162). In the FasL/Fas pathway, cytotoxic CD8-T cells attach to the target cells 
through Fas receptor on the target cells and induce apoptosis through activation of 
caspase cascade pathway (161,162).  
 
 
 
Figure 1.18: Schematic explanation of perforin / granzyme mechanism. Cytotoxic T cell (CD8 T cell) kills 
target cells (tumour or infected cells) by perforin/granzyme pathway. Adopted from OpenStax College 
2013 (163). 
 
 
1.15:  Hypothesis and Aim: 
Pancreatic cancer has one of the worst survival rates of the most common cancers 
worldwide and effective therapy of this disease is rather limited. Therefore, early 
diagnostic markers and new therapeutic option are urgently required to improve survival 
in this disease. PKM2 and LDHA are two crucial glycolytic enzymes which may play a 
role in initiation and progression of pancreatic cancer. In this thesis, I will focus on the 
study of the PKM2 and LDHA enzymes and propose the following hypothesis:   
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“Pyruvate Kinase M2 (PKM2) and Lactate Dehydrogenase A (LDHA) as Novel 
Diagnostic Markers and Therapeutic Targets for Pancreatic Ductal 
Adenocarcinoma (PDAC)” 
In order to achieve this hypothesis the following aims were set: 
1. To determine expression and localization of PKM2 and LDHA in pancreatic 
cancer specimens compared to normal and benign pancreatic disease tissues and 
also correlate the expressions of these two glycolytic enzymes with 
clinicopathological parameters. 
2. To study the expression pattern of PKM2 and LDHA in relation to the host 
immune response and cell proliferation by counting nuclear immunostaining of 
CD8 tumour infiltrating lymphocytes (CD8+ TIL) and the Ki67 proliferation 
marker in pancreatic cancer specimens. 
3. To correlate positive nuclear immunostaining of CD8+ TIL and the Ki67 
proliferation marker with pancreatic cancer clinicopathological parameters.  
4. To measure the plasma activity of PKM2 and LDHA in pancreatic cancer 
patients compared to the normal healthy controls. 
5. To study the expression pattern of PKM2 and LDHA in pancreatic cancer cell 
lines. 
6. To study the cytotoxicity effect of PKM2 inhibition, PKM2 activation and LDHA 
inhibition treatment and compare the effect of single and combination treatment 
on the pancreatic cancer cells viability.              
7. To study the effect of single and combination of PKM2 activation 
(tetramerisation) and LDHA inhibition treatments on tumour growth in mice 
bearing subcutaneous and orthotopic pancreatic cancer xenograft tumours.  
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CHAPTER 2: METHODOLOGY 
2.1: Immunohistochemistry: 
2.1.1: Principle:  
Immunohistochemistry (IHC) is a widely used technique that combines immunology, 
anatomy, physiology and biochemistry together to identify tissue constituents by the 
interaction of specific antibodies with target antigens. This technique is routinely used in 
research and in the clinic. It provides a good sensitivity and specificity and can identify a 
wide range of antigens in tissues (164,165). One of the most important advantages of 
IHC over other techniques is its capability to detect and localise an antigen in a cell or 
tissue (166). 
Immunohistochemistry is extensively used as a diagnostic and prognostic tool. It is used 
to diagnose benign or malignant cells and also for tumour staging by using specific 
tumour markers. Furthermore, IHC can provide useful information about cell type and 
site of origin of metastasis to identify the primary location of the tumour. Moreover, IHC 
can be used to assess the activity and efficacy of specific drugs given for particular 
diseases,  immunohistochemically (164–166).  
The basic principle of IHC involves the binding of a specific antibody to a target antigen, 
followed by the amplification and visualization of that antigen-antibody link.  The target 
immunogen may be physically “hidden” from the antibody because of protein folding 
caused during fixation. A pre-treatment or antigen-retrieval step, where enzymes or heat 
are used to remodel the protein structure and make the antigen accessible, may be 
required to visualize some antigens. 
Target antigen detection can be accomplished by a direct or an indirect method. In the 
direct method the labeled antibody directly interacts with the target immunogen in the 
tissue section. Despite the simplicity and rapidity in this one-step staining method, it is 
rarely used because there is no signal amplification, and the antigen–antibody binding 
appears very weak. However, the indirect immunostaining protocol is the most 
commonly used method for the detection of target antigens. This method can be 
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subdivided into several steps / layers. Firstly, the unlabelled primary antibody (first 
layer) binds to the target antigen in the tissue section and then a labeled secondary 
antibody (second layer) is applied which interacts with the primary antibody (164,165). 
The secondary antibody must be raised against the immunoglobulin G (IgG) of the 
animal species in which the primary antibody was produced. Secondary antibodies may 
be labeled with fluorescent dyes (immunofluorescence or immunoenzyme technique). 
The two-step immunostaining protocol is more sensitive than the one-step protocol 
because the antigen-antibody binding signal can be amplified (164).  
Further amplification and improvement in sensitivity of an antigen-antibody signal can 
be achieved by a three-layer immunostaining technique. In this method, an unlabelled 
secondary antibody is conjugated to several biotin molecules or anti-enzyme antibody to 
produce more stable complexes (165). The most commonly used are the Avidin-Biotin 
Complex (ABC), Labelled Streptavidin Biotin (LSAB) and peroxidase–antiperoxidase 
(PAP) method. However, more recently, a peroxidise-labelled polymer method has been 
introduced to further improve sensitivity of antigen-antibody signal (164).   
For many years, the Peroxidase-antiperoxidase (PAP) method was the most commonly 
used method, but now this procedure is rarely used and replaced by more sensitive 
techniques (164,167). For instance, Streptavidin is used instead of the avidin molecule 
which was originally isolated from Streptococcus avidini. The Streptavidin molecule 
unlike avidin is uncharged relative to animal species; consequently, electrostatic linking 
to tissue section is eliminated (164,167). Furthermore, the use of Streptavidin instead of 
avidin eliminates background staining, since carbohydrate groups, which might bind to 
lectins in tissue sections and are associated with background staining, are not found in 
the Streptavidin molecule. These characteristics of the Streptavidin molecule have made 
this method highly sensitive and approximately 5-10 times more sensitive than the 
standard ABC method (164,167).  
On the other hand, the direct and indirect immunostaining protocols are only able to 
identify one target antigen. However, the identification of two or more antigens in the 
same tissue section can be done by multiple immunostaining (double staining is most 
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common) and different fluorescent dyes or enzymes for visualization of stained 
antibodies (see Figure 2.1).  
 
        
 Figure 2.1: Basic principle of immunohistochemistry double staining method. 
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2.1.2: Patients: 
2.1.2.1: Pancreatic cancer: 
This study included tissue sections from pancreatic biopsies or surgical resection 
specimens from 72 patients with confirmed pancreatic ductal adenocarcinoma (n=61) or 
ampullary adenocarcinoma (n=11) treated during the period January 2005 to January 
2010 at University College Hospital, London. An experienced histopathologist examined 
and confirmed the presence of pancreatic cancer and identified areas of tumour from 
haematoxylin and eosin (H&E) stained sections. Clinical information was obtained 
through the CoPath histology database, and a database was created which included the 
following clinicopathological parameters: gender, age at diagnosis, sample type (biopsy 
or resection), type of tumour (ampulla or ductal), outcome (alive or dead), cause of 
death, length of follow-up if alive, presence or absence of metastatic disease at the time 
of histological diagnosis, whether resection was carried out, residual disease (R) status, 
post-resection recurrence, time to post-resection recurrence (if any), histological stage, 
lymph node involvement, presence of perineural or lymphovascular invasion, degree of 
tumour differentiation, and whether chemotherapy was administered (see summary in 
Table 2.1). All data were collected from the date of histological diagnosis to the date of 
death or the end of data collection on 1/2/2015. 
A total of 39 males and 33 females were included in this study with a median age at 
diagnosis of 65 years (range of 34-84 years). Sixty-one samples were identified as 
pancreatic ductal adenocarcinoma, and 11 samples were confirmed as ampullary 
adenocarcinoma. Forty-five samples were biopsy specimens, whereas the other 27 were 
from resection. Furthermore, 20 patients had metastatic disease at the time of diagnosis. 
The R-status was defined in the patients that had surgical resection as: R0=10, R1=15 
and R2=2. Twenty of the 27 patients (74%) who had undergone resection developed 
recurrent disease during the follow-up period. The median time to recurrence was 9.6 
months (range of 0.3-27.1 months). 
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Sixty-six patients had died, 64 from terminal-stage disease, and two from pulmonary 
emboli. The median survival of the patients who had died was 8.8 months (ranging from 
0.8 to 59.7 months) and the median follow-up of the remaining seven patients who were 
alive was 50.9 months (range of 27.5.1-73.2 months). Ethics committee approval was 
obtained from the Central London REC 3 Research Ethics Committee to perform 
immunohistochemistry on stored biopsy and resection specimens linked with a clinical 
database, with the need for consent waived (REC reference 06/Q0512/106, amendment 
date 30 July 2010). All patient samples were anonymised and de-identified prior to 
analysis. 
2.1.2.2:   Pancreatic cysts and normal pancreatic tissue:  
A set of 72 patients with pancreatic cysts and normal pancreatic tissue were identified 
from a search of the histology database of the Royal Free and University College 
Hospital. Due to lack of clinical data, 8 patients were excluded from the study. In total, 
64 patients were included in the study and all these patients had undergone surgical 
resection for pancreatic cysts or a benign condition during 2006 to 2012. The patients 
were followed up for at least one year after surgery to ensure that they did not develop 
pancreatic cancer. Forty-nine patients were diagnosed with pancreatic cysts (19 IPMN, 
14 SCA, 7 MCN, 2 SPPT and 7 pseudo-cysts), eleven patients had chronic pancreatitis 
and four patients were found to have normal histology (Table 2.1). All H&E-stained 
slides were reviewed by an experienced histopathologist, and diagnosis was reconfirmed. 
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Table 2.1: Summary of clinicopathological characteristics of patients with pancreatic cancer, pancreatic cysts, pancreatitis and controls. 
Variables 
Pancreatic Ductal 
Adenocarcinoma 
(n=61) % (n ) 
Ampullary 
Adenocarcinoma 
(n=11) % (n ) 
Pancreatic 
Cystic Tumour 
(n=42) %(n) 
Chronic 
Pancreatitis 
(n=11) % (n ) 
 
Pseudocyst 
(n=7) %(n ) 
Normal 
Pancreas 
(n=4) %(n ) 
Total 
(n=136) % (n ) 
Sex 
Male 
Female 
 
59% (36) 
41% (25) 
 
27% (3) 
73% (8) 
 
33.4% (14) 
66.6% (28) 
 
55.5% (7) 
44.5% (4) 
 
71.4% (5) 
28.6% (2) 
 
50% (2) 
50% (2) 
 
49.3% (67) 
50.7% (69) 
Age at Diagnosis (years) 
Median (Range) 
 
63 (34-84) 
 
67 (36-78) 
 
62 (17-83) 
 
54 (34-82) 
 
48 (30-54) 
 
80 (32-83) 
 
62 (17-84) 
Histological Samples 
Biopsy 
Resected samples 
 
74% (45) 
26% (16) 
 
0.0% (0) 
100% (11) 
 
0.0% (0) 
100% (42) 
 
0.0% (0) 
100% (11) 
 
0.0% (0) 
100% (7) 
 
0.0% (0) 
100% (4) 
 
33% (45) 
67% (91) 
Tumour Differentiation 
Well 
Well/Mod 
Moderate 
Mod/Poor 
Poor 
 
1.65 % (1) 
0.0 % (0) 
14.75 % (9) 
65.6% (40) 
18% (11) 
 
9% (1) 
9% (1) 
54.6% (6) 
27.3% (3) 
0.0% (0) 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
2.7% (2) 
1.3% (1) 
21% (15) 
60% (43) 
15% (11) 
Survival status 
Alive at last contact 
Dead 
 
1.6% (1) 
98.4% (60) 
 
45.5% (5) 
54.5% (6) 
 
95.2% (40) 
4.8% (2) 
 
100% (11) 
0.0% (0) 
 
100% (7) 
0.0% (0) 
 
100% (4) 
0.0% (0) 
 
50% (68) 
50% (68) 
Median Survival (Months) 8.5 (95% CI: 7.7-13.1) 29.5 (95% CI: 23-49.9) --- --- --- --- 9.3 (95% CI: 10.8 -18.2) 
Metastasis Status 
Patients with metastasis 
Patients without metastasis 
 
32.8 % (20) 
67.2% (41) 
 
0.0% (0) 
100% (11) 
 
--- 
--- 
 
--- 
--- 
 
--- 
--- 
 
--- 
--- 
 
27.8% (20) 
72.2% (52) 
Lymph Node Involvement 
Positive lymph node 
Negative lymph node 
Unknown 
 
18% (11) 
8.3% (5) 
73.7% (45) 
 
45.5% (5) 
54.5% (6) 
0.0% (0) 
 
--- 
--- 
--- 
 
--- 
--- 
--- 
 
--- 
--- 
--- 
 
--- 
--- 
--- 
 
22.2% (16) 
15.3% (11) 
62.5% (45) 
Clinical T-Stage Classification 
T1 
T2 
T3 
T4 
Unknown 
 
0.0% (0) 
0.0% (0) 
18% (11) 
8.3% (5) 
73.7% (45) 
 
0.0% (0) 
63.6% (7) 
0.0% (0) 
36.4% (4) 
0.0% (0) 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
0.0% (0) 
9.7% (7) 
15.3% (11) 
12.5% (9) 
62.5% (45) 
Staging 
Stage I 
Stage II 
Stage III 
Stage IV 
Unknown 
 
0.0% (0) 
14.75% (9) 
8.2% (5) 
3.3% (2) 
73.75% (45) 
 
27.3% (3) 
36.4% (4) 
36.4% (4) 
0.0% (0) 
0.0% (0) 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
 
4.2% (3) 
18% (13) 
12.5% (9) 
2.8% (2) 
62.5% (45) 
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2.1.2.3:   Tissue microarrays (TMAs): 
Commercially available tissue microarrays (TMAs) were purchased as paraffin 
embedded sections (TMA 1 and 2, AccuMaxArray, ISU ABXIS CO., LTD, USA, 
A207V and A307 (II), TMA 3, Insight Biotechnology Limited, UK, BIC14011). TMA 
tissue sections were stained with anti-PKM2 and anti-LDHA antibodies by 
immunohistochemistry as described in 2.1.3.1. A total of 206 tissue cores from 130 
patients were presented in the TMAs, which included 63 cases of pancreatic ductal 
adenocarcinoma in duplicate, 19 pancreatic intraepithelial neoplasia (10 PanIN-1, 7 
PanIN-2 and 2 PanIN-3), 10 chronic pancreatitis and 38 normal pancreatic tissue cores. 
Histology was verified by H&E staining. There were 83 male and 47 female patients 
with a median age of 59 (range of 32-80 years). The clinical data that was provided 
included tumour size, stage, degree of tumour differentiation, lymph node involvement, 
metastatic status and tumour sites. Table 2.2 describes the clinicopathological 
characteristics of the patients. 
2.1.2.4:   Plasma samples: 
Plasma samples from 51 patients with pancreatic cancer and 20 healthy individuals were 
obtained. Following the confirmation of cancer diagnosis by an experienced 
histopathologist, blood samples were obtained during treatment from patients at the 
Royal Free Hospital, University College Hospital (UCL, London, UK), and Charing 
Cross Hospital (IC, London, UK). Blood samples were collected in heparinised tubes, 
which were then centrifuged at 10,000 rpm for 15 minute at 4OC, the plasma carefully 
separated and collected in new tubes and stored in -80C for later analysis. Patient 
information included age (median =68, range 41-94 years), gender (27 male and 24 
female), histological stage of pancreatic cancer (Stage I=1, Stage II=7, Stage III=13, 
Stage IV=20, NA=10) and whether chemotherapy was given. The study was approved 
by the Central London REC 3 Research Ethics Committee, and all patients had given 
written informed consent. The trial was conducted in accordance with the Declaration of 
Helsinki. 
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Table 2.2: Summary of clinical data of pancreatic cancer tissue microarray. 
Variables 
Pancreatic 
Adenocarcinoma 
(n =63)  
n (%) 
PanIN 
(n =19) 
% (n) 
Chronic 
Pancreatitis 
(n = 10) 
% (n) 
Non-neoplastic 
(n =38) 
% (n) 
Total 
(n = 130) 
% (n) 
Sex              
Male 
Female 
 
60.3% (38) 
39.7% (25) 
 
68.4% (13) 
31.6% (6) 
 
60% (6) 
40% (4) 
 
68.4% (26) 
31.6% (12) 
 
63.8% (83) 
36.2% (47) 
Age              
                  Median (Range) 
 
61 (32-80) 
 
51 (33-76) 
 
54 (33-67) 
 
61 (38-73) 
 
59 (32-80) 
Tumour Differentiation 
Well 
Moderately  
Poorly 
Mucinous 
Undifferentiated 
Unknown 
 
3.2% (2) 
 63.5% (40) 
27% (17) 
 3.2%  (2) 
1.6%  (1) 
1.6%  (1) 
 
--- 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
--- 
--- 
 
3.2% (2) 
 63.5% (40) 
27% (17) 
 3.2% (2) 
1.6% (1) 
1.6% (1) 
Lymph Node Involvement  
               Positive lymph node 
             Negative lymph node 
 
54% (34) 
46% (29) 
 
--- 
--- 
 
--- 
--- 
 
--- 
--- 
 
54% (34) 
46% (29) 
Metastasis Status 
Patients with metastasis 
Patients without metastasis 
 
1.6% (1) 
98.4% (62) 
 
--- 
--- 
 
--- 
--- 
 
--- 
--- 
 
1.6% (1) 
98.4% (62) 
Clinical T-Stage Classification 
T1 
T2 
T3 
T4 
 
1.6% (1) 
9.5% (6) 
81% (51) 
7.9% (5) 
 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
 
1.6% (1) 
9.5% (6) 
81% (51) 
7.9% (5) 
Staging 
Stage I 
Stage II 
Stage III 
Stage IV 
 
6.3% (4) 
84.1% (53) 
8% (5) 
1.6% (1) 
 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
 
6.3% (4) 
84.1% (53) 
8% (5) 
1.6% (1) 
Tumour Size (cm) 
                          ≤ 2.5 
                         2.6-3.9 
                          ≥ 4  
 
36.7% (22) 
45% (27) 
18.3% (11) 
 
--- 
--- 
--- 
 
--- 
--- 
--- 
 
--- 
--- 
--- 
 
36.7% (22) 
45% (27) 
18.3% (11) 
Tumour Site         
Head 
Body 
Tail 
Unknown 
      
66.6% (42) 
16% (10) 
12.7% (8) 
4.7% (3) 
 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
 
--- 
--- 
--- 
--- 
      
66.6% (42) 
16% (10) 
12.7% (8) 
4.7% (3) 
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Protocol: 
2.1.2.5:   Single staining: 
The expression of PKM2, LDHA, CD8 and Ki-67 in specimens was evaluated by 
standard immunohistochemistry. Paraffin embedded tissue sections were warmed in a 
heated oven for 30 minutes at 60 ̊C (Memmert, Beschickung-loading model 100-800, 
Germany), then the samples were deparaffinised in xylene and hydrated through a 
series of graded ethanol (70%-95%). Tissue sections were subjected to a heat mediated 
antigen retrieval method by using an autoclave (Autoclave medical device, Prestige 
Medical Limited, Blackburn, England). After cooling to room temperature and rinsing 
in phosphate buffered saline (PBS), endogenous peroxidase activity was inhibited by 
incubation with 3% hydrogen peroxide for 20 minutes. The sections were washed in 
PBS and then incubated with 2.5% normal horse blocking serum (Ready-to-use normal 
horse serum blocking solution, ImmPRESSTM UNIVERSAL KIT, Vector 
Laboratories, UK, Cat# MP-7500) for 20 minutes at room temperature. The sections 
were then incubated with primary antibody (for one hour at room temperature for both 
CD8 and Ki-67, overnight at 4 ̊C for PKM2, LDHA) at a dilution of 1/200 for CD8, 
1/300 for Ki-67, 1/100 for PKM2 and 1/250 for LDHA in PBS. After three washes 
with PBST (PBS-T, 0.05% Tween-20 in 1 × PBS), the sections were incubated with 
horseradish peroxidase (HRP) - conjugated secondary antibody (ImmPRESSTM 
UNIVERSAL anti-mouse/rabbit IgG Reagent, ImmPRESSTM UNIVERSAL KIT, 
Vector Laboratories, UK, Cat# MP-7500) for 30 minutes. The sections were washed 
thrice with PBST and the primary antibody was detected using the DAB detection 
system kit (Dako RealTM EnVisionTM Detection System, Peroxidase/DAB+, 
Rabbit/Mouse, UK, Cat# K5007). The sections were placed in a haematoxylin solution 
for 3 minutes, then gently washed in running water to remove excess haematoxylin, 
and then mounted with aqueous mounting media. 
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2.1.2.6:   Double staining: 
The expression of PKM2/CD8 and PKM2/Ki-67 in pancreatic cancer tissue sections 
were evaluated by using a double immunohistochemical staining kit (ImmPRESSTM 
Universal Reagent, Anti-Mouse/Rabbit IgG, Vector Laboratories, Cat# MP-7500). The 
deparaffinisation, rehydration, antigen retrieval and peroxidase quenching steps were 
carried out as described above for the single staining section method. Sections were 
then incubated for 20 minutes with 2.5% normal horse blocking serum, followed by the 
first primary antibody (monoclonal mouse anti-human and rat pyruvate kinase type M2 
(M2-PK), DF-4, ScheBO®Biotech, Germany, Cat# S-1) at a dilution of 1/100 in PBS 
overnight at 4 C̊. After three washes with PBST, the sections were incubated with 
horseradish peroxidase (HRP) - conjugated secondary antibody for 30 minutes. The 
sections were then washed thrice with PBST and the primary antibody was detected 
using the DAB detection system kit. After that the sections were washed with PBS and 
incubated for 20 minutes with blocking solution (ready to use blocking solution 
Reagent 1, PicTureTM double staining kit, Invitrogen, UK, Cat# 87-9999), followed by 
incubation with the next primary antibody [either CD8 (CD8A Rabbit polyclonal 
antibody, Abnova , UK , Cat# PAB11235) or Ki-67 (Rabbit polyclonal to Ki-67 - 
Proliferation Marker, Abcam, UK, Cat# ab15580)] at a dilution of 1/200 for CD8 and 
1/300 for Ki-67 in PBS for 1 hour. The sections were then washed thrice with PBST 
and incubated for 30 minutes with the secondary antibody for the second primary 
antibody (ready-to-use Gt anti-Rabbit IgG-alkaline phosphatase (AP) polymer 
conjugate, PicTureTM double staining kit, Invitrogen, UK, Cat# 87-9999). After 
washing thrice with TBST the second primary antibody was visualized using fast-red 
chromogen detection system kit (fast-red chromogen tablets, reagent 5B, and ready-to-
use alkaline phosphatase substrate/buffer, Reagent 5A, PicTureTM double staining kit, 
Invitrogen, Cat# 87- 9999). The sections were placed in a haematoxylin solution for 3 
minutes, followed by a gentle wash in running tap water to remove excess 
haematoxylin, and then mounted with aqueous mounting media. 
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In this study, two different systems of substrate/chromogen/enzyme were used; DAB 
chromogen system produced brown colour (PKM2) with immunoglobulin G (IgG)-
horseradish peroxidase, and fast red chromogen system with immunoglobulin G (IgG)-
alkaline phosphatase produced red colour (CD8 or Ki-67). 
Errors can occur in any steps of the immunohistochemistry, especially in concentration 
of antibodies and time of interaction of antibodies and tissue sections. In our 
experiment, I minimised those errors by optimisation of antibody concentration and 
interaction times before starting the experiments.   
 
 
2.1.3: Evaluation of immunohistochemical staining:  
2.1.3.1:   Evaluation of PKM2: 
Immunohistochemical staining was evaluated using a light microscope (AXIO Scope, 
Carl Zeiss Micro-Imaging GmbH, Gottingen, Germany). The assessment of the 
immunostained slides was done independently by two observers and any disparity 
between the results resolved by using a conference microscope. A comprehensive 
scoring formula was used for the semi-quantitative evaluation of PKM2 expression as 
described previously (168). The PKM2 and LDHA staining score is explained in the 
following table (Table 2.3). The intensity of staining was scored as: 1, weak expression; 
2, moderate expression; or 3, strong expression and the extent of staining scored as 1, 
<33% of tumour cells stained positive; 2, 33% to 67% of tumour cells stained positive 
or; 3, >67% tumour cells stained positive. The intensity and the extent scores were then 
multiplied to obtain a single scale of score of 1, 2, 3, 4, 6, and 9. Scores of 1, 2 and 3 
were defined as a weak (or negative) staining, whereas scores 4, 6 and 9 were considered 
as strong (or positive) staining. 
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Table 2.3: Evaluation of PKM2 and LDHA stained according to the intensity and extent. 
Degrees of Intensity of PKM2 staining Extend of PKM2 staining 
0 No expression 0 
1 Weak expression Less than 33% 
2 Moderate expression 33% to 67% 
3 Strong expression More than 67% 
   
2.1.3.2: Evaluation of CD8+ TILs and Ki-67 proliferation marker: 
The number of CD8+ TILs and the number of cells which stained positively for Ki-67 
was determined independently by two observers. Initially, the entire tumour section 
was scanned at low magnification (x100) to identify the region with highest density of 
CD8+/Ki-67 cells and then five random areas within that region were counted at high 
magnification (x400). The average number of CD8+ TILs was calculated and 
expressed as count per high power field (HPF). The cell proliferation index (PI) was 
expressed as a percentage of positive-stained nuclei for Ki-67 among 1000 tumour 
cells using a standardised grid. 
Potential errors can occur during observation and assessment of stained tissue sections 
and counting of nuclear staining. To avoid bias and minimize error, assessment was 
done independently and blindly to the patient’s status by two observers and any 
differences between the results resolved by conference microscope.    
 
 
2.2: Western blot analysis:  
2.2.1: Principle: 
Western blot or immunoblotting is a widely used analytical technique for the 
detection of specific proteins in a mixture of extracted proteins or homogenated 
tissues. This method is based on the separation of proteins according to the electric 
charge, isoelectric point, molecular weight or a combination of them, through gel 
electrophoresis. Negatively charged, low molecular weight, denatured proteins 
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migrate faster through the polyacrylamide gel than high molecular weight proteins 
(169,170). Separated proteins on the gel are transferred to a membrane (either 
nitrocellulose or Polyvinylidene difluoride (PVDF)), and then the target protein is 
stained with a specific antibody. The detection of the target protein takes place either 
in one step or in two steps. In the one step process, the target protein is stained with a 
labelled primary antibody. Whereas, in the two step method, the target protein is 
exposed to the unlabelled primary antibody, then a secondary labelled antibody binds 
to the primary antibody (169–171). The most commonly used conjugations are biotin 
or enzyme such as horseradish peroxidase or alkaline phosphatase. The two-step 
process is more commonly used due to higher sensitivity of antigen-antibody reaction 
(see figure 2.2) (169,170). 
 
 
Figure 2.2: Basic principle of western blot. 
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2.2.2: Method: 
2.2.2.1:   Cell lines: 
Human pancreatic cancer cell lines were purchased either from RIKEN BioResource 
Center (RIKEN BRC, Tsukuba, Japan) or PerknElmer (Caliper LifeSciences, Hopkinton, 
MA, USA). MIApaca-2, PANC-1, PK-1, PK-59, PK-45H, PK45P, KP-4, KLM-1, NOR-
P1 cell lines were purchased from RIKEN BioResource Center, however, BxPc-3Luc2 cell 
line was purchased from Caliper LifeSciences, PerkinElmer LTD. The BxPc-3Luc2 
Bioware Ultra-Light Producing Cell Line is a luciferase expressing cell line, stably 
transfected with the firefly luciferase gene (luc2). The cell line was established by 
transducing lentivirus-containing luciferase 2 gene under the control of the human 
ubiquitin C promoter. PANC-1, PK-1, PK-59, PK-45H, PK45P, KLM-1, NOR-P1 and 
BxPc-3 were maintained in RPMI-1640 supplemented with 10% FBS, 1% 
penicillin/streptomycin and 2mM glutamine (Gibco, Life technologies, UK). Miapaca-2 
was maintained in DMED and KP-4 in DMEM/F12 media. All media were 
supplemented with 10% FBS, 1% penicillin/streptomycin and 2mM glutamine. Cells 
were maintained in a humidified atmosphere of 21% O2, 5% CO2 at 37 °C (Binder 
incubator, Germany, Serial# 10-09701) and harvested with trypsin-EDTA. 
2.2.2.2:   Cell culture: 
All pancreatic cancer cell lines were maintained in cell culture media supplemented with 
10% FBS, 1% penicillin/streptomycin and 2mM glutamine and maintained in a 
humidified atmosphere of 21% O2, 5% CO2 at 37 °C until reach approximately 80% 
confluent, then the cells subcultured for the next experiment. Cell culture media was 
changed, with a pre-warmed solution, every 2-3 days. Adherent cells were washed 
twice with PBS then detached using 0.25% Trypsin-EDTA and then the cells were 
counted under a microscope (Primo Vert, Carl Zeiss Ltd, Gottingen, Germany) by 
using disposal haemocytometer (C-Chip, Disposable Haemocytometer, Digital Bio, 
Korea). For each experiment, approximately one million cells were plated in 75 cm2 
flasks and cultured for 48 hours (proliferation phase) and 120 hours (confluent phase). 
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Adherent cells were washed twice with cold PBS, and scraped with rubber policeman 
cell scraper in 10ml cold PBS. Cells were then centrifuged at 3000 rpm in a pre-
cooled centrifuge (4 ̊C) for 5 minutes (Eppendorf Centrifuge 5810R, Hamburg, 
Germany) and pelleted. The cell pellets were then directly used for isolation and 
extraction of proteins. To avoid and minimize a potential errors, all experiments were 
done in duplicate. 
2.2.2.3: Preparation of total cell protein extracts: 
Cell pellets were re-suspended in complete lysis buffer [lysis buffer (M-PER® 
Mammalian Protein Extraction Reagent, Thermo Scientific, Cat# 78501) + Protease 
Inhibitors Cocktail (Thermo Scientific, Cat# 87785)]. The solution was placed on a 
shaker for 10-15 minutes (Stuart gyro-rocker, BIBBY Sterilin LTD, UK, Cat# SSL3), 
then transferred to micro-centrifuge tubes. Samples were centrifuged at 14000 rpm for 
15 minutes at 4 C̊ (Centrifuge, Thermo Fisher Scientific, Thermo electron LED GmbH 
LR56495, Germany), and then transferred the supernatant to new tubes for analysis. 
To minimize any error occurring during experiments, each sample was analysed in 
duplicate and the experiments were also done in duplicate. 
2.2.2.4:   Total protein assay: 
The total protein concentration of samples was measured by using micro BCA protein 
assay kit (Micro BCATM Protein Assay Kit, Thermo Scientific, USA, Cat # 23235). 
As per manufacturer's protocol, preparation of working reagent was done by mixing 
25 portions of the Micro BCA reagent MA and 24 portions of reagent MB with 1 
portion of MC reagent. Albumin (BSA) standard was serially diluted using deionized 
water for preparation of a standard curve (0.5, 1, 2.5, 5, 10, 20, 40µg/ml). Samples 
were diluted 150, 200 and 300 times with deionized water. After that 150 µl of the 
samples, standards and a blank were pipetted into the 96 well plate in duplicates, then 
150 µl of working solution was added into the wells. The plate was incubated at 37 ̊C 
for 2 hours, then the protein concentration was analysed according to the standard 
curve using MARS Data Analysis Software, FLUOstar Omega-BMG Labtech 
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microplate reader (FLUOstar Omega-BMG Labtech microplate reader, BMG Labtech 
GmbH, Allmendgruen 8, D-77799 Ortenberg, Germany). To avoid a potential errors, 
each sample was analysed in duplicate and experiments were also done in duplicate. 
 
2.2.2.5:   Western blot protocol:  
 Sample preparation: 
For 10 wells pre-cassette SDS-polyacrylamide gel, 15 µg of total protein in 20 µl 
solution was used per well. The samples were prepared by mixing the appropriate 
amount of protein solution with 2 µl of Sample Reducing Agent (10X), (Invitrogen, 
USA, Cat# NP0004), and 5 µl of LDS (lithium dodecyl sulphate) sample loading 
buffer (4X), (Invitrogen, USA, Cat# NP0007) and the solution was then adjusted to 20 
µl by adding molecular grade water.  
 Gel electrophoresis: 
The protein solution was denatured at 70 ̊C for 10 minutes; followed by brief 
centrifugation of the mixture. For gel electrophoresis, NuPAGE 4-12% Bis-Tris gel 
1.0 mm, 10 well gels (Life technologies, USA, REF# NP0321BOX) precast gels were 
used with MOPS SDS Running Buffer (20X),(Life technologies, USA, Cat# NP0001). 
Samples were loaded along with a protein ladder (Novex® Sharp pre-stained protein 
standards, Life technologies, USA, Cat# 57318) and then run at 200 V for 
approximately 1 hour (until the marker reached the bottom of the gel).  
 Transferring proteins to PVDF membrane: 
Polyvinylidene fluoride (PVDF) membranes (InvitrolonTM PVDF Filter Paper 
Sandwich, 0.45µm Pore Size, Invitrogen, USA, Cat# LC2005) were activated by 
rinsing in absolute methanol for 1- 2 minutes, followed by washing twice with distilled 
water and then incubated in transfer buffer (NuPAGE® Transfer Buffer (20X), 
Invitrogen, USA, Cat# NP0006) for 30 minutes. Blotting pads were prepared by 
soaking in cold transfer buffer. Then the air bubbles were removed by squeezing the 
pads while they submerged in the buffer. Immediately after gel electrophoresis, the 
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proteins were transferred electronically from the gel to the polyvinylidene fluoride 
(PVDF) membrane by using the transfer sandwich system. The transfer sandwich 
system consists of blotting pads, filter paper; gel and PVDF membrane were 
assembled in an Xcell blot-Module as illustrated below. 
The Xcell blot-Module was placed into the assembly tray of the western blot tank 
(Xcell SureLockTM , InvitrogenTM Novex Mini-Cell, USA). The blotting module 
was filled with transferring buffer solution, whereas the tank (outer of blotting 
module) was filled with water. Then the system was run at a constant voltage of 20 V 
for 1 hour. 
 
 
 Blocking membrane: 
Following protein transfer, the PVDF membrane was rinsed in TBS (Tris Buffered 
Saline 10X, GBiosciences, USA, Cat# R030) and stained with Ponceau S solution 
(Sigma- Aldrich, St. Louis, MO, USA) to ensure successful transfer, washed 3 times 
with tap water before incubating in 10 ml blocking solution (5% Albumin from Bovine 
Serum BSA in TBST), (Albumin from bovine Serum BSA, Sigma, USA, Cat# A2153-
100G) for 1 hour at room temperature to block the non-specific binding of the primary 
antibody. 
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 Incubation with primary and secondary antibody: 
After the blocking process, the PVDF membrane was incubated overnight at 4 ̊C with 
10 ml diluted primary antibody [mouse anti-PKM2 (DF-4, ScheBo®Biotech, Giessen, 
Germany) or rabbit anti-LDHA antibodies (Cell Signaling, UK)] 1:1000 in 5%BSA. 
The following day the PVDF membrane was washed twice with TBS-Tween 20 (TBS-
T, 0.05% Tween-20 in 1 × TBS) and twice with a diluted blocking solution (diluted 
Blocking solution 1:1 with TBST) for 10 minutes each time. The membrane was then 
incubated with appropriate horseradish peroxidase (HRP) - conjugated secondary 
antibody (Anti-mouse IgG or anti-rabbit, HRP-linked Antibody, Cell Signaling 
Technology, UK) 1:2000 in 5%BSA for 1 hour. Anti- β actin antibody (Cell Signaling, 
UK) was used as a protein loading control. 
 Signal development: 
The PVDF membrane was then washed thrice with TBST for 5 minutes and thrice 
with TBS for 10 minutes. After washing, the chemiluminescent signal was developed 
by incubating the PVDF membrane with ECL chemiluminescent substrate (according 
to the manufacturer’s instructions, the ECL substrate working solution was prepared 
by mixing equal parts of the stable peroxidase with luminal/enhancer solution), 
(Thermo Scientific, USA) for 5 minutes at room temperature. The developed 
chemiluminescent signal was detected and the intensity of the bands were measured 
(FlourChem E digital dark room, Cell Biosciences, Inc. Santa Clara, CA, USA). The 
intensity of the PKM2 and LDHA bands in the different pancreatic cancer cell lines 
were normalized with the intensity of the loading control.  
The error can occur in any steps of western blot experiment, to avoid any error, all the 
experiments were done in duplicate.   
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2.3: Immunocytochemistry: 
The Miapaca-2 cell line was immunocytochemically stained with anti-PKM2 or anti-
LDHA antibodies. Briefly, 25x104 Miapaca-2 cells were seeded in sterilized 2-well 
cell culture chamber slide (Fisher Scientific, UK) and left to grow for 24 hours. Cells 
were washed with cold PBS, and fixed with cold absolute methanol for 15 minutes, 
and then permeabilized in 0.25% triton X-100 in PBS. Cells were then blocked with 
3% BSA for 1 hour at room temperature, following by an overnight incubation at 4°C 
with a primary antibodies specific for PKM2 (1:100 dilution, DF-4, ScheBo®Biotech, 
Giessen, Germany) or LDHA (1:250 dilution, Cell Signaling, UK). Cells were further 
incubated with appropriate secondary antibodies and antigen-antibody reaction was 
visualized using the DAB detection system kit. Cells were incubated in a haematoxylin 
solution for 1 minute, followed by a gentle wash in running water to remove excess 
haematoxylin, and then mounted with aqueous mounting media. All experiments were 
done in duplicate.   
2.4: MTS Assay: 
The effect of single and combination treatment was evaluated in the pancreatic cancer 
cell lines by the MTS assay. Briefly, 3000 cells were plated per well in 96-well plates 
and incubated overnight. LDHA inhibitor (FX11, Toronto Research Chemicals Inc., 
North York, Ontario, Canada), PKM2 activators [PKM2 activator III and IV (TEPP-
46), Cayman Chemical, Ann Arbor, MI, USA) or inhibitor (Shikonin, Calbiochem, 
Merck Millipore, UK) were added alone or in combination for 24, 48, 72 and 96 hours. 
After an indicated time points, 20µl of MTS tetrazolium compound [3-(4, 5–
dimethythiazol-2-yl)] -5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) was added to each well in 100µl of fresh culture medium and plates were 
incubated at 37oC for 1 hour. Absorbance of formazan was measured at 490 nm to 
measure the percentage of viable cells. The IC50, AC50 and combination index (CI) of 
the different treatment regimens calculated using Origin or CompuSyn software from 
the dose-response curves.  
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To avoid and minimize any error occurring during experiments, each sample was 
analysed in duplicate and the experiments were also done in duplicate. 
 
 
Figure 2.3: Structure of MTS tetrazolium and its formazan product. 
 
 
 
2.5: Staining cells with haematoxylin:  
After measuring cytotoxicity of the single-agent and combination treatment by the 
MTS assay, pancreatic cancer cell lines were stained with haematoxylin. Briefly, cell 
culture media was aspirated and cells were washed twice in cold PBS. The cells were 
then fixed with ice-cold absolute methanol for 15 minutes and permeabilized with 
0.25% triton X-100 in PBS for 10 minutes at room temperature. Cells were then 
washed twice in 0.25% triton X-100 in PBS and incubated for 1 minute with 
haematoxylin. Cells were then washed in a running tap water to remove excess 
haematoxylin and left to dry and then captured using a light microscope. All 
experiments were done in duplicate.       
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2.6: Animal Experiments: 
All animal experiments were carried out in the Comparative Biology Unit (CBU), 
School of medicine, Royal Free campus, University College London. Sixty-five, 4-6 
week-old male nude mice (weighing approximately 25g) were purchased from Charles 
River Ltd (Charles River UK Ltd., Margate, Kent, UK), and maintained on a standard 
diet, at a temperature of 19–23°C, and humidity of approximately 50%. All animal 
experiments were conducted according to Home Office guidelines under the Animals 
in Scientific Procedures Act 1986. 
 
2.6.1: Subcutaneous tumour implantation: 
The human pancreatic cancer cell lines, Miapaca-2 and BxPc-3Luc2 were used to 
generate subcutaneous xenografts in nude mice. Briefly, 6x106 cells of Miapaca-2 or 
BxPc-3Luc2 were injected subcutaneously into the right flank of mice, using 27-gage 
needle (figure 2.4 A). Xenografts generated by the Miapapca-2 cell line were allowed 
to grow for two weeks and then mice were randomly divided into the following four 
groups (n=5 per group): 1) untreated control, 2) high combination treated, 3) low 
combination treated,  and 4) LDHA inhibitor (FX11) treated groups. A second 
experiment used the BxPc-3Luc2 cell to generate subcutaneous xenografts. Four days 
post tumour cell inoculation, mice were randomly divided into following five groups 
(n=6 per group) : 1) untreated control, 2) high combination treated, 3) low 
combination treated, 4) single FX11 treated and 5) single PKM2 activator IV (TEPP-
46) treated groups.  
Body weight and tumour volume were measured thrice a week. Tumour volumes were 
measured using a digital Caliper and calculated using the following formula: [Tumour 
Volume = length (mm) x width (mm) x width (mm) x 0.52].  
 
2.6.2: Orthotopic tumour model generation: 
Twelve 4-6 week-old male nude mice underwent an established surgical method for 
orthotopic injection of human pancreatic cancer cells into the pancreas. The 
implantation was carried out under sterile conditions. Mice were anaesthetised under 
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2-3% isoflurane gas, the abdominal was cleaned with iodine solution, and an incision 
was made in the abdominal cavity off the midline and directly above the pancreas to 
allow visualization of the pancreas. Then the pancreas was gently retracted and 
positioned to allow for direct injection of 6x106 BxPc-3Luc2 cells in 50µl PBS mixed 
with 50µl matrigel using a 27-gage needle (figure 2.4 B). Successful delivery of cells 
into the pancreas was observed under magnification using a dissection microscope 
(Leica Wild M691, Wetzlar, Germany). The pancreas was then placed back within the 
abdominal cavity and both the muscle and skin layers sutured (figure 2.4 B). 
Following recovery from surgery, mice were monitored and weighed thrice a week.  
 
Figure 2.4: Development of pancreatic cancer xenograft tumour model. A) Subcutaneous xenograft 
tumour model. B) Orthotopic xenograft tumour model.  
 
2.6.3: Staining of Miapaca-2 cell line with DiR fluorescent dye:  
Miapaca-2 cells were trypsinised in 0.25% Trypsin-EDTA and counted. The cell 
solution was centrifuged at 1100 rpm for 5 minutes at 4°C and the pellet resuspended 
in 50ml PBS containing 10µM DiR fluorescent dye (XenoLight DiR, Perkin Elmer, 
USA, Cat# 125964). The cell solution was then incubated in 21% O2, 5% CO2 at 37 
°C incubator for 20 minutes. Cells were re-counted and re-suspended in cold PBS at a 
concentration of 6x107cells/ml. Subcutaneous or orthotopic xenografts were generated 
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using 6x106 cells. The fluorescence signal was detected at the beginning and the end of 
the experiment by using IVIS instrument.      
 
2.6.4: Drug preparation and treatment regimen:  
PKM2 activator IV (TEPP46, 6-[(3-aminophenyl)methyl]-4,6-dihydro-4-methyl-2-
(methylsulfinyl)-5H-thieno[2’,3’:4,5]pyrrolo[2,3-d]pyridazin-5-one) and LDHA 
inhibitor (FX11, 2,3-Dihydroxy-6-methyl-7-(phenylmethyl)-4-propyl-1-
naphthalenecarboxylic Acid) were dissolved and prepared in 40% (2-hydroxypropyl) 
beta-cyclodextrin solvent. The desired dose of single or combination treatment were 
freshly prepared and injected intraperitoneally on a daily basis for three weeks. In the 
first animal experiment, the untreated (control) animals were injected with 100µl 
vehicle [40% (2-hydroxypropyl) beta-cyclodextrin] and in the high combination 
treated group, mice were injected with a 100µl solution of PKM2 activator IV (TEPP-
46) and LDHA inhibitor (FX11) at a concentration of 25mg/kg and 2mg/kg, 
respectively. Mice in the low combination treated group were administered at a 
concentration of 13mg/kg and 1mg/kg for TEPP-46 and FX11, respectively. In the 
single LDHA inhibitor treated group, mice administered with FX11 at concentration of 
2mg/kg FX11. Osmotic pumps (Alzet micro-osmotic pump, model 1004, Cupertino, 
CA, USA) were used for administered of low combination and single FX11 treated 
mice group and implanted intraperitoneally. The osmotic pump had a reservoir volume 
of 100 µl and delivered drug solution at a rate of 0.11 µl/hr. over 28 days. Pumps were 
filled with 100 µl of FX11 and TEPP-46 (1.9 mg/100µl and 23.5 mg/100µl, 
respectively) or with 100µl of FX11 (1.9 mg) for the low combination and the single 
LDHA inhibitor treated groups, respectively.  
In the second animal experiment: the control group animals were injected daily with 
100µl vehicle [40% (2-hydroxypropyl) beta-cyclodextrin], the high combination 
treated group received daily injections of 100µl TEPP-46 and FX11 at a concentration 
of 30mg/kg and 2.1mg/kg, respectively. Animal from the low combination treated 
group received daily injections of 100µl TEPP-46 and FX11 at a concentration of 
15mg/kg and 1.05mg/kg, respectively. The single LDHA inhibitor treated group 
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received daily injection of 100µl FX11 at a concentration of 2.1mg/kg and the single 
PKM2 activator IV treated group received daily injections of 100µl TEPP-46 at a 
concentration of 30mg/kg.   
Therapy was administered for three weeks; body weight and tumour volume were 
measured thrice a week using digital Caliper and calculated using the following 
formula: [Tumour Volume = length (mm) x width (mm) x width (mm) x 0.52].  
 
2.6.5: End of the experiment: 
Following three weeks of treatment, mice were sacrificed approximately after one hour 
post the last injection; the tumours were harvested and blood samples were collected 
by heart puncture. Tumours were weighed and half were flash-frozen in liquid 
nitrogen and half were fixed in formalin. Blood samples were collected in heparinised 
polystyrene tubes and plasma was immediately separated by centrifuging samples at 
10,000 rpm, for 15 minutes at 4◦C; plasma samples were stored in -80 for later 
analysis.   
In animal studies, error can occur in several steps, especially during injection of cell 
lines, injection of drugs and measurement of tumour volume. To minimize errors, all 
animal experiments were done under supervision of an experienced project license 
holder. The animals were also randomly divided into the groups, blindly to the size of 
the tumour. All the animals were consistently treated with the drugs and the tumour 
volumes precisely measured by bioluminescence imaging as well as manually.   
 
2.7: Bioluminescent imaging: 
2.7.1: Imaging procedure: 
Luciferin (VivoGlo™ Luciferin, In Vivo Grade, Promega UK Ltd, UK) was dissolved 
in PBS and a stock solution of 37.5mg/ml was prepared and sterilised. Mice were 
injected intra-peritoneally with 100µl (150 mg/kg) luciferin solution; 10 minutes later, 
mice were anaesthetised with 2-3% isoflurane gas. Mice were then transferred to the 
IVIS imaging chamber, and anaesthesia gas was reduced to 1.5%. Images were 
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acquired for 5 to10 minutes and in auto-exposure time with both small and medium 
binning.   
2.7.2: In vitro Bioluminescent Assay: 
BxPc-3Luc2 cells were washed with sterilised PBS, trypsinised and counted using 
trypan blue exclusive assay. Cells were re-suspended in fresh complete media and 
seeded in 12 well-plates at a concentration of 30,000 cell/well, and incubated 
overnight. LDHA inhibitor (FX11) and PKM2 activator IV (TEPP46) were added 
either alone or in combination to the cell cultures and incubated for 72 hours. All drugs 
were freshly prepared in complete media and the cell cultures were replaced each day 
with fresh drug solution. At the end of treatment, 150µg/ml D-Luciferin was added to 
each well and cells were imaged after 10 minutes with the IVIS machine.     
2.8: Processing of tumour tissues: 
Tumour samples were fixed in 10% formalin, processed with 70%, 80%, 95% and 
100% ethanol, xylenes and paraffin in tissue processer (LEICA TP1020 tissue 
processor, Nussloch, Germany). Tumour tissues were embedded in paraffin, cut into 5 
µm thick sections and mounted onto Superfrost plus glass slides (Fisher Scientific, 
Loughborough, UK). For histological analysis, slide sections were deparaffinised in 
xylene and hydrated through a series of graded ethanol (70%-95%) followed by 
routine H&E staining. The expression of PKM2, LDHA, CD8 and Ki-67 in tumour 
xenografts was evaluated by standard immunohistochemistry staining methods as 
described in 2.1.3.1 (single staining section).  
2.9: Pyruvate kinase and Lactate dehydrogenase activity assay: 
2.9.1: PK and LDH activity assay in tumour tissues:  
Proteins from the tumour xenograft tissues were extracted by TissueLyser LT 
instrument (Qiagen, USA). Approximately 25mg of tumour tissue was homogenized 
and proteins extracted using TissueLyser LT for 5 minutes at 50 Hertz with one 5mm 
stainless steel bead. Proteins in the tumour tissues were extracted with 500µl of either 
pyruvate kinase or lactate dehydrogenase assay buffer. The tumour tissue lysate was 
  
89 
 
cleared by centrifugation at 13,000 rpm for 15 minutes at 4◦C, and protein 
concentration measured using BCA assay method. Pyruvate kinase and lactate 
dehydrogenase activity assays were performed using PK and LDH assay kits 
(BioVision Incorporated, Milpitas, CA, USA) as per manufacturer’s instructions (as 
described in 2.9.3 and 2.9.4 sections) and activity was normalized to the total protein 
concentration.  
2.9.2: PK and LDH activity assay in human pancreatic cancer cell line: 
One million cells (Miapaca-2 or BxPc-3) were plated per well in 6-well tissue culture 
plates in DMEM or PRMI-1640 media and allowed to attach overnight. The following 
morning, media were replaced with medium containing a DMSO control or the 
indicated doses (5, 10, 25, 50, 100µM) of PKM2 activator IV (TEPP-46) or LDHA 
inhibitor (FX11) then the cells were incubated at 37°C for 6 hours. Following the 
incubation, cells were washed twice with cold PBS on ice, scraped into 200μl of cold 
pyruvate kinase or lactate dehydrogenase assay buffer and sonicated on ice for 4 
cycles of 5 seconds with intervals of 20 seconds, using QSONICA sonicator (Qsonica 
LLC, Newtown, CT, USA). The sonicated cells were centrifuged at 13,000 rpm for 15 
minutes at 4 °C, then the protein concentration quantified by a BCA assay kit. 
Pyruvate Kinase and Lactate Dehydrogenase activity was determined using PK and 
LDH activity assay kit as per manufacturer’s instructions (as described in 2.9.3 and 
2.9.4 sections) and normalized to the total protein concentration. 
2.9.3: Pyruvate Kinase Assay: 
Pyruvate kinase activity in plasma, cell lines and tumour tissue lysates was measured by 
a pyruvate kinase assay kit (BioVision, USA, Cat# K709-100). The kit consisted of PK 
assay buffer, OxiRed Probe, PK enzyme Mix, PK substrate Mix, PK positive control and 
pyruvate standard. All the reagents were prepared according to the manufacturer’s 
instructions, stored at -20 oC and used within one week.  
Standard curve: A stock solution of pyruvate standard was prepared by diluting 10µl 
pyruvate standard to 1ml pyruvate assay buffer to prepare 1nmol/µl of stock solution. A 
standard curve was prepared by 10 fold dilutions of pyruvate stock solution to obtain 
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0.1nmole/µl; the series pyruvate standard was then prepared by adding 0, 2, 4, 6, 8 and 
10µl of pyruvate standard into 96-wells plates in duplicate to obtain 0, 0.2, 0.4, 0.6, 0.8 
and 1nmole/well pyruvate standard solution. The volume was then adjusted to 50µl with 
PK buffer.  
Sample preparation: Human and mouse plasma samples were directly added to the 
assay well plate following a 5-10 times dilution. Cells and tissues were extracted with 
pyruvate assay buffer as described above; 10µl of samples were added to the assay well 
plate and volume of the samples was adjusted to 50µl using pyruvate assay buffer.   
Reaction Mix preparation: For each well, 50µl reaction mix was prepared by mixing 
44µl of assay buffer, 2µl substrate mix, 2µl enzyme mix and 2µl OxiRed probe. 
After preparing appropriate amount of reaction mix, 50µl of this solution was added into 
each well of samples, standards and control using 8 channel pipette, and mixed gently. 
The optical density was then measured at 570nm using FLUOstar Omega-BMG Labtech 
microplate reader (FLUOstar Omega-BMG Labtech microplate reader, BMG Labtech 
GmbH, Allmendgruen 8, D-77799 Ortenberg, Germany). The initial optical density (A1) 
was measured after 2-3 minutes (T1), and the plate was then incubated at 25 ̊C for 10-30 
minutes (T2) to measure the final optical density (A2). The pyruvate kinase activity was 
calculated according to the below formula.  
 
 
B: is the amount of pyruvate generated by PK  between T1 and T2 and 
measured on pyruvate standard curve. 
T1: is the time of the initial measurement (A1) in minutes. 
T2: is the time of the final measurement (A2) in minutes. 
V: is the volume of the sample that added into the assay well in milliliter.  
One unit of pyruvate kinase activity was defined as the amount of the PK enzyme that 
transferred a phosphate group from phosphoenolpyruvate to adenosine diphosphate to 
produce 1 µmole of pyruvate per minute at 25°C.  
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2.9.4: Lactate Dehydrogenase Assay: 
Lactate dehydrogenase activity in plasma, cell lines and tumour tissue lysate was 
measured by a lactate dehydrogenase assay kit (BioVision, USA, Cat# K726-500). The 
assay kit consisted of LDH assay buffer, LDH substrate Mix, NADH standard and an 
LDH positive control. All reagents were prepared according to the manufacturer’s 
instructions and stored at -20°C and used within two weeks. 
NADH standard curve: A standard solution of NADH was prepared by dissolving 
NADH in 400µl deionized distilled water (ddH2O) to obtain 1.25mM NADH solution. A 
standard curve was prepared by adding 0, 2, 4, 6, 8 and 10µl of NADH standard into 96-
well plates in duplicate to obtain 0, 2.5, 5, 7.5, 10 and 12.5nmole/well NADH standard 
solution. The volume was then adjusted to 50µl with LDH buffer. 
Sample preparation: Human and mouse plasma samples were directly added to the 
plate following a 5-10 time dilution; cells and tissues were extracted with LDH assay 
buffer as described above. Then 10µl of each sample was added into the assay well plate 
in duplicate and sample volume was adjusted to 50µl with LDH assay buffer.   
Reaction Mix preparation: For each assay plate well, 50µl reaction mix was prepared 
by mixing 48µl of assay buffer with 2µl substrate mix solution. 
After preparing appropriate amount of reaction mix, 50µl of this solution was added into 
each assay plate well containing the samples, standard and control using 8 channel 
pipette and mixed gently. Optical density was then measured at 450nm using an LT-4000 
microplate reader (LT-4000 microplate reader, Labtech International Ltd, UK). The 
initial optical density (A1) was measured after 2-3 minutes (T1), and the plate was then 
incubated at 37 ̊C for 10-30 minutes (T2) to measure the final optical density (A2). The 
LDH activity was calculated according to the below formula.  
 
 
B: is the amount of the NADH generated by LDH  between T1 and T2 
and measured on NADH standard curve. 
T1: is the time of the initial measurement (A1) in minutes. 
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T2: is the time of the final measurement (A2) in minutes. 
V: is the volume of the sample that added into the assay well in milliliter.  
One unit of lactate dehydrogenase activity was defined as the amount of the LDH 
enzyme that produced 1 µmole of NADH per minute at 37°C. 
To avoid and minimize any error occurring during measurement of PK and LDH 
activity, each sample was analysed in duplicate and all experiments were also done in 
duplicate.      
 
 
2.10: Statistical analysis: 
IBM SPSS Statistical software (Version 22, SPSS Inc., Chicago, IL, USA) was used for 
statistical tests, data analysis and graphics. The Kaplan-Meier method and log-rank test 
were used for analysis of survival time and to identify differences between the groups. 
One-way ANOVA or Kruskal Wallis test was used for comparison of multiple groups. 
Mann-Whitney U-test was used for a nonparametric test. Chi square test was used to 
identify differences between categorical data. Non-parametric correlation analyses 
between continuous variables were performed by Spearman test. A Cox proportional 
hazard regression model was used for univariate and multivariate analysis, and 
multivariate analysis was perform using backword, stepwise Cox regression model. The 
Origin software (OriginLab Corporation, Northampton, MA, USA) and CompuSyn 
software (ComboSyn, Inc., Paramus, NJ. USA) were used for drug dose response 
analysis and calculation of the dose effect curve, IC50, AC50 and combination index (CI) 
of the drugs. All test results were two tailed, with effects summarized using 95% 
confidence intervals. Statistical significance was set at p<0.05.  
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CHAPTER 3: RESULTS 
 
3.1: Pyruvate Kinase M2 and Lactate Dehydrogenase A are overexpressed in 
pancreatic cancer and correlate with poor outcome 
 
3.1.1: RESULTS:  
3.1.1.1: Expression of PKM2 and LDHA in pancreatic cancer: 
Both PKM2 and LDHA were overexpressed in tumour cells compared with normal 
pancreatic tissue. A variable expression pattern of PKM2 was observed in tumour 
tissues, with relatively higher expression in less differentiated areas, in advancing 
margins of tumour nodules and in invasive (muscular and blood vessel) tumours (Figure 
3.1A,B,E and F). Overall, PKM2 expression was predominantly associated with 
aggressive tumours. Preferential expression of PKM2 was observed in binucleated 
proliferating cells in tumour nodules (Figure 3.1D). Expression of PKM2 was noted in 
all cell compartments, including the cell membrane, cytoplasm and/or nucleus (Figure 
3.1C and F). In contrast, LDHA expression was generally high in tumour as well as in 
preneoplastic tissues and pancreatitis without a specific pattern (Figure 3.2). LDHA 
expression was also detected in the cell membrane and/or cytoplasm and occasionally in 
the nucleus. 
Similar expression of PKM2 and LDHA was observed in the UCLH cohort and TMA 
samples, with a staining score of > 3 in 64% and 73% of tumours, respectively, for 
PKM2, and in 76% of tumours for LDHA in both cohorts. In both cohorts, pancreatitis 
samples also highly expressed LDHA compared with PKM2 expression (Figure 3.3).  
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Figure 3.1: Immunohistochemical staining of PKM2 expression in representative pancreatic tumour 
sections. (A) Well differentiated area of tumour showing weak PKM2 expression (red arrow), with high 
expression in poorly differentiated areas (brown colour, yellow arrow). (B) Growing margin of tumour 
nodules with strong expression of PKM2 (red arrow). (C) Membranous expression of PKM2 (red arrow). 
(D) Heterogeneous expression of PKM2 with predominant expression in the proliferating cells (red arrow). 
(E) Strongly positive tumour expression of PKM2 in vascular invasion (red arrow). (F) Strongly positive 
tumour expression of PKM2 with muscular invasion (red arrow). 
 
Figure 3.2: LDHA expression pattern. (A) Membranous expression of LDHA. (B) Cytoplasmic and 
nuclear expression (C) Strong expression in pancreatic cyst with mild expression in the surrounding 
normal pancreatic tissue. (D) Nuclear expression of LDHA in pancreatic cancer. (E) Strong expression in 
PanIN lesion. (F) Negative staining in normal pancreas
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As shown in Fig 3.3, progressively higher PKM2 expression was observed along the 
tumorigenic pathway, with the lowest expression in pancreatic cysts (19%), intermediate 
in PanIN (37%) and highest in cancers (68%). PKM2 expression was approximately 
four-fold higher in pancreatitis (29%) compared with normal pancreatic tissue. Although 
LDHA expression was also significantly increased in cancers compared with normal 
pancreatic tissue (p < 0.0001, ANOVA), there were no significant differences between 
chronic pancreatitis, pancreatic cysts, PanIN and cancer samples (67%, 59%, 73% and 
76%, respectively, Figure 3.3). 
 
Figure 3.3: Percentages of PKM2 and LDHA expression in different type of tissues are shown. PKM2 was 
strongly expressed by pancreatic cancer tissue specimens and was significantly higher than normal, 
pancreatitis, pancreatic cyst and PanIN (P<0.001). Expression of LDHA was significantly high in 
pancreatic cancer than in normal pancreas (P<0.001), whereas, there was no signification differences in 
LDHA expression between pancreatic cancer, PanIN, pancreatic cysts and pancreatitis.   
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3.1.1.2: Association with clinicopathological parameters: 
The correlation between PKM2 and LDHA expression with clinicopathological 
characteristics is shown in Table 3.1. There was a significant inverse correlation between 
PKM2 expression and tumour differentiation in the UCLH cohort, with 83% of PKM2 
positive tumours being less differentiated compared with 64% of PKM2 negative 
tumours (p= 0.047, Chi-square test).  
A significantly higher number of CD8+ TIL was found in tumours with weak PKM2 or 
LDHA expression compared with tumours that had a strong expression (PKM2: 
42.4±43.1 vs. 16.3±24.3, p=0.0001, LDHA: 44.3±40.1 vs. 20.1±30.7, p=0.005 
respectively, Table 3.1). Furthermore, a significant association between tumour cell 
proliferation and expression of both PKM2 and LDHA was observed; the number of 
tumour nuclei expressing Ki-67 was more than 2-fold higher in PKM2 and LDHA 
expressing tumours compared with negative tumours (PKM2: 27.8 ± 12.9 vs. 12.2 ± 14, 
p=0.0001 and LDHA: 25.1 ± 14 vs. 12.3 ± 15.1, p=0.004, Table 3.1).  When staining 
scores, CD8+ TIL count and the number of Ki-67 positive cells were considered as 
continuous variables, a significant inverse correlation between the staining scores and 
CD8+ cell count was observed (PKM2: p<0.001 and LDHA: p= 0.004, Spearman rank 
correlation, Table 3.2, Figures 3.4 and 3.5). A significant direct correlation was noticed 
between the staining scores and Ki-67 count (PKM2: p<0.001 and LDHA: p= 0.001, 
Spearman rank correlation test, Table 3.2, Figures 3.6 and 3.7). 
In the TMA cohort, the expression of PKM2 and LDHA correlated with tumour size. 
PKM2 expression was observed in 54.5%, 77.8% and 90.9% of tumours that were ≤ 2.5, 
2.6-3.9 and ≥ 4 cm in size, respectively. Positive LDHA expression was found in 59.1%, 
77.8% and 100% in tumours that were ≤ 2.5, 2.6-3.9 and ≥ 4 cm in size, respectively 
(Table 1, Figure 3.8). There were no significant differences between PKM2 or LDHA 
expression and tumour location, lymph node involvement, T-stage and metastatic status. 
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Table 3.1: Correlation of PKM2 and LDHA expression with clinicopathological factors. (UCLH cohort and TMA samples). 
 
Positive (High) 
(n=117) n (%)
Negative (Low) 
(n=149) n (%)
Positive (High) 
(n=167) n (%)
Negative (Low) 
(n=99) n (%)
Positive* (High) 
(n=104) n (%)
Negative** (Low) 
(n=162) n (%)
PDAC 124 87 (74.4) 37 (24.8) 96 (57.5) 28 (28.3) 80 (76.9) 44 (27.2)
Ampullary 11 5 (4.3) 6 (4) 7 (4.2) 4 (4) 4 (3.8) 7 (4.3)
Pancreatic cyst 42 8 (6.8) 34 (22.8) 27 (16.2) 15 (15.2) 8 (7.7) 34 (21)
PanIN 19 7 (6) 12 (8.1) 14 (8.4) 5 (5.1) 6 (5.8) 13 (8)
Pancreatistis 21 6 (5.1) 15 (10.1) 14 (8.4) 7 (7.1) 5 (4.8) 16 (9.9)
Pseudocyst 7 1 (0.9) 6 (4) 2 (1.2) 5 (5.1) 1 (1) 6 (3.7)
Normal (Non-neoplastic) 42 3 (2.6) 39 (26.2) 7 (4.2) 35 (35.4) 0 (0) 42 (25.9)
Male 150 65 (55.6) 85 (57) 87 (52.1) 63 (63.6) 55 (52.9) 95 (58.6)
Female 116 52 (44.4) 64 (43) 80 (47.9) 36 (36.4) 49 (47.1) 67 (41.4)
Age at Diagnosis (Years) Median (Range) 135 61 (32-84) 66 (41-82) 0.266 62 (34-84) 64 (32-82) 0.878 61 (34-84) 65 (32-82) 0.552
Well/Moderate 5 4 (4.3) 1 (2.3) 3 (2.9) 2 (6.3) 2 (2.4 3 (5.9)
Moderate 55 36 (39.1) 19 (44.2) 41 (39.8) 14 (43.8) 32 (38.1) 23 (45.1)
Moderate/Poor 71 50 (54.3) 21 (48.8) 55 (53.4) 16 (50) 48 (57.1) 23 (45.1)
Unknown 4 2 (2.2) 2 (4.7) 4 (3.9) 0 (0) 2 (2.4) 2 (3.9)
Patients with metastasis 21 16 (17.4) 5 (11.6) 16 (15.5) 5 (15.6) 15 (17.9) 6 (11.8)
Patients without metastasis 114 76 (82.6) 38 (88.4) 87 (84.5) 27 (84.4) 69 (82.1) 45 (88.2)
Positive lymph node 49 34 (37) 15 (34.9) 37 (35.9) 12 (37.5) 30 (35.7) 19 (37.3)
Negative lymph node 43 30 (32.6) 13 (30.2) 34 (33) 9 (28.1) 27 (32.1) 16 (31.4)
Unknown 43 28 (30.4) 15 (34.9) 32 (31.1) 11 (34.4) 27 (32.1) 16 (31.4)
T1 1 1 (1.1) 0 (0) 1 (1) 0 (0) 1 (1.2) 0 (0)
T2 13 6 (6.5) 7 (16.3) 9 (8.7) 4 (12.5) 5 (6) 8 (15.7)
T3 62 46 (50) 16 (37.2) 49 (47.6) 13 (40.6) 41 (48.8) 21 (41.2)
T4 14 9 (9.8) 5 (11.6) 10 (9.7) 4 (12.5) 8 (9.5) 6 (11.8)
Unknown 45 30 (32.6) 15 (34.9) 34 (33) 11 (34.4) 29 (34.5) 16 (31.4)
Stage I 7 4 (4.3) 3 (7) 5 (4.9) 2 (6.3) 4 (4.8) 3 (5.9)
Stage II 66 46 (50) 20 (46.5) 51 (49.5) 15 (46.9) 40 (47.6) 26 (51)
Stage III 14 9 (9.8) 5 (11.6) 10 (9.7) 4 (12.5) 8 (9.5) 6 (11.8)
Stage IV 3 3 (3.3) 0 (0) 3 (2.9) 0 (0) 3 (3.6) 0 (0)
Unknown 45 30 (32.6) 15 (34.9) 34 (33) 11 (34.4) 29 (34.5) 16 (31.4)
≤ 2.5 22 12 (13) 10 (23.2) 13 (12.6) 9 (28.1) 11 (13.1) 11 (21.5)
2.6-3.9 27 21 (23) 6 (14) 21 (20.4) 6 (18.8) 16 (19) 11 (21.5)
≥ 4 11 10 (11) 1 (2.3) 11 (10.7) 0 (0) 10 (11.9) 1 (2)
Unknown 75 49 (53) 26 (60.5) 58 (56.3) 17 (53.1) 47 (56) 28 (55)
Head 42 27 (29.3) 15 (34.9) 28 (27.2) 14  (43.8) 21 (25) 21 (41)
Body 10 9 (9.8) 1 (2.3) 9 (8.7) 1 (3.1) 9 (10.7) 1 (2)
Tail 8 7 (7.6) 1 (2.3) 8 (7.8) 0 (0) 7 (8.3) 1 (2)
Unknown 75 49 (53.3) 26 (60.5) 58 (56.3) 17 (53.1) 47 (56) 28 (55)
Mean of CD8/HPF Mean±SD 72 16.3±24.3 42.4±43.1 0.0001 20.1±30.7 44.3±40.1 0.005 16.4±24.9 39.5±41.7 0.001
Ki67 Proliferation Index (%) Mean±SD 72 27.8±12.9 12.2±14 0.0001 25.1±14 12.3±15.1 0.004 27.8±12.8 13.7±14.7 0.0001
Tumour Size 
* Both PKM2 and LDHA Positive    **Either PKM2 or LDHA Positive and Both Negative
0.573
Tumour Site 0.17 0.087 0.016
Total N     
(n=266)
Variable P-Value P-Value P-Value
Clinical T-stage 
classiffication
0.214 0.78 0.248
0.019 0.009 0.01
Staging 0.592 0.751
0.99 0.34
Lymph node involvment 0.646 0.615 0.89
PKM2 Expression LDHA Expression Combined Expression
Tumour Types 0.0001
Tumour Differentiation 0.83 0.454
0.0001 0.0001
Sex 0.809 0.067 0.357
0.141
Metastasis status 0.393
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Table 3.2: Summary of the correlations between PKM2, LDHA expression and number of nucleus 
immunostained CD8+TIL and Ki67 proliferation index. 
 
 
 
Figure 3.4: Double immunohistochemical staining of PKM2 and CD8+TIL. Relationship between tumour 
differentiation, PKM2 expression and stained CD8 cells. (A) Well differentiated tumour with negative 
PKM2 expression and high infiltration by CD8+ positive T-lymphocytes. (B) Well differentiated tumour 
with weak PKM2 expression had strong infiltration by CD8+ positive T-lymphocytes. Shows tumour 
autolysis (red arrows). (C) Poorly differentiated tumour strongly positive for PKM2 had sparse infiltration 
by CD8+ positive T-lymphocytes. (D) Intratumoural infiltration by CD8+ cells in a well differentiated and 
PKM2 weakly positive tumour. 
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Figure 3.5: Correlation between PKM2 and LDHA expression with CD8+TIL. (A) Correlation between 
CD8+ tumour infiltrating lymphocytes and PKM2 expression. Tumours with weak PKM2 expression had 
significantly higher number of CD8+TIL than those with strong PKM2 expression (Bar chart, 95% CI). B) 
Number of nucleus stained CD8+TIL significantly decreased with increasing PKM2 expression score 
(R=0.4, p=0.002, Linear Regression Test). C) Pancreatic cancer specimens with weak LDHA expression 
had significantly higher number of nucleus stained CD8+TIL than those with strong LDHA expression 
(Bar chart, 95% CI). D) Number of nucleus stained CD8+TIL significantly decreased with increasing 
LDHA expression in pancreatic cancer specimens (R=0.37, p=0.009, Linear Regression Test).
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Figure 3.6: Immunohistochemical staining of PKM2 and Ki67 in pancreatic cancer. (A) Double 
immunohistochemical staining of Ki67 (red colour, nuclear) and PKM2 (brown colour, cytoplasmic). 
Strongly positive tumour for PKM2 expression had most of the nucleus stained for Ki-67. (B) Single Ki67 
immunostaining with high positive number in tumour area. (C, D) Weak PKM2 expression with few Ki67 
stained cells.
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Figure 3.7: Relationship between PKM2/LDHA expression and Ki67 in pancreatic cancer. A) Correlation 
between mean of Ki-67 proliferation index and PKM2 expression. Tumours with strong PKM2 expression 
were characterized by high number of Ki-67 proliferation index (Bar chart, 95% CI). B) Number of Ki67 
proliferation index was significantly increased with increasing of PKM2 expression score (R=0.485, 
p<0.0001, Linear Regression Test). (C) Pancreatic cancer specimens with strong LDHA expression had 
significantly high number of nucleus stained Ki67 than weak LDHA expression (Bar chart, 95% CI). (D) 
Number of Ki67 proliferation index was significantly increased with increasing LDHA expression score 
(R=0.395, p=0.004, Linear Regression Test).   
 
 
Figure 3.8: PKM2 and LDHA expression in pancreatic cancer tissue microarrays and correlation with 
tumour size. (A) PKM2 expression highly correlate with tumour size and significantly increase with 
increasing of tumour size. (B) Expression of LDHA directly correlate with tumour size and significantly 
increase with increasing tumour size. 
 
 
 
  
102 
 
3.1.1.3: Correlation between PKM2 and LDHA expression and patient survival: 
I next examined whether the expression profile of PKM2 and LDHA predicted survival. 
Patients with tumours scoring > 3 for PKM2 or LDHA expression had significantly 
worse survival compared with those that weakly expressed PKM2 and/or LDHA. Of the 
72 pancreatic cancer samples (UCLH cohort), 46 (64%) strongly expressed PKM2 and 
these patients had a median survival of only 8.9 months compared with 28.9 months in 
the 26 (36%) patients with weak (negative) PKM2 tumour expression (p=0.016, log-rank 
test, Figure 3.9). Similarly, 55 (76.4%) patients with positive LDHA tumour expression 
had a median survival of 10.9 months compared with 34.5 months of the 17 (23.6%) 
patients with weak (negative) LDHA tumour expression (p = 0.029, log-rank test, Figure 
3.9). Moreover, when the expression profile of PKM2 and LDHA was combined, the 
survival of patients with negative expression for both or positive for one was four times 
longer than those with a positive status for both (27.9 months vs. 7.0 months, 
respectively, p = 0.003, log rank test). Among the several survival predictors by the 
univariate analysis (T-stage; p = 0.006, tumour differentiation; p = 0.003, metastatic 
status; p = 0.000), by Cox regression analysis only the combined PKM2 / LDHA 
expression status and tumour differentiation status were independent survival predictors 
(p= 0.003, Hazard ratio (HR) = 4.96 and p=0.015, HR= 3.31, respectively) (Table 3.3).  
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Figure 3.9: Overall patient survival in relation to PKM2 and LDHA expression. Both PKM2 (A) and 
LDHA (B) had a significant prognostic impact on patient survival and the combined expression for both 
markers further stratified the patients into significant groups (C).   
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 Table 3.3: Multivariable analysis of prognostic factors. 
  Variables in equation p-value Hazard ratio 
Step 1 Tumour differentiation 0.096 3.372 
  T-stage 0.877 0.937 
  Metastatic status 0.223 0.333 
  PKM2 and LDHA combined expression 0.007 4.538 
Step 2 Tumour differentiation 0.024 3.109 
  Metastatic status 0.203 0.324 
  PKM2 and LDHA combined expression 0.005 4.642 
Step 3 Tumour differentiation 0.015 3.314 
  PKM2 and LDHA combined expression 0.003 4.959 
 
 
3.1.1.4: Association between tumour types, resection status and survival months: 
To further investigate PKM2 and LDHA expression pattern in pancreatic cancer, I 
evaluated the correlation between expressions of these two important glycolytic enzymes 
with tumour types, resection status and survival rate.  
Twenty-seven of the 72 patients underwent surgical resection for PDAC (n=16) or 
ampullary adenocarcinoma (n=11). Those who underwent surgical resection had a 
significantly longer survival than those who did not undergo surgery (26.5 vs 7.0 
months, P<0.0001; log rank test, Figure 3.10, Table 3.4). As expected, patients with 
ampullary adenocarcinoma had a better prognosis after surgery than those with PDAC, 
with 5 of 11 (45.5%) ampullary carcinoma patients alive at last contact, compared with 
only 1 out of 16 (6.3%) patients with PDAC (P<0.0001; log rank test, Figure 3.10, Table 
3.4). The association of PKM2 and LDHA expression with tumour types, resection status 
and survival in months are described in figure 3.10 and table 3.4.   
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Table 3.4: Summary of correlation between tumour types and resection status and patients survival. 
 
 
Figure 3.10: Survival according to the tumour type and resection status. (A) Patients with ampullary 
tumours had longer survival time than pancreatic adenocarcinoma (p<0.001, log rank test). (B) Resectable 
tumour patients had longer survival time than who did not undergo resection treatment (p<0.001, log rank 
test). (C) Comparing survival time according to the resection in pancreatic adenocarcinoma and ampullary 
resection tumours.   
 
Variables N Survival month Mean ± SD P- value 
Tumour Types 
PDAC 
Ampullary 
 
61 
11 
 
10.41 ± 10.36 
36.5 ± 19.96 
 
0.0001 
Resection status 
YES 
No 
 
27 
45 
 
26.54 ± 18.72 
6.95 ± 4.98 
 
0.0001 
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3.1.1.5: PKM2 and LDHA expression in pancreatic cancer cell lines: 
I also evaluated the level of PKM2 and LDHA expression in pancreatic cancer cell lines 
by western blot. Of 10 pancreatic cancer cell lines, 8 highly expressed PKM2 and 9 
highly expressed LDHA, as defined by intensity of western blot bands (Fig 3.11). The 
PK-59 cell line exhibited weak expression of both LDHA and PKM2, while the KP4 cell 
line weakly expressed PKM2. By immunocytochemistry, both PKM2 and LDHA had 
strong cytoplasmic and nuclear expression (Fig 3.12). 
 
Figure 3.11: Expression of PKM2 and LDHA in pancreatic cancer cell lines as detected by western blot. 
 
 
Figure 3.12: Immunocytochemical staining of Miapaca-2 cell line with PKM2 (A,B,C) and LDHA 
(D,E,F). Strong cytoplasmic and nuclear staining is noticed in proliferating cells. 
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3.1.1.6: Plasma PK and LDH activity in pancreatic cancer and healthy controls: 
Besides studying the expression of PKM2 and LDHA in pancreatic cancer specimens 
and pancreatic cancer cell lines, I also assessed the plasma activity of these two 
glycolytic enzymes. Plasma samples from 51 patients (median age 68 years) with 
pancreatic cancer and 20 healthy controls with a median age of 69 years were obtained. 
Pancreatic cancer patients included 27 men and 24 women with different histological 
stages (Stage I=1, Stage II=7, Stage III=13, Stage IV=20, NA=10), whereas, healthy 
controls included 12 men and 8 women. The activity of PK and LDH in plasma samples 
was measured by using a commercially available PK and LDH activity assay kit 
(BioVision, USA).  
Plasma PK and LDH enzyme activity was significantly higher in patients with pancreatic 
cancer compared to the healthy controls (p < 0.0001, Kruskal-Wallis Test, Figure 3.13), 
and are described in Figure 3.13 and Table 3.5. The activity of PK in pancreatic cancer 
plasma was approximately 2 fold higher than in healthy controls, with mean PK 
activities of 45.5 U/L and 21.6 U/L, respectively. LDH activity in pancreatic cancer 
plasma was approximately 3.5 fold higher than in healthy controls, with values of 685 
U/L and 194 U/L, respectively.  
 
 
Figure 3.13: Plasma pyruvate kinase and lactate dehydrogenase activity in pancreatic cancer compared 
with healthy controls (P < 0.0001, Kruskal-Wallis Test, Bar chart, 95% CI). 
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Table 3.5: Plasma pyruvate kinase and lactate dehydrogenase activity in pancreatic cancer compared to 
the healthy control. 
Diagnosis N 
Age 
Median 
(Range) 
PK activity (U/L) 
(Mean ± SD) 
P- 
Value 
LDH activity (U/L) 
(Mean ± SD) 
P- 
Value 
Pancreatic cancer 51 68 (41-94) 45.5 ± 18.7 0.0001 685.78 ± 167.74 0.0001 
Healthy Control 20 69 (41-80) 21.65 ± 8.5  194.75 ± 77.17  
 
3.1.2: DISCUSSION: 
There is mounting evidence that cancer cells have elevated glucose uptake with a 
concomitant increase in lactate production through sequential catalytic enzyme mediated 
processes (59,172). PKM2 and LDHA are two crucial glycolytic enzymes that facilitate 
these processes to confer cancer cells with a growth advantage over normal cells. To 
date, serum PKM2 has been identified as a diagnostic and prognostic marker with 
comparable sensitivity and specificity to serum CA19-9 marker in pancreatic cancer 
(5,173,174). However, there are limited data on the expression pattern and prognostic 
impact of PKM2 and LDHA in pancreatic cancer (73,175). To the best of our 
knowledge, our study is the first to evaluate the prognostic impact of combined PKM2 
and LDHA expression in the initiation and progression of pancreatic cancer. A recent 
study showed overexpression and phosphorylation of both of these enzymes in thyroid 
cancer compared with benign goitre (176). Our results concur with their findings 
showing significant overexpression of PKM2 and LDHA in pancreatic cancers compared 
with normal pancreatic tissue.  
The step-wise initiation and development of pancreatic cancer often begins with 
pancreatitis, ductal metaplasia, cyst formation or PanIN lesions, leading to pancreatic 
cancer.  Interestingly, our results demonstrate overexpression of LDHA at a very early 
stage along the carcinogenic pathway from pancreatitis through cyst/PanIN to cancer 
with the highest expression in the most aggressive tumours. In contrast, PKM2 
expression increased progressively along the tumorigenic pathway and was lowest in 
cysts, intermediate in PanIN lesions and highest in cancers. Although the exact 
mechanism of this differential expression pattern remains to be elucidated, it is possible 
that the pre-neoplastic lesions acquire the glycolytic phenotype through LDHA 
overexpression and then LDHA itself or other oncogenes induce PKM2 overexpression 
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at later stages when tumour cell proliferation rates are higher. In fact, it has been recently 
shown that the epidermal growth factor receptor (EGFR) induces β-catenin 
transactivation and c-myc expression, upregulating LDHA, which in turn induces 
upregulation of PKM2 expression by alternating splicing of the gene from M1 to M2 
type (177). These findings might partially explain the consistent overexpression of 
LDHA throughout the tumorigenic process and the progressive overexpression of PKM2 
along the carcinogenetic pathway. The expression and enzymatic activity of LDHA and 
PKM2 can also be modulated by tyrosine phosphorylation at various residues (Y10 and 
Y105, respectively) by the oncogenic tyrosine kinase fibroblast growth factor receptor-1 
(178). The differential expression pattern suggests that PKM2 (or a combination of 
PKM2 and LDHA) would be a better choice for discriminating cancer from pre-
neoplastic lesions compared with LDHA alone, except in pancreatitis where both 
markers are highly expressed.  
The main reason for using several pancreatic cancer cell lines was to study the level of 
PKM2 and LDHA expression alongside tissue sections and plasma samples, and to 
compare the expression levels of these two glycolytic enzymes in order to select a 
suitable cell line for both in vitro and in vivo study. The western blot is a semi-
quantitative analysis and is a suitable method for comparing the expression level of these 
two enzymes.  
Interestingly, we noticed consistently high expression of both PKM2 and LDHA in 
Miapaca-2, PK-1 and BxPc-3 cell lines in different stages of cell culture. In fact, these 
pancreatic cancer cell lines are more aggressive and exhibit faster growth than other cell 
lines used in this study. A possible explanation for this is the high expression of the two 
glycolytic enzymes PKM2 and LDHA, which are necessary for cell proliferation and 
growth.  
Treating pancreatic cancer is highly challenging due to late diagnosis, and lack of 
appropriate prognostic markers and effective therapies. Our results demonstrate that both 
PKM2 and LDHA are significant prognostic markers in pancreatic cancer and the 
combination provides improved stratification of outcome. These results are in line with 
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previous publications showing a significant prognostic effect of LDHA or PKM2 in 
other tumour types, including squamous cell carcinoma, cholangiocarcinoma and gastric 
cancer (168,179,180). The exact mechanisms associated with the overexpression of 
PKM2 and LDHA that lead to poor prognosis remain unclear. Very recently, 
Rajeshkumar et al. (2015) found that the LDHA small molecule inhibitor FX11 can 
impede tumour growth, reduce tumour cell proliferation and induce apoptosis in a 
patient-derived mouse xenograft model of pancreatic cancer with mutant TP53, while 
tumours harbouring wild-type TP53 were completely resistant to FX11 (181). In this 
study, I noticed a significant direct correlation between staining scores and the tumour 
cell proliferation index, and by using the double labelling technique, I was able to 
identify Ki-67 positive proliferating cells topographically co-localising in PKM2 positive 
areas. It has been well recognised that these glycolytic enzymes translocate to the 
nucleus and interact with several other oncogenic transcription factors and transcribe 
several cell proliferating signaling pathways including Stat3, β-catenin, HIF-1, Oct-4, 
cyclin D1 (182). Moreover, PKM2 has been implicated in the phosphorylation of the 
chromosomal spindle checkpoint protein Bub3-Bub1-Blinkin complex, which ensures 
fidelity of chromosomal segregation during cell proliferation (183). Although I could not 
find any significant correlation with tumour stage and metastasis status, strong 
expression of PKM2 was observed in metastatic tumours invading muscle and blood 
vessels, indicating the aggressive phenotype of pancreatic tumours expressing the 
glycolytic enzymes. We and others have previously shown in cholangiocarcinoma and 
lung cancer, respectively, that tumour-associated angiogenesis is induced by PKM2 and 
LDHA, which could be another contributing factor to poor prognosis (168,184). 
Host immune evasion is a hallmark of the aggressive tumour phenotype. Although a 
limited number of studies have provided evidence of a link between host immune 
suppression and the tumour glycolytic phenotype, to date, there is no concrete evidence 
showing a correlation between the expression of PKM2, LDHA and CD8+ effector cell 
infiltration. Interestingly, I noticed a significant inverse correlation between the PKM2 
and LDHA expression and CD8+ cell infiltration, with an accumulation of CD8+ cells in 
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tumours that did not express PKM2. Recently, Crane et al. (2014) reported that LDHA 
secreted by glioblastoma cells downregulated the Natural Killer group 2, member D 
receptor on natural killer cells and thus subverted host immune surveillance (185). 
Similarly, Liu et al. (2015) reported that PKM2 expression was related to increased 
infiltration of primary and metastatic tumours by myeloid derived suppressor cells, 
responsible for the suppression of NK cells and induction of host immune suppression by 
regulatory T cells (186). I postulate that the compromised immune surveillance induced 
by enhanced expression of PKM2 and LDHA, and reduced CD8+ effector T-cells might 
be another contributing factor associated with poor prognosis of the glycolytic phenotype 
of pancreatic cancer. 
There are some limitations to the studies; these include limited sample size and lack of 
some clinicopathological information. The scoring system of PKM2 and LDHA 
expression is another limitation, as various scoring systems have been reported 
(168,187–190), and an optimal scoring system for PKM2 and LDHA expression has not 
yet been established. In my study, the PKM2 and LDHA expression score was classified 
as negative or positive, which was based on the intensity and extent of PKM2 and LDHA 
expression across tumour areas. Moreover, surgical resection and chemotherapy might 
have affected the correlation of PKM2 and LDHA expression with overall survival of 
patients.  
In conclusion, I have shown a differential expression pattern for PKM2 and LDHA from 
cysts through PanIN lesions to pancreatic cancer, with upregulation of LDHA throughout 
the carcinogenetic process and a progressive upregulation of PKM2 expression along the 
carcinogenetic pathway. Moreover, the combined expression of these glycolytic enzymes 
is a strong independent marker of poor prognosis, attributable to increased cell 
proliferation, larger tumour size and host immune evasion. Further studies are underway 
to evaluate these markers as possible targets for therapy in pre-clinical models of 
pancreatic cancer.    
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3.2: Activation of PKM2 in combination with inhibition of LDHA synergistically 
inhibit pancreatic cancer cell proliferation in vitro 
 
3.2.1: RESULTS:  
3.2.1.1:  Expression of PKM2 and LDHA in pancreatic cancer cell lines: 
The expression of PKM2 and LDHA was evaluated in ten different pancreatic cancer cell 
lines (Miapaca-2, BxPc-3, PANC-1, PK-1, PK-59, PK-45P, PK-45H, KLM-1, KP-4, 
NOR-P1) by Western blot. The levels of PKM2 and LDHA expression was measured 
when cells reached approximately 50% (proliferation stage) or 90% (confluent stage) 
confluency. The total protein was then quantified and equal amounts of protein were 
loaded into the gel. The intensity of PKM2 and LDHA expression was detected and 
measured using an image grabber.  
I found that the majority of the pancreatic cancer cell lines highly expressed both PKM2 
and LDHA. Out of the 10 cell lines, 9 had high LDHA expression and 8 had high PKM2 
expression, as indicated by intensity of the Western blot bands (Figure 4.1). The PK-59 
cell line exhibited weak expression of both LDHA and PKM2, while the KP4 cell line 
had a weak expression of PKM2 only. The expression of PKM2 was high in the PANC-
1, PK-45H and KLM-1 cell lines during proliferation stage compared to the confluent 
stage. However, there was no difference in PKM2 expression between these two 
different stages in the other pancreatic cancer cell lines. There was no difference in 
LDHA expression between the proliferation and confluent culture stages in all pancreatic 
cancer cell lines. The Miapaca-2, BxPc-3 and PK-1 cell lines highly expressed both 
PKM2 and LDHA at both stages of cell culture confluency. Therefore, the Miapaca-2 
and BxPc-3 cell lines were selected for further studies and for the development of 
tumour xenografts in nude mice. The expression of PKM2 and LDHA in the various 
pancreatic cancer cell lines are shown in figure 4.1.     
The expression of both PKM2 and LDHA was further examined by 
immunocytochemistry in the Miapaca-2 cell line (Figure 3.12). Immunocytochemistry 
staining showed that PKM2 and LDHA were strongly expressed by Miapaca-2 cells. 
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LDHA expression was relatively higher in the nucleus of the cell, whereas expression of 
PKM2 was mostly cytoplasmic (Figure 3.12).   
 
 
 
Figure 3.14: PKM2 and LDHA expression in different pancreatic cancer cell lines and different stages of 
cell culture. A) Western blot analysis and comparison between band intensity in different pancreatic cancer 
cell lines. B) Intensity of PKM2 and LDHA expression normalized with β-actin, represented by bar chart.  
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3.2.1.2:  Effect of PKM2 inhibition on pancreatic cancer cell proliferation: 
Shikonin was used as the PKM2 inhibitor in our studies. In order to investigate the effect 
of Shikonin on pancreatic cancer cell proliferation, PK-1 cells were treated with different 
concentrations (2.5 to 80 µM) of Shikonin over the period of 24, 48, 72 and 96 hours 
(see Appendix 1). The results of this study showed that the Shikonin had a strong 
cytotoxic effect on the viability of PK-1 cells.  
Based on these results, a range of Shikonin concentrations from 1 to 5 µM were selected 
over two time intervals, either 24 and 72 hours or 24 and 96 hours, for further evaluation. 
As shown in the figure 4.2 and table 4.1, Shikonin had high cytotoxicity in the PK-1, PK-
45H, and KLM-1, Miapaca-2, KP4, PK-45 H and PK-59 cell lines, with an IC50 of 2-3 
µM for 24 hour exposure time. Whereas, Shikonin had lower cytotoxicity in PANC-1 
cell line for the 24 hour exposure time, with an IC50 of 3.97µM. The effect of Shikonin 
treatment was then investigated over 72 or 96 hour exposure times in pancreatic cancer 
cell lines. The results showed that Shikonin was highly potent and had the high cytotoxic 
effect in all pancreatic cancer cell lines, with an IC50 of 1-2 µM for both 72 and 96 hours 
exposure times (Figure 4.2 and Table 4.1).  
Shikonin had a high cytotoxic effect on pancreatic cancer cells. As shown in figure 3.16, 
treatment of pancreatic cancer cells with Shikonin lead to morphological change and 
shrinkage of pancreatic cancer cells, which in turn may finally lead to cell death by both 
apoptosis and necrosis.   
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Figure 3.15: The effect of different concentrations of Shikonin on pancreatic cancer cell line proliferation 
after 24, 72 and 96 hours interaction. 
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Table 3.6: The effect of Shikonin on pancreatic cancer cell lines proliferation at different time points, 
expressed by the half maximal inhibitory concentration (IC50). 
 
 
 
 
Figure 3.16: The effect of different concentrations of Shikonin on the PK-1 and PANC-1 cell line after 96 
hours interaction. (A) PK-1 control (DMSO). (B, C) PK-1 cells treated with 2.5µM and 5µM Shikonin for 
96 hours, red arrows show shrink, morphological change, nuclear breakdown, breakdown of the cell and 
rupture of cell membrane of PK-1 cells as a response to treatment. (D) PANC-1 control (DMSO). (B, C) 
PANC-1 treated with 3µM and 5µM Shikonin for 96 hours, red arrows show shrinkage, morphological 
change, nuclear breakdown of PNAC-1 cells as a response to treatment. 
 
 
 
  
Pancreatic cancer cell lines  
Shikonin treatment (µM)  
IC50 of 24 hrs.  
(IC50 ± SE)  
IC50 of 72 hrs.  
(IC50 ± SE)  
IC50 of 96 hrs.  
(IC50 ± SE)  
PK-1  2.98 ± 0.14639  -----  1.976 ± 0.09787  
PANC-1  3.97 ± 1.487  -----   1.422 ± 0.37  
PK-45H  2.836 ± 0.717  -----   1.471 ± 0.373  
KLM-1  3.022 ± 0.726    ----- 1.461 ± 0.514  
MIAPaca-2  1.81 ± 3.08  1.77 ± 2.92  -----   
KP4  2.255 ±7.68  1.747 ± 2.85  -----  
PK-45P  1.88 ± 3.16  1.743 ± 2.84   ----- 
PK-59  2.015 ± 4.93  1.76 ± 2.88   ----- 
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The enzymatic activity of PKM2 was also evaluated in response to Shikonin treatment in 
the Miapaca-2 cell line. The Miapaca-2 cells were treated with various concentrations of 
Shikonin for an hour, following which protein was extracted and the activity of PK 
measured. As shown in the figure 3.17, PK activity indirectly correlated with Shikonin 
concentrations and decreased with increasing concentrations of Shikonin. At 40µM of 
Shikonin concentration, an approximate 70% inhibition of PK activity was observed. 
 
Figure 3.17: Effect of Shikonin on pyruvate kinase activity in the Miapaca-2 cell line. 
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3.2.1.3: Activation of PKM2 with inhibition of LDHA attenuates pancreatic cancer 
cell proliferation: 
Tetramerisation of PKM2 in combination with LDHA inhibition is a novel strategy for 
inhibition of pancreatic cancer cell proliferation. To test our hypothesis, I used and 
optimized two commercially available PKM2 activators (PKM2 activator III, and IV) 
with an LDHA inhibitor (FX11) to get a maximum inhibitory effect.    
   
3.2.1.4: Combination of PKM2 activator III and FX11: 
Pancreatic cancer cell lines were treated with PKM2 activator III (Calbiochem-Merck 
Millipore Ltd, UK) and LDHA inhibitor (FX11, Toronto Research Chemicals Inc., North 
York, Ontario, Canada) or a combination of both (concurrent treatment). PKM2 activator 
III is an N-(4-(4-(2-Methoxyphenyl) piperazine-1-carbonyl) phenyl) quinoline-8-
sulfonamide compound and FX11 is a 2, 3-dihydroxy-6-methyl-7-(phenylmethyl)-4-
propyl-1-naphthalenecarboxylic acid compound. Miapaca-2 and PK-59 pancreatic cancer 
cell lines were used for this study, since Miapaca-2 cells have a high expression of both 
PKM2 and LDHA and the PK-59 cells have a low expression of both.  Cells (3000 per 
well) were plated in 96-well plates and treated at a range of concentrations (0-75 µM) 
with either PKM2 activator III or FX11 or combination of both for 24, 48, 72 and 96 
hours. I found that, activation of PKM2 in combination with LDHA inhibition 
synergistically inhibited both pancreatic cancer cell lines (Figure 4.5 and Table 4.2). 
Notably, the combination therapy had a high inhibitory effect and strong synergism in 
Miapaca-2 cell line for 72 hour exposure time. Treatment with PKM2 activator III alone 
had minimal effect on pancreatic cancer cell proliferation (IC50< 75 µM), however, when 
combined with LDHA inhibitor (FX11), a significant reduction in proliferation was 
observed.   
As PKM2 activator III has a very low solubility in DMSO, it was difficult to determine 
the precise concentration of this agent; therefore, I did not pursue further studies with it.   
 
  
119 
 
 
Figure 3.18: Cytotoxicity of PKM2 activator III, LDHA inhibitor (FX11) and combination treatment at 
different time points. 
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Table 3.7: The effect of PKM2 activator III, LDHA inhibitor (FX11) and combination treatmnet on Miapaca-2 and PK-59 cell lines proliferation at different time 
points, expressed by the half maximal inhibitory or activatory concentration (IC50) or (AC50). 
Cell line Time of Interaction 
AC50 (µM) ± SE IC50 (µM) ± SE IC50 (µM) ± SE 
Combination Index Pharmacological Interaction Results PKM2 Activator III FX11 Combination 
MIAPaca-2 24 hrs > 75 > 75 60.21 ± 4.25 0.571 Synergism 
 48 hrs > 75 70.14 ± 5.5 44.27 ± 2.24 0.572 Synergism 
 72 hrs > 75 60.54 ± 4.78 39.53 ± 2.42 0.41 Synergism 
 96 hrs > 75 53..93 ± 9.69 33..98 ± 4.7 0.49 Synergism 
PK-59 24 hrs > 75 > 75 > 75 0.67 Synergism 
 48 hrs > 75 > 75 > 75 0.55 Synergism 
 72 hrs > 75 76.92  ± 7.25 64.1 ± 3.63 0.58 Synergism 
 96 hrs > 75 73.1 ± 7.55 59.38 ± 3.37 0.59 Synergism 
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3.2.1.5: Combination of PKM2 activator IV and FX11: 
I sought an alternative activator of PKM2 that has better solubility than PKM2 activator 
III; I found another commercially available PKM2 activator (PKM2 activator IV), which 
had a higher aqueous solubility. PKM2 activator IV (TEPP-46) is a 6-((3-Aminophenyl) 
methyl)-4-methyl-2-methylsulfinylthieno [3, 4] pyrrolo [1, 3-d] pyridazin-5-one 
compound from Calbiochem-Merck Millipore Ltd, UK. The effects of PKM2 activator 
IV (TEPP-46) alone or in combination with LHDA inhibitor (FX11) was then evaluated 
in different pancreatic cancer cell lines.   
 
3.2.1.6: Optimisation of PKM2 activator IV and LDHA inhibitor combination: 
In order to obtain maximum effect of the combination therapy on pancreatic cancer cell 
proliferation in vitro, I optimised exposure time and the ratio of PKM2 activator to 
LDHA inhibitor combination. The Miapaca-2 cell line was used for this study, based on 
its high expression of both PKM2 and LDHA as described above. The Maipaca-2 cells 
were treated with PKM2 activator IV (TEPP-46) or LDHA inhibitor (FX11) alone or in 
combination at a range of concentrations from 2.5µM to 100µM, for 24, 48, 72 and 96 
hours exposure times. Our results demonstrate that the maximum inhibitory and 
synergistic effect was obtained at a combination ratio of one-to-one with a 72-hour 
exposure time. The details of optimisation are shown in figure 4.6 and Appendix 1.  
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Figure 3.19: Optimization of PKM2 activator IV (TEPP-46) and LDHA inhibitor (FX11) combination and 
time of treatment. 
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3.2.1.7: Combination therapy synergistically inhibits pancreatic cancer cell 
proliferation: 
The synergistic effect of combination treatment with PKM2 activator IV (TEPP-46) and 
LDHA inhibitor (FX11) was investigated in 9 pancreatic cancer cell lines. Based on our 
results above, a one-to-one concentration ratio of the drugs and 72 hour exposure time 
was used for treatment of pancreatic cancer cell lines. The AC50 and IC50 values for 
TEPP-46, FX11 and combination were then determined. Treatment with TEPP-46 alone, 
had no significant effect on cell proliferation; however, when combined with FX11, there 
was a significant reduction in pancreatic cancer cell proliferation (Figure 4.7). The 
combination treatment had a high inhibitory effect in the Miapaca-2 and BxPc-3 cell 
lines with an IC50 of 40.2 µM and 30.3 µM, respectively.     
Further evaluation of synergism of the combination treatment was conducted by 
calculating the combination index (CI), where 50% growth inhibition was achieved with 
the treatments. Table 4.3 summarizes the AC50 and IC50 of TEPP-46, FX-11 and 
combined drugs, along with the CI of the combination treatment. Combination indices 
were <1, which indicates synergism for the combination treatment with TEPP-46 and 
FX-11. The CI for the combination therapy in the Miapaca-2 and BxPc-3 cell lines was 
0.48 and 0.45, respectively, which is representative of a strong synergistic effect.  
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Figure 3.20: Cytotoxicity of PKM2 activator IV (TEPP-46), LDHA inhibitor (FX11) and combination 
treatment on different pancreatic cancer cell line proliferation after 72 hours of treatment. 
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Table 3.8: The effect of PKM2 activator IV (TEPP-46), LDHA inhibitor (FX11) and combination treatment on proliferation of different pancreatic cancer cell lines after 72 hours 
of interaction, expressed by the half maximal inhibitory or activatory concentration (IC50) or (AC50). 
Cell line Time of Interaction 
AC50 (µM) ± SE IC50 (µM) ± SE IC50 (µM) ± SE Combination 
Index 
Pharmacological 
 Interaction Results PKM2 Activator IV FX11  Combination 
Miapaca-2 72 hrs > 75 60.54 ± 3.1 40.21 ± 1.82 0.48 Synergism  
BxPc-3 72 hrs > 75 49.27 ± 1.53 30.32 ± 1.05 0.45 Synergism  
KP-4 72 hrs > 75 58.4 ± 2.25 43.05 ± 1.3 0.61 Synergism  
PK45P 72 hrs > 75 > 75 66.07 ± 2.2 0.51 Synergism  
PK-59 72 hrs > 75 76.92 ± 3.32 59.03 ± 1.53 0.61 Synergism  
KLM-1 72 hrs > 75 43.3 ± 3.66 36.05 ± 2.5 0.52 Synergism  
PANC-1 72 hrs > 75 76.7 ± 3.28 58 ± 1.85 0.59 Synergism  
PK-1 72 hrs > 75 48.8 ± 2.8 30.8 ± 3.18 0.51 Synergism  
PK-45H 72 hrs > 75 > 75 56 ± 2.9 0.516 Synergism  
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3.2.2: DISCUSSION: 
Pancreatic cancer is one of the deadliest malignancies worldwide. Due to the 
asymptomatic development of pancreatic cancer, early diagnosis of this disease remains 
a challenge. Palliative chemotherapy is the main treatment option for patients with 
locally advanced or metastatic disease. Targeting metabolic enzymes, such as PKM2 and 
LDHA, could be an effective and novel treatment strategy for pancreatic cancer. 
The use of PKM2 inhibitor (Shikonin) as a treatment of pancreatic cancer comes from 
the observation that the down-regulation of the PKM2 gene by siRNA inhibits cancer 
cell proliferation. Our results demonstrate that inhibition of PKM2 by Shikonin has a 
strong cytotoxic effect in a number of pancreatic cancer cell lines with an IC50 of 1-4 
µM. Shikonin can inhibit pancreatic cancer cell proliferation by inhibition of PKM2 
enzyme and halt glycolysis, which may finally lead to cell death. The enzymatic activity 
assay provided the evidence of inhibition of PKM2 by Shikonin in a dose-dependent 
(Figure 3.17). Our data are consistent with a previous report showing that Shikonin and 
its analogue can effectively inhibit cancer cell proliferation by the selective inhibition of 
tumour PKM2 (112). Shikonin not only inhibits the PKM2 enzyme but also affects 
mitochondrial function, inducing reactive oxygen species (ROS) generation and cell 
death by apoptosis (191,192).  
Shikonin has been shown to induce cell death by apoptosis in several cancer cell lines, 
including gastric cancer (193), breast cancer (194), bladder cancer (195), ovarian cancer 
(196), prostate cancer (197) and osteosarcoma cells (192). Wu el al (2004) found that 
high dose Shikonin induces programmed cell death by apoptosis in the early stages of the 
melanoma cells treatment, while necrosis play a major role in cell death after 48 hour of 
treatment of those cells (198). Similarly, Yeh et al (2015) found that low-dose Shikonin 
reduces cell viability and induces apoptosis and cellular senescence through the up-
regulation of cell cycle expression and apoptosis signaling pathway, while both necrosis 
and apoptosis were responsible for lung cancer cell death with high dose Shikonin (199). 
The results of the present study concur with these findings showing pancreatic cancer 
cell death by both apoptosis and necrosis as a response to Shikonin treatment. 
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Since inhibition of glycolysis (by inhibiting PKM2) can be toxic to both normal and 
tumour cells, I decided to evaluate the effects of an PKM2 activator on pancreatic cancer 
cell proliferation and this strategy might be less toxic to normal cells. 
I have previously reported high expression of PKM2 and LDHA in pancreatic cancer 
patient samples and in pancreatic cancer cell lines. In this context, I hypothesized that 
targeting PKM2 (activation) and LDHA (inhibition) could effectively reduce pancreatic 
cancer cell proliferation. 
Indeed, our results demonstrate that activation or tetramerisation of PKM2 in 
combination with the inhibition of LDHA synergistically inhibited pancreatic cancer cell 
proliferation in vitro. As described in the introduction section, PKM2 can be a dimer or 
tetramer. Its tetrameric isoform is predominately found in normal cells and is involved in 
direct glycolysis toward energy production, however, its dimeric isoform is generally 
found in cancer cells, replacing the main pyruvate kinase isoform, driving glycolysis 
towards the anabolic pathway (76,77,87).  
Similarly, LDHA is a key glycolytic enzyme that catalyses the conversion of pyruvate to 
lactate, which is extruded to the extracellular milieu through the mono-carboxylate 
transporter 4 (MTC4). Lactate derived from hypoxic tumour cells can be used as a major 
source of metabolic fuel in well-oxygenated tumour cells. Aerobic tumour cells take up 
lactate through the MCT1 transporter and use it as a main source of energy, sparing 
glucose for hypoxic tumour cells. This mechanism provides an alternate source of energy 
for the survival of tumour cells (135,136).  
Therefore, tetramerisation of PKM2 can inhibit the anabolic pathway and deplete 
glycolytic intermediates, which are precursors for cancer cell proliferation. Inhibition of 
LDHA can also reduce lactate production, causing a depletion of extracellular lactate, 
which is used as an energy source in well oxygenated tumour cells and as a consequence, 
cancer cell proliferation is inhibited. 
Finally, the high expression of PKM2 and LDHA can result in chemoresistance and the 
combination of PKM2 activator and LDHA inhibitor in conjunction with chemotherapy 
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could be an effective therapy for patients with metastatic pancreatic cancer, prolong 
survival and overcome chemoresistance.  
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3.3: Activation of Pyruvate kinase M2 (PKM2) combined with inhibition of 
Lactate dehydrogenase A (LDH-A) as a novel strategy for the treatment of 
pancreatic cancer 
 
3.3.1: RESULTS: 
3.3.1.1: Pancreatic cancer cell line selection: 
To find the suitable pancreatic cancer cell lines for in vitro and in vivo studies, the 
expression of PKM2 and LDHA were studied in 10 different pancreatic cancer cell lines 
(Miapaca-2, BxPc-3, PANC-1, PK-1, PK45H, PK-45P, PK-59, KP-4, KLM-1, NOR-P1) 
at two different stages of cell culture. The expression of these two enzymes was 
evaluated by Western blot in the proliferative and non-proliferative stage (50% and ~ 
90% confluency, respectively).  
I found that Miapaca-2, BxPc-3 and PK-1 cell lines had a stable and relatively high 
expression of PKM2 and LDHA in both stages of cell culture (see Figure 4.1).  
Therefore, I conducted the remainder of the studies in the BxPc-3 and Miapaca-2 cell 
lines. Moreover, BxPc-3 cells were stably transfected with the firefly luciferase gene 
(luc2), to help assess in vivo tumour growth.  
3.3.1.2: Combination therapy synergistically inhibits pancreatic cancer cell 
proliferation: 
The effect of TEPP-46 and FX11 alone or in combination on BxPc-3 and Miapaca-2 cell 
proliferation were assessed. Briefly, TEPP-46 and FX11 alone or in combination were 
applied for 72 hour to both cell lines. Half maximal inhibitory (IC50) and activatory 
(AC50) concentration of FX11, TEPP-46 and combination were assessed and compared 
to each other. Treatment with PKM2 activator IV, TEPP-4, did not have a significant 
effect on a pancreatic cancer cell proliferation; however, when combined with the LDHA 
inhibitor, FX11, a significant reduction in pancreatic cancer cell proliferation was 
observed. As shown in figure 5.1, the combination therapy curve was shifted to the left 
compared to single treatment curves. The IC50 of the combination therapy was 40.2 and 
30.3 µM for the Miapaca-2 and BxPc-3 cell lines, respectively (Table 5.1). 
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To further evaluate synergism of combination treatment, the combination index (CI) of 
50% inhibitory was calculated. Combination index values were < 1, indicating synergism 
for the combination of TEPP-46 and FX11 in both Miapaca-2 and BxPc-3 cell line 
(Table 5.1).  
Miapaca-2 and BxPc-3 cell lines were also stained with haematoxylin to microscopically 
show the effect of the combined treatment on cell histology and viability (Figures 5.2 
and 5.3). As shown in figures 5.2 and 5.3, combination therapy was highly toxic, in a 
concentration of 75 µM significantly reduced the number of viable cells compared to the 
DMSO control or single treatment.    
The inhibitory effect of single and combination treatment was also evaluated by 
evaluating bioluminescence in BxPc-3 cells. Following single or combin9bation 
treatment for 72 hour, cells were incubated with D-luciferin (VivoGlo™ Luciferin, In 
Vivo Grade, Promega UK Ltd, UK) for 10 minutes and bioluminescence was detected 
with IVIS (IVIS Lumina 100, PerkinElmer, Caliper LifeSciences, USA) (Figure 5.4). 
Consistent with the MTS assay and haematoxylin staining, the combination treatment 
had a high cytotoxic effect on BxPc-3 cells, and only few viable cells were detected at a 
concentration of 75µM.        
 
Figure 3.21: The effect of single and combination therapy on (A) Miapaca-2 and (B) BxPc-3 cell lines. 
Combination therapy synergistically attenuated cell proliferation and the curve shifted to the left compared 
to the single treatment. 
 
  
131 
 
 
 
Table 3.9: Summary of the effects of single and combination treatment on pancreatic cancer cell 
proliferation at different time points expressed by the half maximal inhibitory  or activatory concentration 
(IC50 or AC50). 
Cell line 
Time of 
Interaction 
(Hours) 
AC50 (µM) ± SE IC50 (µM) ± SE IC50 (µM) ± SE Combination 
Index 
Pharmacological 
Interaction 
Results 
PKM2 Activator 
IV FX11  Combination 
MIAPaca-2 72  > 75 60.54 ± 3.1 40.21 ± 1.82 0.48 Synergism  
BxPc-3 72  > 75 49.27 ± 1.53 30.32 ± 1.05 0.45 Synergism  
 
 
 
 
 
Figure 3.22: Effect of single and combination therapy on Miapaca-2 cell viability. After 72 hours of 
treatment, cells were washed and fixed in ice cold absolute methanol and permeabilized with 0.25% triton 
X-100 in PBS and stained with haematoxylin.     
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Figure 3.23: Effect of single and combination therapy on BxPc-3 cell viability. After 72 hours of 
treatment, cells were washed and fixed in ice cold absolute methanol and permeabilised with 0.25% triton 
X-100 in PBS and stained with haematoxylin.  
 
 
 
Figure 3.24: Effect of single and combination treatment on the BxPc-3 cells compared to DMSO control. 
After 72 hours of treatment cells were incubated for 10 min with D-luciferin; bioluminescence was 
detected by using IVIS.     
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3.3.1.3: PK and LDH activity measurement:  
To confirm that the inhibitory effect of pancreatic cancer cell proliferation was due to the 
activation of PKM2 and inhibition of LDHA, PK and LDH activity was evaluated in 
treated and in DMSO control cells. Miapaca-2 and BxPc-3 cells were seeded in 6 well-
plates and treated with different concentrations of either TEPP-46 or FX11 (from 0-100 
µM) for 6 hours, PK and LDH activity were then measured by a commercially available 
PK and LDH activity assay Kit (BioVision, USA) and compared with control. A positive 
correlation between PKM2 activator IV (TEPP-46) concentration and PK activity was 
observed. PK activity gradually increased with increasing TEPP-46 concentration; at a 
concentration of 100µM, PK activity was increased by ~2.5 fold in both Miapaca-2 and 
BxPc-3 cells compared to DMSO treated cells (Figure 5.5). However, LDH activity in 
treated cells gradually decreased with increasing FX11 concentrations; at a concentration 
of 100 µM, LDH activity in both Miapaca-2 and BxPc-3 cells decreased by ~70% 
compared to DMSO treated cells (Figure. 5.5).    
 
 
Figure 3.25: Effect of different concentrations of PKM2 activator IV (TEPP-46) and LDHA inhibitor 
(FX11) on PK and LDH activity in Miapaca-2 and BxPc-3 cell lines. 
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3.3.1.4: Combination therapy synergistically attenuates tumour xenograft growth:   
The effect of the combination therapy was further investigated in vivo, in mice bearing 
Miapaca-2 or BxPc-3 tumour xenografts. Mice were treated with single or combination 
agent therapy and compared to vehicle control groups. Miapaca-2 xenografts were 
relatively aggressive and fast growing compared with the BxPc-3Luc2 xenografts.  
3.3.1.4.1 :  Mice bearing Miapaca-2 tumour xenografts:  
Immunocompromised mice were injected with 6x106 Miapaca-2 cells in the right flank. 
Tumours were left to grow for 2 weeks and mice were randomly divided into following 
four groups: (1) high-dose combination therapy (25 mg/kg TEPP-46 + 2 mg/kg FX11), 
(2) low-dose combination therapy (13 mg/kg TEPP-46 + 1 mg/kg FX11), (3) LDHA 
inhibitor therapy (2 mg/kg FX11) and (4) vehicle control. Mice in the high-dose 
combination and vehicle control groups received daily intraperitoneal (IP) injections of 
drugs and solvent, respectively. Mice in the low-dose combination and LDHA inhibitor 
therapy groups had an osmotic pump (Alzet micro-osmotic pump, model 1004, 
Cupertino, CA, USA) implanted intraperitoneally for drugs delivery. The osmotic pumps 
were characterized by reservoir volume of 100µl and a pumping rate of 0.11µl/hr for the 
duration of 28 days. Briefly, pumps were filled with 100µl of FX11 (53.8mM) or with 
100 µl of FX11 and TEPP-46 (53.8mM and 0.47M, respectively). Mice were weighed 
and tumour volumes measured (digital Caliper) twice weekly throughout the duration of 
therapy, which lasted 3 weeks.   
The combination therapy significantly delayed tumour growth compared to the vehicle 
control (p < 0.0001, Kruskal-Wallis test, Figures 5.6). As shown in the figure 5.6, no 
significant differences between tumour volumes were observed between high-dose 
combination and vehicle control groups up to day 13; however, past that day, the high-
dose combination treatment significantly delayed tumour grow and tumour volume was 
significantly smaller than in vehicle control group (p < 0.0001, Kruskal-Wallis test, 
Figures 5.6 and 5.7).  
   
  
135 
 
 
Figure 3.26: Tumour growth curve over 21 days treatment. 
 
No significant differences were detected in tumour volume between low-dose 
combination and LDHA inhibitor groups compared to the vehicle control group. It is 
likely that the drug formulation (FX11 and TEPP-46) crystallised inside the osmotic 
pumps as a result of poor solubility, which could have altered drug release. Furthermore, 
the physiological body temperature of the mice and the duration of the study could have 
promoted drug crystallisation inside the osmotic pumps, as observed upon mouse 
sacrifice at the end of the study. Blood sample analysis and IHC staining for PKM2 and 
LDHA also showed no effect of low-dose combination and FX11 treatment on activity 
of these two glycolytic enzymes in the blood and the expression in tumour tissues, 
confirming a lack of drug delivery through the osmotic pumps.  
IHC analysis of tumour sections from the high-dose combination group showed lower 
expression of PKM2 and LDHA compared with the vehicle control group. Similarly, 
activity of PK and LDH in plasma samples was significantly different in the high-dose 
combination group compared with vehicle control group (P< 0.0001, Kruskal-Wallis 
Test). Plasma PK and LDH activity was 2-fold higher and ~60% lower, respectively, in 
the high-dose combination group compared with the vehicle control group. No 
significant differences in PKM2 and LDHA expression were observed in tumour 
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sections nor in plasma activity of PK and LDH in the low-dose combination or LDHA 
inhibitor treated groups compared to the vehicle control group.  
 
 
Figure 3.27: Miapaca-2 xenograft tumours in mice from different treatment groups. A) Xenograft tumour 
size (red arrow) of high-dose combination group compared to the vehicle control group. B) Tumour 
xenografts in high-dose combination, vehicle control and in situ pancreatic cancer groups, the cell line was 
stained with DIL fluoresce dye and the fluorescence signal was detected by IVIS machine.  
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3.3.1.4.2 :  Mice bearing BxPc-3 tumour xenografts:  
To further confirm the effect of the combination therapy, subcutaneous and orthotopic 
tumour xenografts were established with BxPc-3Luc2 cells. Briefly, 6X106 BxPc-3 cells 
were injected in the right flank of mice for subcutaneous xenografts or surgically 
implanted into the pancreas for the generation of orthotopic xenografts. 
In this experiment, mice bearing subcutaneous BxPc-3 xenografts were treated with 
vehicle control, high-dose combination (30 mg/kg TEPP-46 + 2.1 mg/kg FX11), low-
dose combination (15 mg/kg TEPP-46 + 1.5 mg/kg FX11), LDHA inhibitor (2.1 mg/kg 
FX11) and PKM2 activator IV (30 mg/kg TEPP-46). Mice bearing BxPc-3 orthotopic 
xenografts were administered either vehicle control or high-dose combination treatment. 
The treatment regimen was continued for three weeks; mice were weighed and tumour 
volumes measured thrice per week; bioluminescent images were obtained at the 
beginning and end of the therapy.  
High-dose and low-dose combination therapy and FX11 treatment significantly delayed 
tumour growth compared to the vehicle control (p < 0.0001, Kruskal-Wallis Test, Figure 
5.8). Tumour volume in high-dose combination treated group was also significantly 
smaller than tumour volume in low-dose combination, FX11 and PKM2 activator IV 
treated groups (p= 0.03, p= 0.018 and p < 0.001, respectively, Kruskal-Wallis Test, 
Figures 5.8, 5.9 and 5.10). 
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Figure 3.28: Tumour growth curve over 21 days treatment. 
 
As shown in figure 5.8, high-dose combination was effectively impaired tumour growth 
and the tumour volume remained static over the experiment. However, there were no 
significant differences in tumour growth between PKM2 activator IV and vehicle control 
groups. Bioluminescence imaging revealed similar results (Figures 5.9 and 5.10). At the 
end of therapy, tumour weights from the high-dose and low-dose combination therapy 
and FX11 treatment groups were significantly lower compared with vehicle control 
group tumours (p < 0.0001 and p = 0.001, respectively, Kruskal-Wallis Test, Figures 
5.10 and 5.12A). Tumour weight in high-dose combination treated group was also 
significantly lower than tumour weights in low-dose combination, FX11 and PKM2 
activator IV treated groups (p= 0.023, p= 0.016 and p < 0.001, respectively, Kruskal-
Wallis Test, Figures 5.10 and 5.12A). No significant differences were observed in 
tumour weight from the PKM2 activator IV treated and vehicle control groups (Figures 
5.10 and 5.12A). 
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Figure 3.29: Effect of single and combination treatment on subcutaneous tumour growth compared to the control group. A) vehicle-control group. B) High-dose combination 
treated group. C) Low-dose combination treated group. D) Lactate dehydrogenase inhibitor treated group. E) PKM2 activator treated group. In the beginning and after 21 days of 
treatment.
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                               Figure 3.30: Effect of single and combination treatment on size of subcutaneous tumours after 21 days of 
treatment compared to the control group. 
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Similarly, the high-dose combination therapy significantly impaired tumour growth in 
the orthotopic tumour model and the tumour weight was significantly lower than in 
orthotopic control group (p=0.014, Kruskal-Wallis Test, Figures 5.11 and 5.12B). As 
shown clearly in the figure 3.33, the high-dose combination therapy also abolished liver 
and spleen metastases in orthotopic treated group and metastases were only found in the 
orthotopic control group, while there was no metastases detected in any animal in 
orthotopic treated group.   
 
Figure 3.31: Effect of high-dose combination therapy on orthotopic tumour growth compared to the 
control group. A) High-dose combination treated group. B) Vehicle-control group. In the beginning and 
after 21 days of treatment.     
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Figure 3.32: Subcutaneous and orthotopic tumour weight after 21 days of treatment. Effect of single and 
combination therapy on tumour weight compared with vehicle control group (Bar chart, 95% CI). 
 
 
Figure 3.33: Tumour volume, liver and spleen metastasis in orthotopic control group. (A, B) Tumour 
volume was significantly higher in orthotopic controls compared to the treatment group. (C, D) Liver and 
Spleen metastasis in orthotopic controls (yellow arrows), treatment abolished liver and spleen metastasis.  
 3.3.1.5: Histopathological analysis of tumour sections:  
Approximately an hour after the last injection, mice were sacrificed, blood was collected 
and tumours harvested and weighed; half were formalin fixed and half were liquid 
nitrogen frozen for later analysis. Following tissue processing, tumour sections were cut 
and stained with haematoxylin and eosin and also immunohistochemically stained with 
anti-PKM2, anti-LDHA, anti-Ki67 and anti-CD8 antibodies.  
I found that the number of Ki67-positive cells was significantly lower in tumour sections 
from high-dose combination, low-dose combination and FX11 treated groups compared 
with the vehicle control group (p ˂ 0.001, Kruskal-Wallis Test, Figures 5.14 and 5.15). 
The number of Ki67-positive cells was also significantly lower in tumour sections from 
high-dose combination treated group compared with the number of Ki67-positive cell in 
low-dose combination, FX11 and PKM2 activator IV treated groups (p ˂ 0.001, Kruskal-
Wallis Test, Figures 5.14 and 5.15). There was no significant difference in number of 
Ki67-positive cells between the PKM2 activator IV treated and control groups.    
PKM2 and LDHA expression was also evaluated in tumour sections (Figure 5.15). 
PKM2 and LDHA expression was lower in tumour sections from the high-dose, low-
dose combination and FX11 treated groups compared with the control group, whereas 
expression in sections from the PKM2 activator IV treated group was slightly lower than 
the control group (Figure 5.15). 
Although CD8+TIL staining was not detected in the subcutaneous xenografts, high 
expression was detected in orthotopic tumours from the combination treatment group 
(Figure 5.16). These results are suggestive of immune cell reactivation in response to the 
combination treatment in the orthotopic model.  
 
 
  
144 
 
 
Figure 3.34: Ki67 proliferation index in control and different treatment groups. Significantly lower 
proliferation index in high-dose, low-dose combination and FX11 treated groups compared with vehicle 
control group in different treated groups compared to the vehicle control group. The mean number of Ki67 
proliferation index significantly higher in high, low combination and FX11 treated group than in vehicle 
control group (p ˂ 0.001, Kruskal-Wallis test, Bar chart, 95% CI). No significant differences in Ki67 
proliferation index between PKM2 activator IV treated and control group. 
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Figure 3.35: H&E staining and PKM2, LDHA and Ki67 expression in BxPc-3 pancreatic cancer 
xenografts in response to therapy. Lower expression of PKM2, LDHA and Ki67 were observed in the 
high-dose and low-dose combination therapy and FX11 treated group compared with control groups. 
Slightly differences in the expression of these three markers was observed between PKM2 activator IV 
treated and control groups (Scale bar= 100 µm).  
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Figure 3.36: Immunohistochemical staining of CD8+TILs in orthotopic tumours. The red arrow shows 
tumour area and the yellow arrow shows nuclear CD8+ staining. High expression of CD8+ cells was 
observed in tumour sections from the combination treatment group compared with the controls.  
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3.3.1.6: PK and LDH activity in tumour lysate and plasma:  
Activity of the PK and LDH enzymes was evaluated in mice tumour lysates and plasma 
using a commercially available kit (BioVision, UK). Surprisingly, we found very close 
or similar relative values of PK and LDH activities in both mice tumour lysates and 
plasma as a response to treatment. PK activity in tumour lysates and plasma was 
significantly higher in the high-dose, low-dose combination and PKM2 activator IV 
treated groups compared with the vehicle control group (p < 0.001, Kruskal-Wallis Test, 
Figure 5.17A and B). PK activity was approximately 2-fold higher in the high-dose 
combination and PKM2 activator IV treated groups compared with control group. No 
significant differences in PK activity were found between the FX11 treated and vehicle 
control groups. LDH activity in tumour lysates and plasma was significantly lower in the 
high-dose, low-dose combination and FX11 treated groups compared with vehicle 
control group (p < 0.001, Kruskal-Wallis Test, Figure 5.17 C and D). LDH activity was 
decreased by 60% in high-dose combination and FX11 treated groups compared with the 
vehicle control group. Similar activity was observed in the PKM2 activator IV treated 
and vehicle control groups.  
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Figure 3.37: Relative values of pyruvate kinase (PK) and lactate dehydrogenase (LDH) activity in tumour 
lysate and plasma from mice with subcutaneous or orthotopic BxPc-3 xenografts (Bar chart, 95% CI). A) 
Relative values of PK activity in plasma 1hr post injection B) Relative values of PK activity in tumour 
lysates. C) Relative values of LDH activity in plasma 1hr post injection. D) Relative values of LDH 
activity in tumour lysates.   
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3.3.1.7: Toxicity: 
Toxicity was evaluated as a measure of liver enzyme function (ALT: alanine 
transaminase, AST: aspartate transaminase) albumin, and change in mice weight in 
response to the treatment regimen. There were no significant differences in these 
measures between the treatment and control groups, indicating that the therapy with 
TEPP-46 and/or FX11 had no toxic side effects (Figure 5.18). 
 
Figure 3.38: Toxicity evaluation in response to therapy (Bar chart, 95% CI). Effect of drugs on (A) 
Alanine Transaminase (ALT), (B) Aspartate Aminotransferase (AST), (C) Albumin and (D) body weight. 
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3.3.2: DISCUSSION: 
Cancer cells have an altered cellular energy metabolism with an elevated glucose uptake 
and a concomitant increase in lactate production (51,53). Therefore, I proposed that 
targeting cancer cell metabolism could potentially inhibit tumour growth. Our studies 
demonstrate that activation/tetramerisation of PKM2 in combination with the inhibition 
of LDHA, impaired pancreatic cancer cell proliferation and growth both in vitro and in 
vivo.    
Up-regulation of LDHA or PKM2 expression has been reported in several tumour types 
including pancreatic cancer (20,73), gastric carcinoma (200), cholangiocarcinoma (201) 
and non-small cell lung cancer (202), and has been proposed to have a key role in 
tumour initiation, progression and resistance to chemotherapy (113,203).  
High expression of LDHA can increase lactate production, which is used as a source of 
energy by well-oxygenated tumour cells, while glucose is spared for hypoxic tumour 
cells (134,136). Inhibition of LDHA can reduce the ability of cancer cells to metabolize 
pyruvate to lactate, halting the regeneration of NAD+, which is required for sustained 
glycolysis, and hence resulting in the inhibition of tumour cell proliferation. Indeed, 
inhibition of LDHA has been reported to impair lymphoma and pancreatic cancer growth 
via decreasing of ATP level, inducing oxidative stress and cell death. (72).  
PKM2 also plays a key role in the initiation and progression of cancer. PKM2 can occur 
as a dimer or a tetramer, dimeric form has been reported to predominate in tumour cells 
and direct glycolysis toward accumulation of glycolytic intermediates and anabolic 
pathway. Therefore, activation or tetramerisation of PKM2 could interfere cancer cell 
metabolism and proliferation.  
Recently, several PKM2 activators have been developed, including TEPP-46 which has 
been reported to impair progression and growth of lung tumour xenografts (113). X-ray 
crystallography has revealed that the PKM2 activator binding site is completely different 
from the allosteric binding site and the activator can strengthen binding of PKM2 
subunits and FBP (PKM2 allosteric activator) and lock PKM2 in tetrameric isoform 
(113).   
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Based on these findings, I hypothesised that tetramerisation of PKM2 in combination 
with the inhibition of LDHA can impede pancreatic tumour cell progression and growth. 
Indeed I demonstrate that this combination approach synergistically inhibited pancreatic 
cancer cell proliferation in vitro and significantly delayed tumour growth of pancreatic 
cancer xenografts in mice.   
Moreover, non-metabolic function of PKM2 has been recently reported, which involves 
the translocation of the dimeric from of PKM2 from the cytoplasm to the nucleus, where 
it has been implicated to act as a transcriptional co-activator of genes such as HIF-1 and 
OCT-4 (52,59). LDHA and PDK1 transcription induced by HIF-1, has been reported in 
hepatocellular and cervical carcinoma, deriving tumour progression and survival 
(100,177). Therefore, tetramerisation of PKM2 not only depletes glycolytic intermediates, 
but could also impede translocation of PKM2 into the nuclear and hence inhibit the 
transcription of LDHA and, consequently, cancer cell proliferation.  
Indeed, our results demonstrate a decrease in number of nuclei Ki67 expression and 
reduction in PKM2 and LDHA expression with the combination treatment. Moreover, 
the number of CD8+ tumour infiltrating lymphocytes was increased in response to the 
combined therapy in the orthotopic xenografts. I have previously shown that high PKM2 
and LDHA expression is associated with a decrease in the number of CD8+TILs and a 
reduced anti-immune response, which is in line with our current findings. These results 
suggest that the combination treatment could have reactivated immune response 
(CD8+TIL) against the tumour. The activation or tetramerisation of PKM2 combined 
with LDHA inhibition could facilitate the interaction between major histocompatibility 
class I (MHC I) protein with CD8+TIL and reactivate immune response against tumour 
cells, further contributing to tumour growth inhibition.  
Moreover, the combination regimen could be safely administered without any 
demonstrable toxicity. There was no noticeable lethargy or inability of any treated mice 
to drink or eat, and there was no death or reduced body weight in the treatment groups. 
There were also no significant differences in plasma hepatic enzymes between treated 
and control groups to suggest any liver toxicity.    
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There are some limitations to the animal experiments, which include small number of 
animals in each group and short length of treatment. Moreover, due to the small size of 
animals, a limited amount of plasma samples was collected, which was insufficient for 
full biochemical analysis to assess drug toxicity (renal toxicity in particular). 
In conclusion, tetramerisation of PKM2 combined with inhibition of LDHA significantly 
inhibits tumour growth while also re-activating anti-tumour immune response 
(CD8+TILs) without toxic side effects, and therefore, is a promising new therapeutic 
approach for pancreatic cancer. 
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CHAPTER 4: GENERAL DISCUSSION 
4.1: DISCUSSION: 
Despite significant advances in the understanding of cancer biology and the development 
of novel treatments, imaging and surgical techniques, the prognosis for patients with 
pancreatic cancer remains very poor. Pancreatic cancer is the tenth most common cancer 
and the fifth cause of cancer-related deaths in the UK (2). Over the last forty years, 
whilst most cancer survival rates have improved, the 5 -year survival rate of patients 
with pancreatic cancer has not changed and remains ≤ 4%. This poor prognosis can be 
attributed to late stage diagnosis, at which point surgical resection is no longer an option. 
However, patients eligible for surgery have a ~25% chance of surviving beyond 5 years 
(5). There are few therapies, with palliative chemotherapy as the main treatment option 
for patients with locally advanced or metastatic disease (6). Therefore, early diagnostic 
markers and new therapeutic strategies are urgently needed to improve survival rates and 
reduce the toxic side effects associated with current treatment. Gemcitabine and 5-
fluorouracil are the standard treatment option for patients with advanced pancreatic 
cancer. Recently, therapy with FOLFIRINOX has shown improved survival rates 
compared with single-agent gemcitabine, but is accompanied by severe side-effects 
(6,204).  
In this context, novel therapies are required. For instance, a high glycolytic rate is a 
common feature of cancer cells, and therefore, targeting glycolytic enzymes might be a 
feasible target for cancer therapy. Indeed, number of studies have combined glycolytic 
enzymes inhibitors, such as LDHA inhibitors (NHI-1 and NHI-2), with gemcitabine for 
treatment of pancreatic cancer and have shown synergistic effects in both hypoxic and 
normoxic culture conditions. (74). However, our work focused on the study of two 
important glycolytic enzymes, PKM2 and LDHA, and their potential as diagnostic 
markers and therapeutic target for pancreatic cancer, aiming for improvement of the 
prognosis and survival rate of pancreatic cancer patients. 
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The results of our studies showed that PKM2 and LDHA are up-regulated in pancreatic 
cancer and correlated with poor outcome. Interestingly, overexpression of LDHA 
occurred at quite an early stage along the carcinogenetic pathway from pancreatitis 
through cyst/PanIN to cancer, with the highest expression in the most aggressive cancers. 
In contrast, PKM2 expression increased progressively along the tumorigenic pathway, 
with the lowest in the cysts, intermediate expression in PanIN lesions and the highest in 
cancers. High expression of PKM2 and LDHA significantly correlated with tumour type, 
tumour size and a worse overall survival of pancreatic cancer patients, and poorly 
differentiated tumours also had higher PKM2 and LDHA expression. Moreover, high 
expression of PKM2 and LDHA were observed in both pancreatic cancer cell lines and 
plasma samples of pancreatic cancer patients compared with that from healthy 
volunteers. Overexpression of PKM2 and LDHA were also directly correlated with Ki-
67 proliferation marker and inversely proportion with CD8-TILs.  
Additionally, our findings demonstrated that the combination of PKM2 activation and 
LDHA inhibition treatment synergistically inhibited pancreatic cancer cell proliferation 
in cell culture experiments and significantly impeded tumour growth in pancreatic cancer 
xenograft models. Our treatment strategy significantly reduced the number of Ki-67 
proliferation markers and increased the number of CD8+ TILs around tumours and 
abolished metastases in the animal model. The results also showed that inhibition of 
PKM2 by Shikonin attenuated pancreatic cancer cell proliferation and increased cancer 
cell death in vitro. Our results suggest that this combination therapy may be a novel 
therapeutic option for pancreatic cancer.       
Although the exact mechanism of the differential expression pattern of PKM2 and 
LDHA in pancreatic cancer remains to be elucidated, it could be possible that the pre-
neoplastic lesions acquire the glycolytic phenotype through LDHA overexpression and 
then LDHA itself or other oncogenes induce PKM2 overexpression at later stages, when 
cells need to proliferate at a faster pace for tumour-growth. 
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Indeed, up-regulation of PKM2 or LDHA has been reported in a broad spectrum of 
tumours and has been implicated in tumour initiation and progression 
(73,168,201,202,205,206). More recently, while this thesis was in preparation, two 
studies have shown the overexpression of both PKM2 and LDHA in tongue squamous 
cell carcinoma (TSCC) compared with normal tongue mucosa (206) and in thyroid 
cancer compared with benign goitre (176). The result of the present study concur with 
these findings showing significant overexpression of these two markers in pancreatic 
cancer tissue sections compared to the normal pancreatic tissues. High expression of 
PKM2 and LDHA were also observed in 8 and 9 out of the 10 pancreatic cancer cell 
lines, respectively. 
Elevated uptake of glucose by tumour cells is associated with an increase in lactate 
production (59,172). Since PKM2 and LDHA are two crucial glycolytic enzymes that 
facilitate processes associated with the glycolytic phenotype, a very important question 
arises: is there an association between the expressions of these enzymes in pancreatic 
cancer? Our findings provide evidence that the expression of PKM2 significantly 
correlates with the expression of LDHA in pancreatic cancer. Therefore, the synergistic 
activation of these two metabolic enzymes during the initiation and progression of 
pancreatic cancer, might serve as a novel diagnostic biomarker for detection of 
pancreatic cancer. Previous studies have identified both PKM2 and LDHA as target 
genes for similar oncogenic transcription factors, such as HIF-1 and Myc, in various 
cancer types (49,51,54,207). Moreover, PKM2 interacts with HIF-1 in the nucleus and 
functions as a transcriptional co-activator to stimulate the expression of HIF-1 target 
genes, including SLC2A1, LDHA, and PDK1, in hepatocellular and cervical carcinoma 
cells (177,208). PKM2 and LDHA in combination seem to synergistically catalyse the 
glycolytic process to promote oncogenic metabolic reprogramming; however, the details 
and the mechanism of this association are not clear and require further investigation.   
In addition to the crucial role of reprogramming cancer cell metabolism, recent findings 
have identified a non-enzymatic function of PKM2 in the nucleus. PKM2 can be 
translocated from the cytoplasm to the nucleus, acting as a transcriptional co-activator of 
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various target genes, such as HIF-1α and OCT-4, and it can also stimulate the expression 
of HIF-1 target genes, including LDHA and PDK1, in hepatocellular and cervical 
carcinoma cells, (51–53,57,59,101). These findings provide a further link for PKM2 in 
the tumorigenic process.  
Indeed, PKM2 and LDHA expression has been reported both in the cytoplasm and 
nucleus in human glioblastoma, colorectal and gastric cancers (86,200,206). Our results 
demonstrate that PKM2 and LDHA are mainly expressed in the cytoplasm and partially 
in the nucleus. PKM2 and LDHA function as a glycolytic enzymes in the cytoplasm; 
however, their actual function in the nucleus is not fully understood and requires further 
investigation.             
The high plasma activity of both PK and LDH were found in patients with pancreatic 
cancer compared with that from healthy donors. These results were in agreement with 
our immunohistochemistry study results, which shows overexpression of these two 
glycolytic enzymes in pancreatic cancer, and consistent with previous reports that 
showed significant higher levels of serum PK and LDH in pancreatic cancer patients 
compared with the healthy control (5,20,209). A high level (or activity) of plasma PK 
and LDH is correlated with poor prognosis and shorter survival rates in patients with 
pancreatic cancer (5,20,76,209–211). High plasma levels of PKM2 or LDHA have also 
been reported in several other tumour types, including gastric (21,212); lung (213,214); 
breast (215,216); renal cell carcinoma (217,218); and biliary tract cancer (168,219). A 
high plasma level of PKM2 and LDHA could be a useful marker for diagnosis of 
pancreatic cancer; furthermore, the plasma level of these two glycolytic enzymes could 
be important in monitoring the patient’s response to the chemotherapy.      
Immune response plays a crucial role in host immune defence against tumour growth and 
progression; however, the failure of the immune system to recognise and eliminate 
tumour cells may cause growth and spread of cancer. CD8+TILs are important 
components of the immune system that play a major role in the elimination and control 
of cancer growth and development (160). Previous studies have shown a significant 
direct correlation between the number of CD8+ TILs and the occurrence of apoptosis in 
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tumour cells (158,159). A number of studies have also shown that the number of effector 
CD8+ TILs is decreased in patients with melanoma, colorectal, lung and pancreatic 
cancer (162,220–222). Tumour cells can evade immune response by various 
mechanisms. For instance, the loss of major histocompatibility complex class I (MHC I) 
or surface antigens can prevent recognition of tumour cells by CD8+T cells. However, 
the ability of PKM2 and LDHA to modulate tumour immune response is unclear. The 
result of our studies found that the number of CD8+TIL was significantly higher in 
patients with weak PKM2 and LDHA expression, who also had a significantly higher 
survival rates, compared with those that had a higher expression. High expression of 
these two enzymes were prevented accumulation of CD8+TILs in or around the tumour. 
However, further studies are required to understand the mechanism of this association.  
A previous study reported that the interaction between SOCS3 (suppressor of cytokine 
signaling 3) with PKM2 in dendritic cells lead to the impairment of immune response 
against cancer cells, while the dendritic cells are in the tumour environment, the 
expression of SOCS3 is upregulated by tumour-derived factors. The interaction of 
upregulated SOCS3 with PKM2 leads to decreased ATP production by decreasing the 
activity of PKM2, which ultimately causes dysfunction of dendritic cells, with reduced 
ability to present antigens and an impaired immune response (223). 
Our results also clearly showed that the expression of LDHA negatively correlates with 
CD8+TILs, high expression of LDHA leads to the production of high amount of lactate 
and increases the acidity of tumour micro-environment, which ultimately leads to the 
impairment of the immune response (49). Our results are consistent with previous 
findings that showed that tumour cell acidity impairs CD8+ tumour specific effector T 
cells in both human and animal model (224). Collectively, the high expression of PKM2 
and LDHA in pancreatic cancer may obstruct the interaction between the immune 
response and pancreatic cancer cells and contribute to poor response to the both chemo 
and radiotherapy.   
On the other hand, a high rate of glycolysis is one of the hallmarks of tumour cells. The 
most important advantage of increased glycolysis in tumour cells is the production of 
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energy without oxygen consumption, and the generation of glycolytic intermediates such 
as triglycerides, phospholipids, and nucleotides, which are used as macromolecules for 
biosynthesis of new cells. Previous research findings have demonstrated that oncogenic 
tyrosine kinase fibroblast growth factor receptor-1 (FGFR-1) can regulate and 
phosphorylate both PKM2 and LDHA. Phosphorylation of PKM2 at tyrosine 105 (Y105) 
prevents tetramerisation and inactivates PKM2; however, phosphorylation of LDHA at 
tyrosine 10 (Y10) by FGFR-1 promotes tetramerisation and activation of LDHA (176). 
As a consequence of up-regulation and phosphorylation of PKM2 and LDHA, tumour 
cells proliferate and grow faster. Therefore, I proposed that targeting both PKM2 and 
LDHA enzymes could be an effective new therapeutic strategy for treatment of 
pancreatic cancer. Here, I clearly documented that activation or tetramerisation of PKM2 
in combination with the inhibition of LDHA impaired pancreatic cancer cell proliferation 
in vitro and significantly impaired tumour growth in pancreatic cancer xenograft models.   
To investigate the role of PKM2 in pancreatic cancer cell proliferation and tumour 
growth, firstly, the effect of PKM2 inhibition on cell proliferation was evaluated by 
using Shikonin as a PKM2 inhibitor. The results of our study showed that Shikonin had a 
strong cytotoxic effect on different types of pancreatic cancer cell lines with low IC50 
values. Shikonin can inhibit pancreatic cancer cell proliferation by inhibiting PKM2 
activity, and hence glycolysis, causing cell death by triggering programmed cell death. 
Our results are consistent with a previous report showing that Shikonin and its analogues 
can effectively inhibit cancer cell proliferation by the selective inhibition of tumour 
PKM2 (112).  
Although Shikonin effectively inhibited pancreatic cancer cell proliferation in vitro, 
Shikonin was not selected for in vivo experiment. There are some reasons for non-
selection of Shikonin in animal experiment models, one reason is due to multiple effects 
of Shikonin leading to cell death which is not purely due to the inhibition of PKM2, 
which our hypothesis is based on. Wiench et al (2012) found that Shikonin can induce 
apoptosis in different cancer cell lines by directly affecting mitochondrial function and 
disruption of mitochondrial membrane potential, leading to generation of reactive 
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oxygen species (ROS) and ultimately cell death (191). More recently, Gara et al (2015) 
demonstrated in prostate cancer that Shikonin can induce and activate endoplasmic 
reticulum stress and also increase generation of ROS and enhance pro-apoptotic 
signaling through affecting mitochondrial function (197).  
On the other hand, the inhibition of glycolysis can be toxic to both normal and cancer 
cells, and the use of Shikonin can damage and kill healthy as well as cancer cells in 
animal models. Therefore, the PKM2 activator in combination with an LDHA inhibitor 
was used as a treatment strategy in the in vivo study. Activation of PKM2 may not be 
toxic to the normal non-proliferating cell, and inhibition of LDHA is also not associated 
with major side effects. In patients with hereditary LDHA deficiency, the only side-
effect of the lack of LDHA is the development of myoglobinuria after intense exercise. 
Hence, the combination treatment strategy may be non-toxic to the normal cell and 
unlikely to cause major side effects. 
The active form of PKM2 (tetramer) impedes tumour growth, whereas the inactive form 
of PKM2 (dimer) contributes to the progression and growth of tumours. Several studies 
have shown that the replacement of PKM2 by PKM1 can inhibit cancer cell proliferation 
in vitro and impairs tumour growth in xenograft models (59,113). In line with these 
observations, researchers have been interested in the development of PKM2 activators 
and several small molecular activators have been identified. Anastasiou et al. (2012) 
studied the effect of tetramerisation of PKM2 on tumour cell proliferation by using small 
molecular activators, and found that the activation of PKM2 can inhibit cancer cell 
proliferation through interfering with the anabolic pathway. The results of this study also 
showed that the activation of PKM2 decreased pools of ribose phosphate and the amino 
acid serine, which are key precursors of lipid, amino acid and nucleotide metabolism, 
both in vitro and in vivo. This research group has developed numerous PKM2 activators; 
TEPP-46 is an example of a potent PKM2 activator and has been shown to impaired 
tumour growth in the xenograft models. Moreover, x-ray crystallography studies have 
shown that the activator binding site differ from the allosteric binding site, and the 
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activator can strengthen binding of subunits and FBP (PKM2 allosteric activator) and 
lock PKM2 in the tetrameric form. 
In a related study, Kung et al. (2012) found that the activation of PKM2, using a small 
molecular activator, known as compound 9 or PKM2 activator III, induced serine 
autotrophy in cancer cells and locked PKM2 in an active tetrameric form, forcing tumour 
cells to reprogram their metabolism, which is less metabolically flexible compared with 
normal cells.    
Tetramerisation of PKM2 might have further effect on the attenuation of cancer cell 
proliferation. Recent research findings identified non-metabolic function of PKM2, in 
particular circumstance, dimeric form of PKM2 can translocate to the nucleus and 
functioning as a protein kinase to regulate gene expressions. These findings suggest that 
the tetramerisation of PKM2 not only depletes glycolytic intermediates, but also impedes 
translocation of PKM2 from the cytoplasm into the nucleus and hence can inhibit the 
transcription of LDHA, and consequently, the cancer cell proliferation.  
Our results demonstrate that the activation of PKM2 alone did not have a significant 
effect on cell viability and tumour growth; however, in combination with LDHA 
inhibition, pancreatic cancer cell proliferation was inhibited in a synergistic manner and 
xenograft tumour growth was significantly impaired.   
High expression and activity of LDHA in pancreatic cancer was observed in our study, 
which could increase the lactate production. High lactate production has some 
advantages to tumour cells and has an important role in the progression, metastasis and 
resistance to chemotherapy by changing the acidity of extracellular microenvironment. 
Moreover, lactate can be used as fuel by aerobic tumour cells, sparing glucose for 
hypoxic tumour cells. Accordingly, the inhibition of LDHA can reduce lactate 
production and consequently attenuate pancreatic cancer cell proliferation and growth by 
forcing aerobic tumour cells to use glucose as a main source of energy, depleting glucose 
for the hypoxic tumour cells and then resulting in tumour cell death due to depletion of 
glucose.    
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The anti-tumour effect of LDHA inhibition has been known for many years; however, 
the lack of highly selective and potent inhibitors has posed some difficulty. A number of 
moderately potent LDHA inhibitors have been identified and the effort of finding highly 
potent inhibitors has continued. Recently, Anne Le et al. (2010) studied the effect of 
LDHA inhibition on progression and growth of human lymphoma and pancreatic cancer 
cells by FX11, which is a potent LDHA inhibitor; they found that inhibition of LDHA 
inhibited cancer cell proliferation and growth both in vitro and in vivo. The study also 
reported that inhibition of LDHA can increase oxygen consumption, reduce lactate 
production and ATP levels, increase reactive oxygen species (ROS) and induce oxidative 
stress, causing inhibition of cancer cell proliferation and finally death (72). Moreover, 
the combination of FX11 with an inhibitor of NAD+ synthesis (FK866) has 
demonstrated a synergistic effect on the inhibition of P493 human lymphoma cell 
proliferation in vitro and impaired tumour growth in vivo (72).    
In the present studies, PKM2 activator (TEPP-46) in combination with the LDHA 
inhibitor (FX11) was used as a therapeutic strategy for pancreatic cancer. 
Tetramerisation of PKM2 can inhibit the anabolic pathway and deplete glycolytic 
intermediates and inhibition of LDHA, on the other hand, can reduce lactate production 
and deplete extracellular lactate. Therefore, combination of PKM2 activation and LDHA 
inhibition hinders cancer cell proliferation due to interference with the anabolic pathway; 
well-oxygenated tumour cells are forced to use glucose as their main energy source, 
which may cause the death of hypoxic tumour cells. As a consequence, tumour cell 
proliferation and growth are inhibited; leaving a low number of surviving tumour cells in 
well-oxygenated regions, resulting in tumour shrinkage, providing the opportunity for 
surgery. Our findings also suggest that the activation of PKM2 in combination with 
LDHA inhibition leads to the accumulation of pyruvate inside the cell and then shunting 
it into the mitochondria. As a results of the shunting pyruvate into the mitochondria 
oxygen consumption might enhanced, ATP level reduced and finally induce oxidative 
stress and pancreatic cancer cell death. On the other hand, the high expression of LDHA 
and PKM2 could result in resistance to both chemo and radiotherapy by increasing 
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acidity of the extracellular microenvironment; therefore, combination of PKM2 
activation and LDHA inhibition might increase tumour cell sensitivity to both chemo and 
radiotherapy and be an effective approach in patients with metastatic pancreatic cancer.         
Our findings also demonstrate that combination of PKM2 activation and LDHA 
inhibition significantly decreased the number of Ki67-positive cells and reduced PKM2 
and LDHA expression. Furthermore, the correlation between combination therapy and 
host immune response (CD8+TILs, CD8+ tumour infiltrating lymphocytes) was found. 
Our previous findings suggested that the high PKM2 and LDHA expression in pancreatic 
cancer potentially prevent accumulation of CD8+TIL cells peri- and intra-tumoural, and 
thus blunt the anti-tumour host immune response. Interestingly, the results of the present 
study were consistent with our previous findings. Higher number of CD8+TIL cells were 
found around orthotopic tumours that treated with the combination drugs, while there 
was no or negligible number of CD8+TIL cells in orthotopic control tumours. These 
results suggest that the combination treatment could have reactivated the immune 
response (CD8+TILs) against the tumour and may facilitate the interaction between 
major histocompatibility class I (MHC I) with CD8+TILs and reactivate immune 
response against tumour cells, which further contribute to the inhibition of tumour cell 
proliferation and growth. Furthermore, the combination therapy was well-tolerated by 
mice, as evaluated by weight loss and hepatic enzymes function.  
To summarise, tetramerisation of PKM2 in combination with inhibition of LDHA 
significantly impede pancreatic cancer cell proliferation and tumour growth and might 
also reactivate anti-tumour immune response, inducing further cancer cell death.     
A comment should be made of potential errors in the methodology of the research 
studies, which can include instrumental error, methodological errors, errors in 
preparation or addition of the regents and during assessment of the staining or counting 
of the stained cells. Generally, experimental error can be divided into systematic and 
random error. In our study, we avoided systematic error by precisely setting up the 
instrument and using blank and sometimes positive controls to avoid any error that may 
be caused by the instrument. Random errors were minimized by repeating at least twice 
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the same experiment and the average of these two experiments was taken and used for 
the interpretation of the results. If any big differences between two repeated experiments 
were observed a third and sometimes fourth repetition of the experiment was performed 
to confirm the results. To avoid bias in the assessment of immunohistochemistry 
staining, the stained tissue sections were assessed independently and blindly to the status 
and stage of the patients by two observers and any differences were resolved by 
conference microscope. The same strategy was used for the counting of stained Ki-67 
and CD8+TIL stained cells. Finally, animal experiments were done under observation 
and supervision of an experienced project licence holder. Tumour sizes were measured 
and compared with bioluminescence images to confirm the accuracy of the tumour size 
measurements.    
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4.2: CONCLUSION:  
PKM2 and LDHA are overexpressed in pancreatic cancer and significantly correlate 
with a poor outcome. Activation of PKM2 in combination with inhibition of LDHA 
synergistically inhibited pancreatic cancer cell proliferation and significantly impaired 
the growth of pancreatic cancer xenograft tumours. Therefore, this combination might 
represent a novel strategy for the treatment of pancreatic cancer. PKM2 and LDHA may 
contribute to the aggressiveness of pancreatic cancer and confer anergy against host anti-
tumour immune response. As such, activation of PKM2 in combination with inhibition 
of LDHA may reactivate anti-tumour immune response and induce tumour cell death. 
Our results suggest that PKM2 and LDHA may serve as diagnostic and prognostic 
markers and as potential therapeutic targets for pancreatic cancer. Furthermore, the 
combination of PKM2 activation and LDHA inhibition in conjunction with 
chemotherapy could be an effective therapy for patients with metastatic pancreatic 
cancer, and might improve quality of life and survival rates.  
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4.3: FUTURE WORK: 
The therapeutic strategy for pancreatic cancer described here is not complete and further 
studies are ongoing. Our project can be taken forward in a number of ways before 
moving to clinical trials. These include the mechanistic investigations of some cell 
signaling pathways disrupted by the combination of PKM2 activation and LDHA 
inhibition. Proteomic analysis is another planned approach to understand the effect of 
combination treatment on the function and levels of cell proteins, particularly the 
glycolytic metabolome.   
Additionally, gene analysis is another important part of our ongoing project, The dimeric 
form of PKM2 can be translocated from the cytoplasm to nucleus and acts as a 
transcriptional co-activator of some genes including Stat 3,  β-catenin, HIF-1 and Oct-4. 
The study of genes in response to combination treatment in pancreatic cancer could be 
important to know whether the treatment regimen has an effect on the down-regulation 
of those genes involved in the progression of pancreatic cancer.              
Finally, in our study combination treatment inhibited pancreatic cancer cell proliferation 
and tumour growth and also abolished metastasis. We expect the use of combination 
treatment in conjunction with chemotherapy will increase the sensitivity of 
chemotherapy and may improve the quality of life and survival in patients with 
metastatic disease. Consistent with our expectation, very recently, Kim et al (2015) 
found that the knockdown of PKM2 increased the sensitivity of gemcitabine treatment in 
pancreatic cancer and significantly enhanced gemcitabine-enhanced cell apoptosis 
through the activation of caspase cascade and poly ADP-ribose polymerase (PARP) 
cleavage (225). In a related study, Wang et al (2015) found that the knockdown of 
PKM2 gene enhanced the sensitivity of radiotherapy in non-small cell lung cancer 
through increasing apoptosis rate and endoplasmic reticulum stress (226). Hence, the 
conjunction of combination treatment with chemotherapy could be an effective treatment 
for patients with metastatic pancreatic cancer and it is our future research work. 
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Table 1: TNM classification of pancreatic cancer according to the American Joint Committee on 
Cancer (AJCC). 
I- Classification according to tumour size (T) 
TX The tumour cannot be assessed.  
T0 No evidence of a primary tumour. 
Tis Cancer in situ (few tumour cells found)   
T1 Tumour inside pancreas and less than 2 cm in size. 
T2 Tumour still inside pancreas but the size of it larger than 2 cm. 
T3 The tumour has started to grow into the near surrounding 
pancreas tissue but it has not extended to the nerves or blood 
vessels.  
T4 The tumour has spread further outside the pancreas to the 
nearest large blood vessels or nerves  
II- Classification according to lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 The tumour has not extended to the regional lymph nodes 
N1 The tumour has extended to the regional lymph nodes 
III- Classification according to metastasis (M) 
M0 The cancer has not spread to distant lymph nodes or to the other 
organ such as lung, liver, brain, etc. 
M1 The cancer has spread (Metastasis) to other organs. 
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Table 2: Staging of pancreatic cancer according to the American Joint Committee on Cancer 
(AJCC). 
Stages Meaning TNM system 
Stage 0 
The tumour is just on the outer layer of pancreatic duct 
cells and it is not gone down to the deeper tissue layers 
and it is not spread.  
Tis,N0,M0 
Stage IA The tumour inside pancreas with less than 2 cm in size and it has not extended to distant or near lymph nodes. T1,N0,M0 
Stage IB The tumour inside pancreas with larger than 2 cm in size and it has not extended to distant or near lymph nodes. T2,N0,M0 
Stage IIA 
The tumour has started to grow into near surrounding 
tissues outside pancreas but it has not extended to large 
blood vessels or near lymph nodes. 
T3,N0,M0 
Stage IIB 
The tumour is either inside the pancreas or extended to 
surrounding but it has not spread to the main nerves or 
large blood vessels. The tumour has extended to the near 
lymph nodes but not distant. 
T1-3,N1,M0 
Stage III 
The tumour has spread to surrounding of pancreas and it 
has extended to near large blood vessels or main nerves. 
It may or may not extend to near lymph nodes and it has 
not extended to distant sites.   
T4,Any N,M0 
Stage IV The cancer has extended and metastasized to the other distant organs such as liver and lung.  
Any T, Any 
N,M1 
 
 
  
A) Optimization of Shikonin concentration, the figures show the effect of Shikonin treatment on 
PK-1 cell viability (%):  
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B) Optimization of PKM2 activator and LDHA inhibitor combination ratio, the tables show the 
effect of single and combination treatment on cell viability (%): 
 24 hrs PKM2 Activator IV Concentration (µM) 
  0 6.25 12.5 25 50 100 
FX
11
 C
on
ce
nt
ra
tio
n 
(µ
M
) 0 100 99.8 96.28 92.5 88.87 80.05 
2.5 97.76 91.54 93.4 86.64 95.47 84.96 
5 90.4 88.26 94.21 90 92.18 80.83 
10 87.88 97.78 86 92.22 91.39 80.44 
20 83.37 82.54 85.16 78.83 82.2 71.78 
40 78.76 87 87.48 84.57 75.04 71.45 
60 76.73 85.44 86.26 79.63 74.06 70.2 
100 57.63 64.3 56 53.3 49.25 42.84 
 
 48 hrs PKM2 Activator IV Concentration (µM) 
  0 6.25 12.5 25 50 100 
FX
11
 C
on
ce
nt
ra
tio
n 
(µ
M
) 0 100 99.13 96.84 90.54 84.41 73.62 
2.5 93.91 88.62 97.23 97.88 90.15 70.33 
5 88.43 80.01 95.59 93.79 87.88 68.48 
10 88.10 99.12 78.16 95.30 92.49 68.34 
20 85.50 89.27 94.47 77.93 81.91 63.00 
40 75.01 89.66 84.84 78.07 65.19 50.51 
60 59.85 66.50 66.63 55.15 44.37 38.82 
100 23.36 31.41 32.67 26.17 24.01 17.74 
 
 72 hrs PKM2 Activator IV Concentration (µM) 
  0 6.25 12.5 25 50 100 
FX
11
 C
on
ce
nt
ra
tio
n 
(µ
M
) 0 100 99.92 96.61 81.10 70.64 46.70 
2.5 96.57 88.65 93.72 77.68 67.79 55.42 
5 90.69 70.50 78.69 69.59 61.73 53.73 
10 85.84 93.52 64.51 73.75 50.80 49.05 
20 80.90 94.29 81.23 51.76 40.35 42.00 
40 72.99 72.40 70.92 57.29 30.37 29.77 
60 45.30 51.93 47.55 32.00 18.92 26.56 
100 13.08 18.49 17.44 11.54 7.21 5.03 
 
 96 hrs PKM2 Activator IV Concentration (µM) 
  0 6.25 12.5 25 50 100 
FX
11
 C
on
ce
nt
ra
tio
n 
(µ
M
) 0 100 92.12 87.24 72.74 56.45 41.40 
2.5 95.12 91.46 88.70 67.77 52.19 40.75 
5 88.74 72.08 88.73 62.05 51.14 39.79 
10 83.47 92.06 61.22 66.68 52.51 31.25 
20 80.79 87.71 83.66 49.96 49.05 36.25 
40 71.54 83.20 84.40 45.04 25.54 26.83 
60 43.76 48.96 45.68 28.03 17.82 14.79 
100 12.50 16.96 16.13 10.62 6.29 3.52 
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